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1. Abbreviations 
AD Alzheimer’s disease IβS Interferon-β-induced signature 
ADAM A disintegrin metalloprotease logFC Log2 Fold change 
APH Anterior pharynx defective MCI Mild-cognitive impairment 
ASH Acute sustained hypoxia MDM Monocyte-derived macrophage 
ATP Adenosine triphosphate MPI Microglia proximity index 
Aβ Amyloid-β NF-κB Nuclear factor-κB 
AβPP Amyloid-β precursor protein NFTs Neurofibrillary tangles 
BSA Bovine serum albumin O2 Oxygen 
C83 or 
αCTF  
α C-terminal fragment p P-value 
C99 or 
βCTF 
 Β C-terminal fragment PBS Phosphate-buffered saline 
CNS Central Nervous System PCR Polymerase Chain Reaction 
CO2 Carbon dioxide PHD Prolyl 4-hydroxylase domain 
COPD Chronic obstructive pulmonary 
disease 
PS Presinilin 
CSH Chronic sustained hypoxia P-Tau Hyperphosphorylated-Tau 
dH2O Distilled water qRT-PCR Reverse transcription real-time 
polymerase chain reaction 
dNTP Deoxyribonucleotide ROS Reactive oxygen species 
FACS Fluorescence-activated cell 
sorting 
sAD Sporadic Alzheimer’s disease 
fAD Familial Alzheimer’s disease SDS-
PAGE 
Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
fAβ Fibrillar amyloid-β sAβPPα Soluble amyloid-β precursor protein 
α 
FIH Factor inhibiting HIF sAβPPβ Soluble amyloid-β precursor protein 
β 
GSEA Gene set enrichment analyses Thio-S Thioflavine-S 
GWAS Genome-wide association studies TNFα Tumor necrosis factor α 
HIF Hypoxia-inducible factor TLR Toll-like receptor 
HMS Hypoxia-induced microglia 
signature 
VEGF Vascular endothelial growth factor 
HREs Hypoxia-response elements VHL von Hippel-Lindau tumor suppressor 
IDE Insulin-degrading enzyme WB Western blot 
IFN Interferon   
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2. Introduction 
2.1. Alzheimer’s disease 
2.1.1. Main hallmarks and physiopathology 
Frau Auguste Deter, a 51-year-old patient with aphasia and memory loss, was 
admitted at Frankfurt Asylum in 1901, where Dr. Alois Alzheimer got interested in 
her clinical picture. After her death, in 1907, Dr. Alois Alzheimer published his 
“Peculiar Disease of the Cerebral Cortex”, a histological analysis of Auguste’s brain 
cortex describing deposits of plaques and fibrils rearranged into bundles and 
networks. He had just made the first description of a frequent kind of dementia in 
the elderly and its main histopathological hallmarks; a condition that was 
deservedly named after him as Alzheimer’s disease (AD) (Hunting, 2015; Kay et al., 
1964; Strassnig & Ganguli, 2005). 
Patients suffering from this progressive neurodegenerative disease show extensive 
cortical atrophy, presumably causing subsequent dementia, and prominent lateral 
ventricles enlargement (Dickerson et al., 2009). The presence of microinfarctions 
is also frequent, as cerebrovascular disorders are usually linked to aging in general 
and AD in particular (Serrano-Pozo et al., 2011). Microscopically, AD is 
characterized by the presence of extracellular protein deposits called amyloid 
plaques and dystrophic neurites containing fibers of hyperphosphorylated Tau (P-
Tau) protein called neurofibrillary tangles (NFTs), which can also appear as 
extracellular aggregates. These AD distinctive features correlate with microglial 
activation, astrogliosis, synapse loss, and neuronal damage, which culminate in 
dementia. Particularly, vascular dysregulation and synapse loss are considered as 
the more predictive features for cognitive decline in the disease (DeKosky & Scheff, 
1990; Iturria-Medina et al., 2016). 
Amyloid plaques emerge from accumulation, aggregation, and deposition of 
amyloid-β (Aβ) peptides and display diverse morphology and neuronal toxicity. In 
spite of the different attempts to chronologically classify amyloid plaques on the 
basis of their formation and evolution, a more practical approach has been used to 
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discriminate between two main types of amyloid plaques according to their 
staining properties and morphology. Dense-core plaques exhibit Thioflavine-S 
(Thio-S) staining due to their β-sheet structure and are associated with neuronal 
damage and glial activation (Itagaki et al., 1989; Serrano-Pozo, Muzikansky, et al., 
2013). These dense-core plaques can be subsequently subdivided into filamentous 
plaques or compact plaques. Dense-core filamentous plaques exert higher toxic 
effects on surrounding neurons than compact plaques due to their more fibrillar 
conformation (Yuan et al., 2016). Unlike dense-core plaques, diffuse plaques 
cannot be visualized upon Thio-S staining and do not display surrounding 
neuronal damage. Indeed, diffuse plaques are a frequent aging-related feature in 
cognitively healthy subjects. Interestingly, even though dense-core amyloid 
plaques produce neuronal damage, there is no clear association between plaque 
burden and the degree of cognitive impairment (Arriagada et al., 1992; 
Giannakopoulos et al., 2003). 
On the other hand, microtubule-associated Tau protein in a misfolded and 
hyperphosphorylated state constitute the main component of NFTs. The 
hyperphosphorylation event takes place in specific regions of tau protein and it 
has been suggested to precede tau protein aggregation (Augustinack et al., 2002). 
The NFTs can be found within neurons as diffuse puncta that do not correlate with 
evident neuronal alterations or as inner neuronal fibrils that impair neuronal 
morphology. Extracellular NFTs emerge from tangle-bearing neurons death (Braak 
et al., 1994; Su et al., 1993). Both the amount and distribution of NFTs parallel AD 
neurodegeneration and corresponding cognitive decline, although it is unclear 
whether it constitutes an essential step for subsequent neuronal death or a 
protective mechanism exerted by neurons (Bierer et al., 1995; Serrano-Pozo et al., 
2011).  
Despite the massive amount of data generated regarding AD in the last century, we 
barely understand the molecular mechanisms involved in this disease that affects 
more than 24 million people worldwide. Available approved treatments target AD 
symptoms but cannot slow down the disease progression, and future perspectives 
include a 4-fold increase in AD prevalence in the next 40 years (Farlow et al., 
2008). Therefore, AD represents one of the biggest challenges for public health and 
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involves remarkable economical issues, what justifies the intense search for 
underlying causative mechanisms to target this disorder (Kumar et al., 2015; Reitz 
& Mayeux, 2014).  
2.1.2. Aβ accumulation 
Aβ peptides are produced in physiological conditions and cleared by different 
mechanisms, but their accumulation and deposition occur upon imbalance 
between Aβ generation and removal by degradation and drainage (Hardy et al., 
2002; Selkoe & Dennis, 2003; Tarasoff-Conway et al., 2015; Zlokovic et al., 2000). 
Aβ generation can result from sequential cleavages of Aβ precursor protein 
(AβPP), a type-I transmembrane protein encoded in App gene, which is located in 
human chromosome 21 (Figure 1) (George-Hyslop et al., 1987; Zhang et al., 2011). 
Despite having been extensively studied, the physiological function of AβPP 
remains largely elusive. In this sense, several functions have been proposed for 
AβPP protein including synaptogenesis, neurite outgrowth, cell adhesion, protein 
trafficking and signaling receptor but most of these functions require further in 
vivo validation (Zheng & Koo, 2006).  
AβPP can be processed by α-cleavage or β-cleavage. The non-amyloidogenic 
pathway, the main route of Aβ processing, is initiated by α-cleavage of AβPP in the 
plasma membrane. This proteolytic activity takes place within the Aβ domain of 
AβPP, preventing Aβ generation and producing a large soluble peptide called 
soluble amyloid precursor protein α (sAβPPα), with reported neurotrophic 
activities, and an 83 amino acid C-terminal fragment (αCTF or C83) with no clear 
functions (Nhan et al., 2015; Sisodia, 1992). The A disintegrin and metalloprotease 
(ADAM) family members ADAM9, ADAM10, and ADAM17/TACE are located in the 
plasma membrane and carry out the α-cleavage, although the main α-secretase 
activity is catalyzed by ADAM10. αCTF constitutes the substrate for ɣ-secretase 
complex, which is integrated by four different subunits: presenilin (PS) 1 or PS2, 
nicastrin, PS enhancer 2 and anterior pharynx defective 1a or 1b (APH1a or 
APH1b) (De Strooper et al., 2012). P83 and AICD fragments result from the 
catalytic activity of this complex. Unlike P83, which is rapidly degraded, AICD has 
been proposed to possess signal transduction functions. In the presence of 
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caspases, AICD can be subsequently cleaved, releasing C31 fragment, which exerts 
cytotoxic effects (Park et al., 2009). 
 
Figure 1. Schematic diagram of amyloid-β precursor protein (AβPP) 
processing, adapted from Zhang et al., 2011 (Y. Zhang et al., 2011).  
In the non-amyloidogenic AβPP processing, sequential α-cleavage and ɣ-cleavage 
prevent amyloid-β (Aβ) production. In the amyloidogenic AβPP processing, β-
cleavage conserves intact Aβ peptide structure and ɣ-cleavage separates different 
Aβ peptide versions from AICD fragment. sAβPPα, soluble amyloid-β precursor 
protein α; sAβPPβ, soluble amyloid-β precursor protein β; αCTF or C83, α C-terminal 
fragment; βCTF or C99, β C-terminal fragment.  
The amyloidogenic pathway originates from β-cleavage of AβPP by BACE1, 
considered as the rate-limiting enzyme for Aβ generation. This enzyme catalyzes 
the cleavage of AβPP by proteolysis in a different position from α-cleavage that 
keeps intact the Aβ peptide within a longer fragment of 99 amino acids C-terminal 
fragment (βCTF or C99). Unlike sAβPPα, the soluble peptide produced upon BACE1 
proteolytic cleavage of AβPP called soluble amyloid precursor protein β (sAβPPβ) 
does not seem to show neurotrophic functions. β-cleavage is followed by ɣ-
cleavage, what results in AICD and Aβ peptides production of different lengths, 
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being Aβ1-40 and Aβ1-42 the most frequent ones (Haass et al., 2012; Saido & 
Leissring, 2012; Zhang et al., 2011; Zheng & Koo, 2006). 
Aβ can be cleared from the brain by various overlapping and interacting clearance 
systems including cellular uptake and enzymatic degradation, transport across the 
blood–brain barrier and blood–cerebrospinal fluid barrier, interstitial fluid bulk 
flow, and cerebrospinal fluid absorption into the circulatory and lymphatic 
systems (Tarasoff-Conway et al., 2015). However, experimental evidence suggests 
that the contribution of Aβ-degrading enzymes to counterbalance Aβ production 
through irreversible catalysis is of particular relevance. Neprilysin and insulin-
degrading enzyme (IDE) are both among the most relevant and extensively 
characterized Aβ-degrading enzymes. Although IDE is a ubiquitously expressed 
protein in the brain, neprilysin expression is restricted to neuronal presynaptic 
terminals (Fukami et al., 2002; Jha et al., 2015). On the other hand, BACE2 protein 
is the Aβ-degrading enzyme with the highest in vitro capacity of Aβ proteolysis and 
is expressed in glial cells, but not in neurons (Saido & Leissring, 2012). 
2.1.3. Etiology and epidemiology 
AD cases are classified into familial AD (fAD) or sporadic AD (sAD) according to 
their etiology. fAD represents a 4 % of all AD cases and is caused by autosomal 
dominant mutations that directly impact on AβPP processing. These mutations 
affect App gene, encoding for AβPP, Psen1 gene, encoding for PS1, or Psen2 gene, 
encoding for PS2. As a result, patients carrying these mutations increase Aβ 
generation, leading to fAD, cerebral amyloid angiopathy or both (Bettens et al., 
2013; Rovelet-Lecrux et al., 2006). Therefore, a scenario of pure Aβ accumulation-
driven AD is provided by these mutations in which amyloid plaque formation 
precedes vascular pathology, NFTs, neuronal damage, and dementia. In this sense, 
the amyloid cascade hypothesis was proposed by Hardy and Higgins, claiming that 
Aβ deposition was the causative event for AD pathology. Accordingly, Aβ 
accumulation leads to downstream effects and eventual dementia (Hardy & 
Higgins, 1992).   
On the other hand, the vast majority of AD cases are classified as sAD because the 
upstream events leading to Aβ accumulation remain unknown. Genome-Wide 
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Association Studies (GWAS) performed in different cohorts of patients have 
revealed that genetic modifications altering endolysosomal function, lipid 
metabolism or immune response are more likely to predispose to sAD. Genetic 
polymorphisms in Clu, Cr1, Picalm, Bin1, Epha1, Abca7, Cd33 or Trem2 genes are 
among the alleles implicated in endolysosomal, lipid metabolism and immune 
responses impairment associated with sAD. In particular, the most relevant genetic 
risk factor for sAD is Apoe ε4 allele, encoding for the most abundant apolipoprotein 
in the human brain and involved in lipid transport and metabolism, Aβ aggregation 
and clearance, synaptic plasticity, and neuroinflammation (Pimenova et al., 2018). 
In spite of the increasing number of risk genetic factors identified, a growing body 
of evidence involves epigenetic modifications and environment as essential 
determinants in the development sAD (Bettens et al., 2013; Corder et al., 1993; 
Pimenova et al., 2018; Yu et al., 2014). In this sense, population-based studies on 
demented subjects reported a correlation between the combination of AD and 
cerebrovascular impairment and dementia (Neuropathology Group. Medical 
Research Council Cognitive Function and Aging Study, 2001; Schneider et al., 
2007). Indeed, several studies suggest that factors predisposing to cerebrovascular 
disease or stroke are also associated with AD, although the precise link between 
these conditions is unclear. Among these factors, atrial fibrillation, atherosclerosis, 
and diabetes are common predisposing conditions for both AD and ischemic stroke 
in the elderly. In fact, Apoe ε4 allele expression not only increases AD development 
but also induces a 3-fold increase in vascular disease (Kalaria, 2000).  
Recent epidemiological studies have specifically reported comorbidity between 
hypoxia-associated conditions and dementia. Resulting hypoxia from sleep-
disordered breathing old patients consistently associated with dementia and mild 
cognitive impairment (MCI) (Yaffe et al., 2011). Studies on chronic obstructive 
pulmonary disease (COPD) have also revealed an increased risk of MCI and 
dementia that is proportional to duration the of COPD (Rusanen et al., 2013; Singh 
et al., 2014). In contrast, treatment with continuous positive airway pressure to 
obstructive sleep apnea patients also suffering from AD, slows down or even 
improves cognitive impairment (Cooke et al., 2009).  
- 15 - 
 
Table 1. Literature review on regulation of amyloid-β (Aβ) metabolism by 
hypoxia (Serrano-Pozo et al., 2017). 
Abbreviations: ↓, significant decrease; ↑, significant increase; =, no significant 
change; d, days; EM, electron microscopy; F, female; FA, formic acid; h, hours; hu, 
human; M, male; Mme = neprilysin mRNA; mo, month; mu, murine; MWM, Morris 
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water maze (↓ indicates worse performance); NA, not available; NFT, neurofibrillary 
tangle; OF, open field; syn, synaptophysin; TST, tail suspension test (↓ indicates 
worse performance). Note, mRNAs are expressed in Italics, whereas proteins are 
Capitalized. 
Several studies have attributed this comorbidity between hypoxia-associated 
conditions and AD to a more pro-amyloidogenic AβPP processing that culminates 
in increased Aβ accumulation through a number of mechanisms. However, the 
methodological approaches conducted in these studies were based on in vitro 
models, hypoxia/reoxygenation repetitive cycles, hypobaric chambers, or even 
asphyxiation strategies (Table 1), what can explain the disparity of the results 
obtained (Chen et al., 2003; Guglielmotto et al., 2009; Li et al., 2009; Sun et al., 
2006; Zhang et al., 2013). Therefore, there is a lack of investigations addressing 
pure hypoxia contribution to AβPP processing and Aβ dynamics in vivo under fine-
controlled conditions. 
2.2. Hypoxia 
2.2.1. Hypoxia and response mechanisms 
Aerobic organisms require an appropriate oxygen (O2) supply to maintain 
systemic and cellular homeostasis. O2 serves as a substrate for enzymatic activities 
in signaling pathways and remarkably, constitutes the final electron acceptor in 
the mitochondrial respiratory chain after oxidative phosphorylation, the main 
source of energy in form of adenosine triphosphate (ATP) in aerobic organisms. 
Hypoxia occurs when cell O2 requirements exceed O2 delivery from blood, a 
situation that takes place under physiological and pathological scenarios.  In this 
sense, hypoxic situations are associated to high altitude climbing, many 
developmental processes, and specific regions of some organs, like the intestinal 
epithelium (Colgan & Taylor, 2010; Grocott et al., 2009; Semenza, 2012). Even 
transient or local hypoxemia may result in irreversible damage to cells and tissues, 
as exemplified by devastating consequences of stroke, myocardial infarction or 
chronic lung disease. Hence, living organisms exhibit acute and chronic 
adaptations to minimize the consequences of O2 insufficiency. 
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In response to acute hypoxia, various mechanisms sense O2 decrease and elaborate 
responses to recover O2 levels to the normal range. The carotid bodies recognize 
acute hypoxemic conditions and activate respiratory (hyperventilation) and 
cardiovascular (cardiac output increase) responses to recover O2 levels (Lopez-
Barneo et al., 2001). Other fast-responding mechanisms involve neuroepithelial 
bodies and smooth muscle cells from the pulmonary artery. Smooth muscle cells 
contract the lumen of the vessels of hypoxic regions in the lung to redistribute 
blood perfusion to oxygenated areas, while dilate peripheral arteries dilate to favor 
O2 delivery into tissues (Franco-Obregón & López-Barneo, 1996; Weir & Archer, 
1995). In the bronchiolar epithelium, neuroepithelial bodies can send information 
on hypoxic stimuli to the central nervous system (CNS) (Liu et al., 2014).  
Unlike the fast acute hypoxia response systems, the adaptive mechanisms to 
trigger chronic hypoxia responses take from hours to days. Chronic hypoxia 
involves hypoxia-inducible factors (HIF)s stabilization, transcription factors that 
orchestrate complex responses in all metazoan species to enhance O2 supply to 
cells and adapt cell physiology to low O2 tensions (Kaelin & Ratcliffe, 2008). 
2.2.2. HIF pathway and its regulation 
HIF proteins are heterodimeric transcription factors composed of a constitutive 
transcribed HIF1β subunit, also known as ARNT, and an α subunit (HIFα) that is 
unstable in normoxic conditions. Upon α/β dimerization and association to p300 
and CBP co-activator proteins, HIF induces the transcription of lots of different 
genes after binding to DNA regions called hypoxia-response elements (HRE)s. One 
of the main consequences of HIF transcriptional activation is the shift from a 
respiratory to a glycolytic metabolism in order to guarantee energy supply in 
hypoxic conditions. However, many other physiological responses are induced like 
angiogenesis or erythrocytosis (Kaelin & Ratcliffe, 2008; Schofield & Ratcliffe, 
2004; Semenza, 2012). Although three HIFα subunits have been described, HIF1α 
and HIF2α are the most extensively studied. While HIF1α is ubiquitously 
expressed, HIF2α presence is more restricted to certain cell types and tissues and 
in vivo studies have attributed specific physiological functions for HIF2α (Patel & 
Simon, 2008). 
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Two major post-translational mechanisms are implicated in the regulation of HIFα 
by affecting both HIFα protein stability and transcriptional activity (Figure 2). 
   
Figure 2. Regulation of Hypoxia-inducible factor (HIF) protein stability and 
transcriptional activity by oxygen (O2) (Schofield & Ratcliffe, 2004).   
In the presence of O2, prolyl-hydroxylases (PHDs) hydroxylate HIFα, marking it for 
proteosomal degradation via von Hippel-Lindau (VHL) ubiquitination. Moreover, 
factor inhibiting HIF (FIH) hydroxylates HIF preventing its transcriptional activity. 
Conversely, in low O2 conditions, HIF activates transcription of its target genes since 
hydroxylases are inactive. Pro, proline; Asn, asparagine. 
Different members of the prolyl 4-hydroxylase domain (PHD) family, encoded by 
Egln genes, are the most important regulatory elements of HIFα. In normoxia, 
these proteins hydroxylate one or two highly conserved proline residues of HIFα, 
what generates a binding site for the von Hippel-Lindau tumor suppressor protein 
(VHL), a component of a ubiquitin ligase complex. Consequently, hydroxylated 
HIFα becomes polyubiquitinated and therefore, targeted for proteasomal 
degradation. PHD1, PHD2, and PHD3 are the most studied members of PHD 
families. All of them catalyze O2-dependent hydroxylation of HIFα by using 2-
oxoglutarate as a co-substrate, splitting carbon dioxide (CO2) and succinate after 
the enzymatic prolyl-hydroxylation. Hence, they become inactive in hypoxia due to 
the reduction in O2 levels. The different PHD members are ubiquitously expressed, 
although certain tissue-dependent expression and different intracellular 
localizations are reported (Kaelin, 2005; Metzen et al., 2003). PHD functions are 
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not fully redundant. As an example, PHD2 constitutes the main HIF1α steady-state 
low levels controller in normoxia (Berra et al., 2003). Importantly, Egln1 and Egln3 
genes, respectively encoding for PHD2 and PHD3, are target genes of HIFα, so a 
negative feedback loop exists between HIFα stabilization and PHD2 and PHD3 
induction (del Peso et al., 2003; Ginouves et al., 2008). The second major check-
point preventing HIFα transcriptional induction under normoxia is exerted by the 
factor inhibiting HIF (FIH). This enzyme hydroxylates a specific asparaginyl 
residue within HIFα that prevents its binding with p300 and CBP transcriptional 
co-activators. Hence, its hydroxylase activity is also prevented by lack of O2 in 
hypoxia (Schofield & Ratcliffe, 2004).  
2.2.3. HIF pathway and inflammatory innate immune 
response 
A close bi-directional relationship exists between hypoxia and inflammation. On 
the one hand, a growing body of evidence demonstrates that hypoxia can trigger 
inflammation. That is the case of high altitude conditions, which lead to increased 
inflammatory cytokines load in the bloodstream and can provoke pulmonary and 
cerebral edema. Moreover, ischemia produced during organ transplantation 
results in organ inflammation and increases draft rejection. Also, enlarged 
adipocytes attract macrophages as they lack appropriate O2 supply. On the other 
hand, inflamed lesions tend to turn hypoxic often due to an increased metabolic 
demand and a reduction in metabolites supply due to vasculopathy, as is the case 
of acute lung injury, intestinal inflammation or pathogen infections (Eltzschig & 
Carmeliet, 2011). Importantly, hypoxia during inflammation is nowadays 
considered a remarkable regulator of the immune response, since many immune 
cells migrate from oxygenated areas to hypoxic inflamed regions to exert their 
function (Cramer et al., 2003). Indeed, it has even been proposed that HIF1α 
involvement in immune response constitutes a control system that ensures 
enhanced inflammatory activities only in hypoxic required locations (Zinkernagel 
et al., 2007). 
Two central transcription factors are intimately related in the cross-talk between 
hypoxia and inflammation, HIFα and the nuclear factor-kappaB (NF-κB). IKK 
complex activation signaling involves the expression of anti-apoptotic genes via 
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NF-κB. It is believed that hypoxia can activate IKK complex, with a mechanism 
involving PHDs and FIH, to exert a pro-survival effect on immune cells under 
hypoxic conditions (Cummins et al., 2006; Eltzschig & Carmeliet, 2011). At the 
same time, hypoxia also enhances NF-κB-mediated cytokine production and cell 
adhesion. HIF1α transcriptional activity also promotes NF-κB amplification by 
inducing toll-like receptor (Tlr) 2 and Tlr6 mRNA, upstream activators of NF-κB 
signaling (Kuhlicke et al., 2007). Accordingly, NF-κB signaling increases Hif1a 
mRNA levels, both upon non-hypoxic stimulation and in basal conditions, what 
demonstrates the synergistic cooperation between HIF and NF-κB pathways (Rius 
et al., 2008; Taylor, 2008; Uden et al., 2008). Some pro-inflammatory factors like 
the cytokines tumor necrosis factor α (TNFα) or interleukin-1β (IL-1β) can induce 
HIF1α accumulation through NF-κB-dependent mechanisms in normoxia without 
altering Hif1a mRNA expression levels (Jung et al., 2003; Zhou et al., 2003). Also, 
reactive O2 species (ROS) promote HIF1α accumulation by different mechanisms. 
Thus, considering the intricate molecular relationships between hypoxia and 
inflammatory response, and taking into account that consequences of 
inflammatory and hypoxic responses are highly cell-type dependent, further 
investigations will be needed to fully clarify this cross-talk (Palazon et al., 2014; 
Taylor, 2008).  
Many physiological responses of innate immunity, the first barrier of defense to 
confront infections, are extremely affected by hypoxia (Harris et al., 2014). The 
most preponderant cells in innate immunity are neutrophils, monocytes, and 
macrophages. Neutrophils and monocytes are bone marrow-derived phagocytes 
that constantly patrol the bloodstream looking for any inflammation, damage or 
infection clues. In contrast, macrophages are tissue-resident phagocytes of 
embryonic origin with self-renewal capacity that respond to local tissue stimuli 
(Guilliams et al., 2014). All these phagocytes migrate to hypoxic foci of 
inflammation, damage, and infection within tissues following a chemotactic 
gradient and rapidly adapting to decreasing local O2 tensions. This adaptation 
entails a profound metabolic reprogramming towards an anaerobic ATP 
generation via glycolysis mediated by HIF1α (G L Semenza et al., 1994; Zinkernagel 
et al., 2007). Importantly, not only HIF pathway plays a role in energy production, 
but also regulates many other aspects of immune response and increasing 
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evidence suggests that energy metabolism and immune responses are intertwined 
events (Riboldi et al., 2013). 
Our knowledge on the processes regulated by HIF pathway in innate immunity has 
substantially increased with the implementation of conditional specific myeloid 
knock-out mice. Importantly, myeloid-specific deletion of Hif1a with lysMCre does 
not alter the number of circulatory neutrophils or monocytes (Cramer et al., 2003). 
However, other profound alterations are observed in these cells upon HIFα/PHD 
deficiency or accumulation models. 
Remarkable insights have been performed in neutrophils function regarding HIF 
pathway by using conditional knock-out specific models. Notable data are 
provided by Walsmley et al., who described that hypoxia has a pro-survival effect 
mediated by PHD3, involving NF-κB activity and delaying inflammatory resolution 
(Walmsley et al., 2005, 2011). However, for a comprehensive purpose regarding 
this thesis, we will focus on innate immune response to hypoxia in macrophages 
and monocyte-derived macrophages (MDM). 
2.2.4. HIF pathway and macrophages 
Tissue-resident macrophages and monocytes are attracted by chemotactic agents 
emerging from inflamed areas like infectious foci, ischemic areas, chronically 
inflamed regions, wound healings, solid tumors, etc., in which O2 tension is 
substantially lower than in the bloodstream and surrounding local areas. Once 
these cells encounter the hypoxic foci, they stop migration due to hypoxia signaling 
and acquire different functional phenotypes; indeed, monocytes differentiate into 
MDM (Strehl et al., 2014). As previously mentioned, one of the most important 
adaptations is a profound metabolic shift towards a glycolysis-based ATP 
production, with further consequences for immune response. In fact, a more 
glycolytic phenotype is associated with a stronger pro-inflammatory macrophage 
activation while a decreased glycolytic rate correlates with less pro-inflammatory 
macrophages (Haschemi et al., 2012).  
HIF1α deficiency results in decreased motility, aggregation and invasion of 
infected areas. Moreover, killing capacity of this macrophages after phagocytosis is 
also reduced (Cramer et al., 2003). Conversely, Vhl-conditional deletion in 
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macrophages and MDM enhances antibactericidal activities by increasing nitric 
oxide (NO), an antimicrobial compound, and TNF-α production (Peyssonnaux et al., 
2005). In this sense, it has been described that HIFα stabilization in MDM and 
monocytes also occur in solid tumors, highly hypoxic cell aggregates. Tumor cells 
accumulate HIF1α and as a result, produce macrophage and monocyte 
chemoattractants like VEGF, endothelins or semaphorins, which promote their 
migration towards these tumors (Casazza et al., 2013; Grimshaw et al., 2002; Leek 
et al., 2000; Palazon et al., 2014). Once recruited in the tumor, the hypoxic 
environment turns them into HI1α-mediated angiogenesis promoters, what has 
detrimental outcomes like tumor growth (Riboldi et al., 2013). 
Different genetic loss-of-function studies have recently revealed that specific PHDs 
exert non-redundant in vivo functions in macrophages (Kiss et al., 2012). PHD3 
constitutes an important regulator of the immune response in macrophages, 
although controversial findings have been proposed regarding this protein in 
macrophage physiology. In response to abdominal sepsis, PHD3-deficient 
macrophages differentiate into potent pro-inflammatory cells and elaborate an 
overwhelming response mediated by HIF1α and NF-κB, with detrimental 
outcomes (Kiss et al., 2012). However, a different study associated pro-
inflammatory macrophage phenotype with PHD3 accumulation in tissues 
undergoing inflammatory responses and tumors (Escribese et al., 2012). Thus, 
further studies would be needed to unveil the contribution of PHD3 to macrophage 
activation in different scenarios and macrophage populations. 
2.3. Microglia 
2.3.1. Origin and functions 
Microglia are the tissue-resident macrophages of the CNS. These cells originate 
from erythromyeloid progenitors in the yolk sac that migrate and populate the CNS 
parenchyma prior to its vasculogenesis, where they are maintained by self-renewal 
under steady-state conditions, autoimmune disorders and degenerative conditions 
(Ginhoux et al., 2010; Nayak et al., 2014). 
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They were first described by Rio-Hortega in 1919 as very plastic cells in 
morphological terms, something that we now know is closely related to their 
enormous functional versatility (Rio-Hortega, 1919). In basal conditions, they 
present a relatively small soma with their nucleus surrounded by a narrow 
cytoplasmic halo that projects a number of fine ramified processes. Microglia in 
this “surveying” state are permanently monitoring their local environment, 
contracting and extending their branches, as demonstrated with in vivo imaging 
technologies (Nimmerjahn et al., 2005). These phagocytes take part in a number of 
processes aimed at conserving CNS homeostasis. Their varied homeostatic 
functions include neurotrophism, synaptic pruning, neuronal apoptosis during 
brain development, and cleanup of debris (Nayak et al., 2014). 
Transformation of microglial morphology occurs upon detection of homeostasis 
disturbance. Morphological changes usually include a larger cell body with 
retracted processes and involve further phenotypic and functional modifications. 
The alteration of functional microglial status is considered as microglial activation, 
which occurs in many different conditions like parenchymal injury, infection, 
neurodegenerative disorders, etc. In these conditions, microglia exhibit a vast 
array of functional responses to confront any potential insult (Figure 3) (Lucin & 
Wyss-Coray, 2009). Importantly, however, detrimental and beneficial outcomes 
are attributed to microglial activation in different conditions, what reveals the 
potential therapeutic targeting of these cells (Nayak et al., 2014; Ransohoff & 
Perry, 2009). For the objectives postulated in this thesis below, we will focus on 
microglial responses to AD. 
2.3.2. Microglia in AD 
As previously described, microglial activation is a prominent feature of AD. Upon 
amyloid deposition, microglia migrate towards amyloid plaques and surround 
them, extending projections that interact with amyloid plaques (Itagaki et al., 
1989; Serrano-Pozo et al., 2011; Serrano-Pozo et al., 2013).  These processes entail 
deep transcriptional readjustments that are highly influenced by microglia 
proximity to amyloid plaques and even give rise to particular microglial subtypes 
(Keren-Shaul et al., 2017).  
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Figure 3. Microglia/Macrophage regulation within the central nervous system 
(CNS) (Lucin & Wyss-Coray, 2009).  
Microglia/macrophages are activated following the stimulation of a number or 
recognition and phagocytic receptors. The outcome of this activation is regulated by 
signals also integrated by microglia/macrophages, originated from neurons and 
other cell types. As a result, different responses are promoted like the release of pro-
inflammatory or growth factors. ADP/ATP, adenosine di/triphosphate; AGE, 
advanced glycation end product; BDNF, brain-derived neurotrophic factor; EGF, 
epidermal growth factor; GABA, gamma-aminobutyric acid; H2O2, hydrogen 
peroxide; HMGB1, high-mobility group box 1; IL-1β, interleukin 1 β; LPS, 
lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; MCSF, macrophage 
colony-stimulating factor; NGF, nerve growth factor; NO, nitric oxide; NOO-, 
peroxynitrite; NT-3,4, neurotrophin- 3,4; O2-, superoxide; PACAP, pituitary adenylate 
cyclase-activating peptide; PS, phosphatidylserine; RAGE, receptor for advanced 
glycation end products; RANTES, regulated upon activation, normal T cell expressed 
and secreted; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TNFα, 
tumor necrosis factor-α; TREM2, triggering receptor expressed by myeloid cells-2; 
UDP/UTP, uridine di/triphosphate.  
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Analysis of genetic risk factors correlating with sAD has placed microglia in the 
spotlight of intense research. GWAS with patient samples have revealed that 
polymorphisms in genes with prominent or exclusive functions in microglia are 
related to AD. These polymorphisms are implicated in varied functional modules 
like lipid transport, endolysosomal functioning, and microglial migration and 
phagocytosis, among others (Pimenova et al., 2018). However, the outcome of 
these functional modules in AD provokes intense controversy because lots of 
literature attributes beneficial, inconsequential or even detrimental effects to these 
modules. It has been described that migration and microglial surrounding activity 
of amyloid plaques isolates neurons physically from direct contact with the Aβ 
contained in the plaques, preventing neuronal toxicity (Condello et al., 2015; Yuan 
et al., 2016). Moreover, microglial uptake of Aβ is involved in Aβ clearance, which 
associates with a better outcome for AD (Lee & Landreth, 2010). However, 
exacerbated microglial inflammatory responses can lead to the production of toxic 
factors harmful to neurons and promote uncontrolled synapse engulfment 
(Hansen et al., 2018). Therefore, microglia must exert a relevant role in AD and 
their activation and functional phenotype must be tightly controlled. 
2.3.3. Microglia in hypoxia and AD 
Given the comorbidity between hypoxia and AD, the importance of microglia 
response in AD, and the prominent role of hypoxia in the modulation of innate 
immunity, our laboratory postulated to define the transcriptional changes 
underlying microglia response to hypoxia. We exposed microglial primary cultures 
to 1 % or 21 % O2 for 6 h and analyzed microglial expression profile by 
microarrays. Then, we defined the Hypoxia-induced Microglia Signature (HMS), 
containing the up-regulated genes in hypoxia (p < 0.01 and logFC >0.5) (Figure 4, 
A). In order to test the relevance of hypoxic microglial response in the microglia 
from AD mouse models, we performed Gene Set Enrichment Analyses (GSEA) with 
microarray data publicly available of isolated adult microglia from old App-Psen1 
mice, an AD mouse model, isolated by Fluorescence-Activated Cell Sorting (FACS) 
(Orre et al., 2014). A prominent overrepresentation of HMS was found in the 
microglia of this AD mouse model, suggesting a highly hypoxic expression pattern 
in these microglia (Figure 4, B). In order to test in vivo HMS dependence on HIF1α, 
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microglial specific conditional deletion of Hif1a gene upon tamoxifen treatment 
was performed in 12-month-old Cx3cr1-Cre::ERT2; Hif1a Flox/Flox; App-Psen1 mice. 
Transcriptional analysis by reverse transcription real-time polymerase chain 
reaction (qRT-PCR) confirmed a drastic reduction in the levels of Hif1a mRNA and 
a corresponding reduction in representative HMS-related genes, including a partial 
but statistically significant reduction of Egln3 mRNA levels (Figure 5) 
(Unpublished data). 
 
Figure 4. Hypoxia-induced Microglia Signature (HMS) is over-represented in 
App-Psen1 mice (unpublished data). 
Microglial primary cultures of CD-1 mice were submitted to hypoxia (1 % O2) or 
normoxia (21 % O2) for 6 h and mRNA expression profile was analyzed by 
microarray. (A) Volcano plot showing Hypoxia-induced Microglia Signature (HMS)-
contained genes (p < 0.01, LogFC > 0.5). (B)  HMS enrichment in the global gene 
expression changes observed in adult microglia from 15 to 18-month-old App-Psen1 
(AD) versus wild-type (WT) mice (Orre et al., 2014) using Gene Set Enrichment 
Analysis (GSEA) (left panel). Centre panel shows the heat map of the top 30 ranking 
leading edge genes included in the HMS. Red symbolizes up-regulation and blue, 
down-regulation. 
Importantly, the most induced gene coincident in both microglia exposed to 
hypoxia (Figure 4, B, list of genes) and the microglia from App-Psen1 mice is 
Egln3 (Orre et al., 2014). This suggests a potentially relevant function for PHD3 in 
AD microglia. 
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Figure 5. Hypoxia-induced Microglia Signature (HMS) expression in vivo is 
dependent on Hypoxia-inducible factor-1 α (HIF-1α) in App-Psen1 mice 
(unpublished data). 
Adult microglia were isolated using fluorescence-activated cell sorting (FACS) from 
12-month-old Cx3cr1-Cre::ERT2; Hif1a Flox/Flox; App-Psen1 mice treated with vehicle 
(C) or tamoxifen (T; 30 d; magenta) (left panel). Hif1a mRNA levels (left) from wild-
type (WT) Cx3cr1-Cre::ERT2; Hif1a Flox/Flox; App-Psen1 mice were quantified by 
reverse transcription real-time polymerase chain reaction (qRT-PCR) (n = 4 – 5 
mice; ** p < 0.01; *** p < 0.001; Mann Whitney’s test). Egln3, Ero1l, Mxi1 and Bhlhe40 
mRNA levels were estimated in microglia isolated from 12-month-old Cx3cr1-
Cre::ERT2; Hif1a Flox/Flox; App-Psen1 mice treated with vehicle (C; grey) or tamoxifen 
(T; 30 d; magenta) using qRT-PCR. Hmbs was used as housekeeping control (n = 4 – 
5 mice; * p < 0.05; *** p < 0.001; Mann Whitney’s test for Egln3 and Bhlhe40; 
Student’s t-test for Ero1l and Mxi1). 
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3. Objectives 
1. Investigating the in vivo effects of acute and chronic sustained hypoxia on 
AβPP production and processing and on Aβ degradation. 
2. Characterizing the role of PHD3 in AD, with especial focus on microglia 
responses. 
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4. Results 
In order to facilitate a comprehensive and conceptual organization, the results 
section is presented according to the objectives. 
4.1. Objective 1: Hypoxia on AβPP 
processing 
4.1.1. Validation of hypoxic treatments  
As stated in the introduction, previous studies had explained the comorbidity 
between hypoxia and AD based on hypoxia-mediated up-regulation of AβPP 
protein levels, Aβ-producing enzymes, and/or down-regulation of Aβ-degrading 
enzymes, which implies a potentiation of the amyloidogenic processing of AβPP 
protein. As a result, Aβ accumulation is promoted, giving rise to a 
neurodegenerative cascade that leads to synaptic dysfunction, formation of NFTs 
and neuronal death (Hardy et al., 2002; Shankar & Walsh, 2009). These studies had 
used different strategies including hypoxia and reoxygenation cycles, in vitro 
models or asphyxiation methods, among others (Table 1) (Chen et al., 2003; 
Guglielmotto et al., 2009; Li et al., 2009; Sun et al., 2006; Zhang et al., 2013). In 
order to elucidate in vivo pure hypoxia-mediated modifications on AβPP 
protein synthesis, processing or Aβ accumulation, we utilized hermetic chambers 
where O2, CO2, and humidity levels were strictly controlled along the entire 
exposition. On the other hand, we used acute sustained hypoxia (ASH) and chronic 
sustained hypoxia (CSH) protocols to allow a more reliably mimicking of some 
hypoxic conditions epidemiologically linked to AD, like stroke or COPD. 
For this purpose, mice were exposed to 9 % O2 uninterruptedly, through 
automated control by the hypoxia chamber, for different periods of time. ASH 
treatment corresponded to incubation of mice for 4 or 16 h (Figure 6, A). On the 
other hand, CSH was achieved by exposing mice to 21 or 30 d to this same O2 
tension (Figure 6, A). Our approach induced pure hypoxemia, reducing O2 
saturation and PaO2, without provoking hypercapnia or acidosis (D’Anglemont de 
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Tassigny et al., 2015), which are associated to further consequences like increased 
pulmonary hypertension and edema (Howell et al., 2004). 
 Figure 6. Hypoxia protocols and validation of hypoxic response.  
(A) Schematic of acute (up, ASH) and chronic (down, ACH) sustained hypoxia 
protocols used in this study. White arrowheads represent reoxygenation (21 % 
oxygen (O2)) for 24 h. (B) Up, western blot (WB) for hypoxia-inducible factor-1α 
(HIF1α) in brain extracts from 2–3 month-old wild-type mice subjected to normoxia 
(N) (21 % O2, 16 h) or ASH (H) (9 % O2) for either 4 h or 16 h. Down, quantification 
of HIF1α WB (N, black bar; ASH for 4 h, grey bar; ASH for 16 h, white bar). * p < 0.05; 
Kruskal-Wallis ANOVA with Dunn’s multiple comparison test, n = 3 per group. (C) 
Vascular endothelial growth factor (Vegfa) mRNA levels measured by reverse 
transcription real-time polymerase chain reaction (qRT-PCR) in 2–3 month-old wild-
type mice in N (21 % O2, black bar) for 16 h, after ASH (H, 9 % O2, 16 h, grey bar) and 
ASH followed by N (H+N, reoxygenation, white bar) for 24 h. 18S mRNA was used as 
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housekeeping control. * p < 0.05; Kruskal-Wallis ANOVA with Dunn’s multiple 
comparison test, n = 4 per group. (D) Vegfa mRNA levels measured by qRT-PCR in 2–
3 month-old wild-type mice in N (21 % O2, black bar) for 21 d, after CSH (H, 9 % O2, 
21 d, grey bar) and CSH followed by N (H+N, reoxygenation, white bar) for 24 h. 18S 
mRNA was used as housekeeping control. * p < 0.05; Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test, n = 4 per group. (E) VEGF protein levels were 
measured by ELISA in 2–3 month-old wild-type mice subjected to either CSH (H, 9 % 
O2, 30 d,) or N (21 % O2, 30 d) within the same chamber. Mann-Whitney U test, n = 4 
per group. (B-E) Bars ± error bars represent mean ± s.e.m. α-tub, α-tubulin 
In order to validate the triggering of hypoxia responses under the ASH protocol, we 
obtained hemibrain extracts of wild-type C57/BI6J mice after ASH treatment and 
analyzed HIF1α protein levels by western blot (WB) and vascular endothelial 
growth factor gene (Vegfa) induction by qRT-PCR, since it is a well-described 
HIF1α target gene whose expression is up-regulated by hypoxia (Forsythe et al., 
1996; Shima et al., 1995). HIF1α content was significantly increased after 4 h of 
ASH and a non-significant increment, probably due to negative feedback loop 
exerted by PHDs (Ginouves et al., 2008), was observed after 16 h, regarding 
control littermate mice exposed to 21 % O2 in the same chamber for the same 
period of time (Figure 6, B). ASH treatment for 16 h also induced a 5-fold 
induction of Vegfa mRNA levels that was completely reverted after 24 h of 
reoxygenation (21 % O2), in comparison with control littermates exposed to 21 % 
O2 (Figure 6, C). The effects of CSH were also evaluated using a similar approach in 
hemibrain extracts from wild-type C57/BI6J mice. After 21 d of hypoxia, Vegfa 
mRNA amount showed a trend to increase that became statistically significant due 
to the slight increment after 24 h in normoxia, highlighting that 24 h of 21 % O2 is 
insufficient to recover Vegfa mRNA expression levels to basal normoxic conditions 
(Figure 6, D). VEGF protein amount was non-significantly increased after 30 d in 
hypoxic conditions with respect to normoxic treatment, something that we 
measured by ELISA (Figure 6, E). Altogether, these results indicate that a hypoxic 
program is activated in wild-type mice, elicited by our ASH and CSH protocols.  
4.1.2. ASH does not affect the mRNA levels of Aβ-related 
genes in wild-type mice 
Aβ accumulation occurs upon imbalance between production and clearance 
systems (Tarasoff-Conway et al., 2015). AβPP accumulation and subsequent 
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processing towards a more amyloidogenic pathway or reduced transcription rates 
of genes encoding for Aβ-degrading enzymes can break this balance, favoring Aβ 
accumulation. In order to test a possible role of ASH in the regulation of App gene, 
genes involved in α-cleavage (Adam9, Adam10, and Adam17/Tace), β-cleavage 
(Bace1), and ɣ-cleavage (Psen1, Psen2, Ncstn, Pen2, Aph1a, and Aph1b-c) and genes 
encoding for Aβ-degrading enzymes (Bace2, Ide, and Mme) referred to as Aβ-
related genes, we exposed wild-type C57/BI6J mice to 16 h of maintained hypoxia 
(9 % O2) followed or not by reoxygenation (24 h, 21 % O2) and analyzed the 
expression of the Aβ-related genes in hemibrain extracts by qRT-PCR regarding 
normoxia conditions in the same chambers. We used the subsequent renormoxia 
treatment in order to reveal any changes that could be attributed to reoxygenation 
rather than to pure hypoxemia per se.  
App gene transcriptional activity was not altered in this context regarding 
normoxic conditions either under 16 h of ASH or after 24 h of reoxygenation, 
ruling out the possibility that an increased transcription of AβPP-encoding gene 
could eventually lead to an augmented Aβ accumulation (Figure 7, A). Then, we 
analyzed the expression of genes encoding for enzymes with α-secretase activity, 
which promote a non-amyloidogenic processing of AβPP protein by cleavage 
within Aβ itself. No differences between ASH and normoxia, before and after 
reoxygenation, were observed in the expression of Adam9, Adam10 or 
Adam17/Tace genes (Figure 7, B-D). On the other hand, many studies provide 
convincing evidence that place BACE1 protein as the main enzyme mediating β-
secretase cleavage, the rate-limiting factor in Aβ production from AβPP protein 
(Cai et al., 2001; Vassar et al., 1999; Yan et al., 1999). Hence, we measured mRNA 
levels of Bace1 gene and found no differences in hypoxia or after reoxygenation 
regarding normoxia (Figure 7, E). As up-regulation of genes encoding for ɣ-
secretase complex components has correlated with increased Aβ levels (Li et al., 
2009; Liu et al., 2016; Smith et al., 2004), we analyzed the expression of genes 
encoding for the main components of the ɣ-secretase complex. Except for a 
significant mild induction of Psen1 gene registered in reoxygenation after hypoxia 
versus normoxia, our results exhibited the same mRNA levels for Psen1, Psen2, 
Ncstn, Pen2, Aph1a, and Aph1b-c genes (Figure 7, F-K) in ASH, before and after 
reoxygenation, and normoxia. Finally, we discarded changes in the transcription of 
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the genes Bace2, Ide, and Mme in response to our ASH protocol (Figure 7, L-N). 
These results demonstrate that ASH for 16 h is not impacting on the transcription 
of genes encoding for the Aβ-related proteins, implicated in Aβ accumulation from 
AβPP processing and degradation. 
Figure 7. Aβ-related genes mRNA levels are not modified by acute sustained 
hypoxia (ASH) in wild-type mice. 
Relative mRNA levels of genes encoding for amyloid-β precursor protein (AβPP) (A), 
the α-secretases from A disintegrin and metalloprotease (ADAM) family ADAM9 (B), 
- 36 - 
ADAM10 (C) and ADAM17/TACE (D), β-secretase BACE1 (E), all the components of 
ɣ-secretase complex presenilin (PS)1 (F), PS2 (G), nicastrin (H), PS enhancer (Pen)2 
(I), anterior pharynx defective (APH)1a (J) and APH1b-c (K), and the Aβ-degrading 
enzymes BACE2 (L), insulin-degrading enzyme (IDE) (M) and neprilysin (N) were 
estimated by reverse transcription real-time polymerase chain reaction (qRT-PCR) 
in brains from 2-3 month-old wild-type mice subjected to normoxia (N, 21 % oxygen 
(O2), black bars) for 16 h or ASH (H, 9 % O2, 16 h, grey bars), followed or not by N 
(H+N, reoxygenation, white bars) for 24 h, within the same chamber. 18S was used 
as housekeeping control. * p < 0.05, Kruskal-Wallis ANOVA with Dunn’s multiple 
comparison test, n = 4 per group. (A-N) Bars ± error bars represent mean ± s.e.m. 
4.1.3. CSH does not modify the mRNA levels of Aβ-related 
genes in wild-type mice 
Given that ASH did not alter the transcriptional response of Aβ-related genes in 
wild-type mice, we tested whether a longer hypoxia exposition could affect the 
mRNA levels of Aβ-related genes. For this purpose, we used a CSH approach that 
consisted on submitting wild-type C57/BI6J mice to hypoxia (9 % O2) for 21 d, 
followed or not by reoxygenation (21 % O2, 24 h). We also exposed wild-type 
C57/BI6J mice to normoxic conditions (21 % O2) for the same period of time and 
within the same hypoxia chambers in order to arrange an appropriate control 
group. We extracted mRNA content from the mouse brains within the chambers 
and analyzed mRNA levels of Aβ-related enzymes by qRT-PCR. Very similarly to 
transcriptional responses exhibited after ASH, non-statistically significant 
differences in the expression pattern or mRNA stability of any of the analyzed 
genes were detected, either under hypoxia or after reoxygenation in comparison 
with normoxia (Figure 8), except for App gene, whose induction was identified 
after reoxygenation (Figure 8, A). These results show that our previously 
validated CSH protocol for 21 d is not affecting the transcriptional activity or 
mRNA stability of genes encoding for the main proteins implicated in Aβ 
generation and degradation in wild-type mice.  
Altogether, ASH and CSH results suggest that no transcriptional shift from a 
preponderant non-amyloidogenic AβPP processing to an elevated amyloidogenic 
AβPP processing is promoted by hypoxia in wild-type mice. 
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Figure 8. Aβ-related genes mRNA levels are not modified by chronic sustained 
hypoxia (CSH) in wild-type mice. 
Relative mRNA levels of genes encoding for amyloid-β precursor protein (AβPP) (A), 
the α-secretases from a disintegrin and metalloprotease (ADAM) family ADAM9 (B), 
ADAM10 (C) and ADAM17/TACE (D), β-secretase BACE1 (E), all the components of 
ɣ-secretase complex presenilin (PS)1 (F), PS2 (G), nicastrin (H), PS enhancer (Pen)2 
(I), anterior pharynx defective (APH)1a (J) and APH1b-c (K), and the Aβ-degrading 
enzymes BACE2 (L), insulin-degrading enzyme (IDE) (M) and neprilysin (N) were 
estimated by reverse transcription real-time polymerase chain reaction (qRT-PCR) 
in brains from 2-3 month-old wild-type mice subjected to normoxia (N, 21 % oxygen 
(O2), black bars) for 21 d or CSH (H, 9 % O2, 21 d, grey bars), followed or not by N 
- 38 - 
(H+N, reoxygenation, white bars) for 24 h, within the same chamber. 18S was used 
as housekeeping control. * p < 0.05, Kruskal-Wallis ANOVA with Dunn’s multiple 
comparison test, n = 4 for normoxia group and n = 5 for the two hypoxia groups. (A-
N) Bars ± error bars represent mean ± s.e.m. 
4.1.4. AβPP processing is not changed by either ASH or CSH 
Although we did not observe any alteration in the mRNA levels of Aβ-related 
genes, it was still possible that ASH or CSH could affect protein levels of AβPP 
processing by-products and relevant enzymes. We analyzed the amount of the 
rate-limiting enzyme in Aβ generation BACE1 and AβPP protein levels in 
hemibrain extracts of wild-type C57/BI6J mice exposed to ASH (for 4 h or 16 h) or 
CSH (for 30 days). BACE1 protein had been described to increase in response to 
acute insults like ischemia and energy deprivation (O’Connor et al., 2008; Tesco et 
al., 2007), something also reported by several in vivo and in vitro studies 
(Guglielmotto et al., 2009; Liu et al., 2016; Moussavi et al., 2012; Sun et al., 2006; 
Zhang et al., 2007). BACE1 amount remained unchanged after 4 h or 30 d of 
hypoxia (9 % O2) versus normoxia (21 % O2) by Western blot (WB) (Figure 9, A). 
However, unlike previous studies, it not only did not accumulate but significantly 
decreased after 16 h hypoxic treatment (Figure 9, A). On the other hand, AβPP 
protein levels measured by WB were not modified after 4 h, 16 h or 30 d of hypoxic 
treatment (Figure 9, B).  
Although these results do not suggest a pro-amyloidogenic function either for ASH 
or CSH, we tried to measure Aβ peptides by ELISA in order to discard other 
potential factors that could be contributing to its accumulation. Unfortunately, Aβ 
peptides levels in wild-type mice were under the minimum threshold for detection 
with ELISA, so we decided to analyze the ratio between C99 and C83 by WB since 
an increased ratio indicates a pro-amyloidogenic AβPP processing. In the 
comparison of ASH or CSH with normoxia, no differences were exhibited in 
C99/C83 ratio (Figure 9, C). As a control, we estimated the C99/C83 ratio in App-
Psen1 mice (Figure 9, C). These data strongly support an inconsequential effect of 
ASH or CSH in Aβ accumulation regarding AβPP production, processing, and 
degradation in wild-type mice. 
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Figure 9. Neither acute sustained hypoxia (ASH) nor chronic sustained hypoxia 
(CSH) alter amyloid-β precursor protein (AβPP) processing.  
(A) BACE1 protein levels were measured by western blot (WB) in the brains of 2–3 
month-old wild-type mice subjected to ASH (H 4 h or 16 h, 9 % oxygen (O2)), CSH (H 
30 d, 9 % O2), or normoxia (N 4 h, 16 h or 30 d, 21 % O2) for the corresponding 
period of time within the same chamber. Right bar graphs depict the quantification 
of WBs using pan-cadherin (Pan-cad) as loading control (normoxia, N, black bars; 
hypoxia, H, grey bars). * p < 0.05, Mann-Whitney U test, n = 4 per group. (B) Levels of 
full-length AβPP (FL-AβPP) were measured by WB in the brains of 2–3 month-old 
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wild-type mice subjected to ASH (H 4 h or 16 h, 9 % O2), CSH (H 30 d, 9 % O2), or 
normoxia (N 4h, 16 h or 30 d, 21 % O2) for the corresponding period of time within 
the same chamber. Right bar graphs depict the quantification of WBs using α-tubulin 
(α-tub) as loading control (normoxia, N, black bars; hypoxia, H, grey bars). * p < 0.05, 
Mann-Whitney U test, n = 4 per group. (C) The α C-terminal fragment (C99) and β C-
terminal fragment (C83) fragments of AβPP were measured by WB and the C99/C83 
ratio was calculated in the brains of 2–3 month-old wild-type mice subjected to CSH 
(H 30 d, 9 % O2), or normoxia (N 4h, 16 h or 30 d, 21 % O2) for the corresponding 
period of time within the same chamber. The rightmost lane of the Tris-tricine gel 
was loaded with a protein extract from an App-Psen1 (APP/PS1) transgenic mouse 
as positive control. The membrane was reprobed with an anti-Ribosomal Protein 
L26 (RPL26) antibody to demonstrate equal protein load in all gel lanes. Right bar 
graphs depict the quantification of WBs using α-tubulin (α-tub) as loading control 
(normoxia, N, black bars; hypoxia, H, grey bars). * p < 0.05, Mann-Whitney U test, n = 
4 per group. (A-C) Bars ± error bars represent mean ± s.e.m.  
4.1.5. Aβ accumulation, AβPP production, and soluble AβPPα 
amount are not affected by CSH  in App/Psen1 mice 
We have previously presented evidence on that neither ASH nor CSH impact on 
both transcription and protein levels of Aβ-related genes and rate-limiting 
enzymes, as well as on the amount of AβPP processing by-products. However, it is 
unknown if CSH could modify Aβ content by altering AβPP synthesis or processing 
in the presence of amyloid plaques, potentially resembling the AD situation. To 
conduct this study, we submitted App-Psen1 mice, AD mouse models that exhibit a 
prominent Aβ accumulation, of 8 months old, representing a low Aβ burden 
situation, and 14 months old, as a high Aβ burden paradigm, to hypoxia (9 % O2) 
and normoxia (21 % O2) in the same chambers for 21 days.  
Figure 10. Chronic sustained hypoxia (CSH) 
increases hematocrit in App-Psen1 mice. 
Hematocrit of 14-month-old App-Psen1 mice 
subjected to CSH (H, 21 days, 9 % O2, black bar) 
or normoxia (N, 21 days, 21 % O2, grey bar), 
within the same chamber was measured. ** p < 
0.01; Mann-Whitney U test, n = 4 per group. Bars 
± error bars represent mean ± s.e.m. 
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Figure 11. Chronic sustained hypoxia (CSH) does not modify the levels of 
amyloid-β (Aβ)1-40, Aβ1-42, full-length amyloid-β precursor protein (FL-AβPP) 
or soluble AβPP α (sAβPPα). 
(A-B) Aβ1-40 (up) and Aβ1-42 (down) levels were measured by ELISA in 8-month-old 
(A) and 14-month-old (B) App-Psen1 mice exposed to normoxia (N, 21 d, 21 % 
oxygen (O2), black bars) or CSH (H, 21 d, 9 % O2, grey bars), within the same 
chamber. * p < 0.05; Mann-Whitney U test, n = 3-4 per group. (C-D) FL-AβPP protein 
levels were measured by western blot (WB, up) in the brains of 8-month-old (C) and 
14-month-old (D) App-Psen1 mice exposed to normoxia (N, 21 d, 21 % O2) or CSH 
(H, 21 d, 9 % O2), within the same chamber. Bar graphs (down) depict the 
quantification of WBs using α-tubulin (α-tub) as loading control (normoxia, N, black 
bars; hypoxia, H, grey bars). * p < 0.05; Mann-Whitney U test, n = 3 per group. (E-F) 
sAβPPα protein levels were measured by WB (up) in the brains of 8-month-old (E) 
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and 14-month-old (F) App-Psen1 mice exposed to normoxia (N, 21 d, 21 % O2) or 
CSH (H, 21 d, 9 % O2), within the same chamber. Bar graphs (down) depict the 
quantification of WBs using α-tub (E) or β-actin (F) as loading controls (normoxia, N, 
black bars; hypoxia, H, grey bars). * p < 0.05; Mann-Whitney U test, n = 3 per group. 
(A-F) Bars ± error bars represent mean ± s.e.m. 
Since hematocrit has been described to increase under hypoxic conditions as a 
physiological response to maintain the O2 levels in the blood (Schuster et al., 1989; 
Semenza et al., 1991), we measured the hematocrit in the animals used in order to 
confirm a hypoxic response. Average hematocrit levels for wild-type mice in 
normobaric normoxia range from 42.0±1.2 % (D’Anglemont de Tassigny et al., 
2015; Schreier et al., 2014) to about 75 % at 9 % O2 (data not shown). We found 
very similar hematocrit values, both in normoxia and after CSH, in App-Psen1 mice 
to previously described wild-type values, confirming a hypoxic response triggered 
by CSH in App-Psen1 mice (Figure 10). 
ELISA quantification of cortical Aβ1-40 and Aβ1-42 levels showed similar amounts of 
these Aβ peptides in CSH regarding normoxia, both in 8-month-old and 14-month-
old App-Psen1 mice (Figure 11, A-B). Accordingly, we did not obtain significant 
changes in AβPP protein levels in CSH versus normoxia at any of the ages, analyzed 
by WB (Figure 11, C-D). Moreover, sAβPPα levels also remained stable after CSH 
treatment in both young and aged App-Psen1 mice (Figure 11, E-F), suggesting the 
inexistence of any shift in AβPP processing. 
4.2. Objective 2: PHD3 and AD microglia 
4.2.1. Egln3 mRNA is expressed in microglia surrounding 
plaques 
Egln3 mRNA levels were quantified in many different cell populations by single-
cell RNA sequencing in the mouse somatosensory cortex and CA-1 hippocampal 
areas. This approach revealed modest Egln3 mRNA levels in some interneuronal 
populations and virtually absent Egln3 expression in microglia (Zeisel et al., 2015). 
However, Egln3 expression is strongly increased in FACS-isolated microglia from 
AD mouse models, according to microarray data (Orre et al., 2014). We performed 
in situ hybridization experiments to confirm Egln3 expression in microglia from 
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App-Psen1 mice cortical areas and to explore the distribution of Egln3-
overexpressing microglia. We found non-microglial cells expressing Egln3 mRNA 
that could correspond to interneuronal cells, as previously described (Zeisel et al., 
2015). Remarkably, Egln3-expressing microglia was almost exclusively restricted 
to amyloid plaques vicinity (Figure 12), suggesting no potential effects for Elgn3 
ablation in microglia far from amyloid plaques, since they did not virtually express 
Elgn3.  
Figure 12. Egln3 mRNA expression in microglia is restricted to amyloid 
plaques periphery 
(A-B) Representative cortical coronal sections from 8 month-old App-Psen1 mice 
after in situ hybridization with Egln3 (brown) probe, immunostaining with anti-
IBA1 (green) antibody and staining with DAPI (blue). Left panel shows fluorescent 
IBA1 and DAPI markers, central panel shows bright field Egln3 probe, and right 
panel shows colocalization of left and central panels. Asterisks indicate the position 
of amyloid plaques in the right panels. Scale bars are 20 µm. (A) High magnification 
image of microglia surrounding an amyloid plaque. (B) Low magnification image of 
microglia surrounding and far from amyloid plaque. 
These results suggest that Egln3 mRNA expression in microglia is specifically 
induced in amyloid plaques vicinity.  
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4.2.2. PHD3 does not regulate Aβ-induced microglial 
proliferation but limits CD45 protein levels 
As described in the introduction, microglia are highly versatile cells that can adopt 
many different phenotypes in response to environmental cues (Hanisch & 
Kettenmann, 2007). In AD, microglia acquire an activated state that induces a 
series of dynamic changes, including an increased proliferation, morphological 
variations, and modification of the cell surface phenotype (Itagaki et al., 1989; 
Kamphuis et al., 2012; Olmos-Alonso et al., 2016; Serrano-Pozo et al., 2011; Streit 
et al., 2014). Importantly, Egln3 knock-out mice develop with minor sympatho-
adrenal alterations (Bishop et al., 2008). In this sense, we did not observe any 
apparent morphological or behavioral alterations or significant differences in mice 
weight throughout the entire study.  
As a first approach to explore a possible role of PHD3 in AD microglia, we 
measured the proportion of CD11b/CD45 microglia by flow cytometry (Orre, et al., 
2014) in three experimental groups of mice:  control, including wild-type and Egln3 
–/– mice, since there were no differences in  any of the evaluated parameters by 
flow cytometry, App-Psen1 and Egln3 –/–; App-Psen1 mice. We selected the 
microglial population based on the gating strategy included in material and 
methods section. CD11b/CD45 positive microglial population is contained in the 
depicted gates (Figure 13, A-C). 
The proportion of microglia was significantly higher in Aβ-accumulating mice 
regarding the control group. However, it was very similar between App-Psen1 and 
Egln3 –/–; App-Psen1 mice (Figure 13, D). To confirm whether microglia number 
was conserved between App-Psen1 and Egln3 –/–; App-Psen1 mice, we used 
stereological methods to count microglia cells in cortical sections per area stained 
with anti-ionized calcium-binding adapter molecule 1 (IBA1) antibody, an 
extensively used microglial marker, colocalizing with the DNA dye DAPI to 
unequivocally visualize individual cells. We did not observe differences in 
microglia density between these two genotypes (Figure 14), corroborating the 
result obtained by flow cytometry. This result suggests that Egln3 deletion is not 
altering microglia proliferation capacity in AD. 
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Figure 13. Microglia proliferation is not affected by prolyl-hydroxylase 3 
(PHD3) absence, but their CD45 protein levels are increased. 
(A-C) Flow cytometry density plots showing ex vivo-isolated adult microglia from 
12-month-old control (wild-type and Egln3 –/– mice) (A), App-Psen1 (B) and Egln3 –/–; 
App-Psen1 (C) mice. Microglia are included in the depicted gates and are 
characterized by surface expression of CD45 and CD11b. Representative 
percentages of the incipient or evident microglial subpopulations according to CD45 
protein levels are shown. (D) Quantification of total microglial (left) or CD45high 
microglial subpopulation (right) proportion from all single isolated cells registered 
in density plots A-C. Control (C), light grey bars; App-Psen1, dark grey bars, and 
Egln3 –/–; App-Psen1, black bars. *** p < 0.001, ANOVA with Tukey’s post-test, n = 9 
for control group and n = 5 for the rest of the groups. Bars ± error bars represent 
mean ± s.e.m. 
Interestingly, although no differences were shown in microglial proportion, 
enriched levels of CD45 surface marker were detected in Egln3 –/–; App-Psen1 in 
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comparison with App-Psen1 microglia, giving rise to a second identifiable 
microglial population (Figure 13, D). 
 
Figure 14. Stereological cell counting confirms unmodified microglia numbers 
in Alzheimer’s disease (AD) upon prolyl-hydroxylase 3 (PHD3) ablation. 
(A-B) Representative cortical coronal sections from 6 month-old App-Psen1 (A) and 
Egln3 –/–; App-Psen1 (B) mice immunostained with the microglial marker anti-IBA1 
(red) antibody and stained with the amyloid plaques dye Thioflavine-S (Thio-S, 
green). DAPI (blue) was used to label nuclei. Scale bars, 50 µm. (C) Number of 
microglia cells per µm2 of cortical area number of App-Psen1 (grey bar) and Egln3 –/–
; App-Psen1 (black bar) mice (n = 18 hemicortices from 6 App-Psen1, n = 12 
hemicortices from 4 Egln3 –/–; App-Psen1 mice; * p < 0.05; Mann Whitney’s test). Bars 
± error bars represent mean ± s.e.m. 
These results demonstrate that PHD3 is not involved in microglial proliferation in 
AD mouse models but its absence results in a phenotypic modification evidenced 
by increased surface expression of the CD45 protein. 
4.2.3. PHD3 restricts Aβ phagocytosis and its absence 
reduces total Aβ content 
CD45 is a tyrosine phosphatase found in lymphoid and myeloid cells whose 
overexpression in microglia is associated with activated states (Charbonneau et al., 
1988; Crotti & Ransohoff, 2016). Some reports have attributed enhanced 
phagocytic capacity to microglia expressing elevated levels of CD45 protein 
(Rangaraju et al., 2018; Zhu et al., 2011). Given that isolated microglia cells from 
Egln3–/–; App-Psen1 mice exhibited increased CD45 expression levels, we tested 
whether the phagocytic capability of Egln3–/–; App-Psen1 microglia was altered in 
vivo. To address this question, we based on a previously described protocol 
(Heneka et al., 2013). In brief, we injected mice with methoxy-XO4, a fluorescent 
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compound with high-affinity binding to Aβ that is incorporated in microglia upon 
stained Aβ uptake. Three hours after the injection, we quantified the proportion of 
microglia incorporating methoxy-XO4 by flow cytometry and found a trend to 
augment in the case of Egln3–/–; App-Psen1 microglia (Figure 15). 
 Figure 15. A modest increase in amyloid-β (Aβ) phagocytosis is elicited by 
prolyl-hydroxylase 3 (PHD3) deficiency in microglia. 
(A-B) Flow cytometry contour plots showing Aβ phagocytosis by microglia isolated 
from adult 12-month-old App-Psen1 (A) and Egln3 –/–; App-Psen1 (B) mice 3 h after 
intraperitoneal injection of methoxy-XO4. (C) Relative measurements regarding 
App-Psen1 phagocytosis (App-Psen1, grey bar; Egln3 –/–; App-Psen1, black bar). * p < 
0.05; Student’s t-test; n = 3 mice. Bars ± error bars represent mean ± s.e.m.  
Aβ peptides can be removed from the brain by various overlapping and interacting 
clearance systems including cellular uptake and enzymatic degradation, transport 
across the blood–brain and blood–cerebrospinal fluid barriers, interstitial fluid 
bulk flow, and cerebrospinal fluid absorption into the circulatory and lymphatic 
systems (Tarasoff-Conway et al., 2015). In particular, increased phagocytosis of Aβ 
has been linked to reductions in overall brain Aβ content (Chung et al., 1999; 
Colton, 2009; Combs, 2009; Condello et al., 2017). We postulated that the 
aforementioned trend to increase the phagocytic capacity of microglia from Egln3–
/–; App-Psen1 could imply a reduction in cortical Aβ content. To tackle this 
question, we obtained cortical homogenates from App-Psen1 and Egln3 –/–; App-
Psen1 mice in guanidine-containing buffer in order to extract total Aβ content from 
our samples and performed ELISA for human Aβ1-40 and Aβ1-42 peptides, the two 
main toxic Aβ species (Burdick et al., 1992), in collaboration with Dr. Navarro, 
from Dr. Vitorica’s laboratory. Our results showed a trend to reduce total Aβ1-40 
content coupled by a significant decrease in the levels of Aβ1-42 (Figure 16, A). 
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Figure 16. Lack of prolyl-hydroxylase 3 (PHD3) produces a reduction in total 
amyloid-β (Aβ) peptide levels but an increase in soluble Aβ peptides fraction. 
(A-B) Aβ1-40 and Aβ1-42 measurement by ELISA of hemicortical extracts from 6-
month-old App-Psen1 (grey bars) and Egln3 –/–; App-Psen1 (black bars) mice. (A) 
Total Aβ1-40 and Aβ1-42 content. * p < 0.05; Student’s t-test; n = 5 App-Psen1 mice and 
n = 4 Egln3 –/–; App-Psen1 mice. (B) Soluble Aβ1-40 and Aβ1-42 content. * p < 0.05; 
Student’s t-test; n = 4 mice per group. Bars ± error bars represent mean ± s.e.m. 
A growing body of evidence points to greater neurotoxic effects of soluble 
conformations of Aβ peptides (Haass & Selkoe, 2007; Walsh & Selkoe, 2007) so we 
wondered if soluble Aβ content in Egln3–/–; App-Psen1 mice was modified. To 
address this question, we used the previously described ELISA essay, but 
employing isolated soluble fractions from cortical extracts. Although they account 
for a very short proportion of total Aβ content, we obtained a significant increase 
of Aβ1-40 amount concomitantly with a trend to increase Aβ1-42 in Egln3–/–; App-
Psen1 regarding App-Psen1 mice (Figure 16, B). 
Thus, PHD3 deficiency promotes a modest increase in microglial Aβ phagocytosis, 
correlating with diminished total Aβ1-42 content but increased soluble Aβ1-40 
fraction. 
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4.2.4. PHD3 deficiency induces changes in Aβ deposition 
The different Aβ isoforms exhibit diverse solubility and aggregation properties 
(Chung et al., 1999). We wondered whether the detected decrease in total Aβ1-40 
and Aβ1-42 correlated with changes in the area occupied by Aβ plaques, in their 
numbers or in their structure. To this aim, we stained cortical sections with an 
anti-Aβ antibody and Thio-S, which stains β-sheet amyloid structures (Figure 17), 
and analyzed the percentage of the cortex covered by dense-core amyloid plaques. 
Non-significant differences were observed in this parameter in Egln3–/–; App-Psen1 
versus App-Psen1 mice with none of the employed markers, although we observed 
a trend to an increment (Figure 18, A). Next, we extended our examination to 
other parameters like density of amyloid plaques, in terms of number of plaques 
per area, and average size of plaques, both in the case of Thio-S stained sections. 
Our results showed a significantly raised density of amyloid plaques in Egln3–/–; 
App-Psen1 (Figure 18, B) that was coincident with a significantly lower average 
size of Aβ plaques (Figure 18, C). Closer evaluation of plaques size revealed that 
this reduced average size was due to a bigger amount of relatively small plaques 
(less than 194 µm2) in Egln3–/–; App-Psen1 mice, without altering the number of 
bigger plaques (Figure 18, D). 
Yuan et al. described in 2016 that amyloid plaques can appear in several 
compaction degrees. Filamentous plaques emerge from β-sheet folding of diffuse 
plaques and they can acquire a compact conformation upon compaction 
potentially  mediated by microglia, given the close interaction between  fibrillar Aβ 
(fAβ) structures and microglial processes (Yuan et al., 2016). In order to ascertain 
which kind of amyloid plaques deposition was responsible for the increased 
number of amyloid plaques in Egln3 –/–; App-Psen1, we quantified with 
stereological methodologies the amount of filamentous and compact amyloid 
plaques per cortical area unit upon Thio-S staining. We obtained a remarkable 
increase in the number of compact plaques per cortical area in Egln3–/–; App-Psen1 
with respect to App-Psen1 mice and no differences in filamentous ones (Figure 18, 
E). 
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Figure 17. Changes in amyloid-β (Aβ) deposition are observed upon prolyl-
hydroxylase 3 (PHD3) absence.  
(A-B) Representative superimages of cortical coronal sections from 6 month-old 
App-Psen1 (left) and Egln3 –/–; App-Psen1 (right) mice immunostained with anti-
Aβ (A) antibody and stained with the amyloid plaques dye Thioflavine-S (Thio-S, B). 
Insets represent higher magnification of areas included in dashed gates. Scale bars 
are 500 µm for the superimages and 250 µm for the insets.  
The anti-Aβ antibody or Thio-S staining are not sensitive enough to accurately 
quantify fAβ structures. Hence, in order to extend our analysis on Aβ plaques 
structure and burden, we immunochemically stained hemibrain slices of App-
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Psen1 and Egln3 –/–; App-Psen1 mice using anti-OC antibody, which recognizes 
amyloid fibrillar conformations and fAβ oligomers. We found an extensive OC 
signal colocalizing with dense-core nuclei of the plaques but also in pure fibrillar 
structures, mostly surrounding compact plaque’s nuclei or, to a lesser extent, as 
dense-core-devoid Aβ deposits. Since we were particularly focused in the analysis 
of the fAβ region, we generated segmented binary masks applying an upper and a 
lower threshold that excluded dense-core-belonging signal (Figure 19).  
 
Figure 18. Prolyl-hydroxylase 3 (PHD3) deficiency in Alzheimer’s disease (AD) 
mice shows increased number of small cortical compact amyloid plaques. 
(A) Quantification of the percentage of cortical area occupied by amyloid plaques in 
immunostained with anti-amyloid-β (Aβ) antibody (left) or Thioflavine-S (Thio-S) 
C 
D 
E 
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staining from superimages described in Fig. 17, A and B, respectively. App-Psen1 
mice, grey bars; Egln3 –/–; App-Psen1 mice, black bars. * p < 0.05; Student’s t-test; n = 
18 hemicortices from 6 mice per genotype for anti-Aβ immunostaining and n = 9 
hemicortices from 3 mice per genotype for Thio-S staining. (B-C) Amyloid plaques 
number per area unit (B) and average size (C) from superimages described in Fig. 
17, B. App-Psen1 mice, grey bars; Egln3 –/–; App-Psen1 mice, black bars. ** p < 0.01; 
Student’s t-test; n = 9 hemicortices from 3 mice per genotype. (D) Average number 
of amyloid plaques in each size interval from superimages described in Fig. 17, B. 
App-Psen1 mice, grey bars; Egln3 –/–; App-Psen1 mice, black bars. * p < 0.05; ** p < 
0.01; *** p < 0.001; Student’s t-test; n = 9 hemicortices from 3 mice per genotype. (E) 
Number of compact (left) and filamentous (right) amyloid plaques per area unit 
stereologically quantified in complete hemicortices of App-Psen1 mice (grey bars) 
and Egln3 –/–; App-Psen1 mice (black bars). *** p < 0.001; Student’s t-test; n = 18 
hemicortices from 6 mice per genotype. Bars ± error bars represent mean ± s.e.m. 
Quantification of percentage of cortical area covered by fAβ, excluding dense-core 
OC immunohistochemical staining, reflected a significant augmentation of fAβ 
covered area in the case of Egln3–/–; App-Psen1 regarding App-Psen1 mice (Figure 
20).  
 
Figure 20. Segmentated binary masks by using Fiji software to detect fibrillar 
amyloid-β (fAβ) not colocalizing with the dense-core of compact amyloid 
plaques. 
Representative area of a superimage of hemicortical coronal sections from a 6 
month-old App-Psen1 mouse stained with anti-OC antibody (left). Right panel shows 
the segmented binary mask resulting from left panel after processing with Fiji 
software by setting lower and upper appropriate thresholds to quantify fAβ. Scale 
bars are 250 µm.  
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To sum up, our data indicate that PHD3 deficiency in the App-Psen1 AD mouse 
model results in an elevated number of small compact amyloid plaques and fAβ 
occupied area without altering the number of filamentous plaques or total 
occupied area by dense-core amyloid plaques.  
 
Figure 20. Prolyl-hydroxylase 3 (PHD3) deficient 
Alzheimer’s disease (AD) mice show changes in 
fibrillar amyloid-β (fAβ) deposition. 
(A) Representative superimages of cortical coronal 
sections from 6 month-old App-Psen1 (left) and Egln3 
–/–; App-Psen1 (right) mice stained with anti-OC 
antibody. Scale bars are 500 µm. (B) Quantification of 
fAβ occupied area in the total cortex of the 
superimages described in (A). App-Psen1 mice, grey 
bars; Egln3 –/–; App-Psen1 mice, black bars. * p < 0.05; 
Student’s t-test; n = 18 hemicortices from 6 mice per 
genotype. Bars ± error bars represent mean ± s.e.m. 
4.2.5. A decreased neurotoxicity is exhibited upon Egln3 
deletion 
 
It has been described that fAβ configurations exert a more neurotoxic effect than 
compact formations (Condello et al., 2015; Yuan et al., 2016). Given that Egln3 –/–; 
App-Psen1 mice presented higher fAβ coverage, we measured neuronal 
A 
B 
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dystrophies around Aβ plaques using a phosphorylated-Tau protein antibody 
(Figure 21). We selected random compact plaques of the same size (Figure 21, B) 
from the cortex of Egln3 –/–; App-Psen1 and App-Psen1 mice stained with anti-
phosphorylated-Tau antibody and Thio-S and estimated P-Tau occupied area 
around the plaques. Unexpectedly, we observed a significantly reduced proportion 
of P-Tau around plaques (Figure 21, C) in Egln3 –/–; App-Psen1 mice. 
Figure 21. Neuronal dystrophies surrounding compact amyloid plaques are 
reduced upon prolyl-hydroxylase 3 (PHD3) ablation in AD mice. 
(A) Representative images of cortical random compact amyloid-β (Aβ) plaques from 
6 month-old App-Psen1 (left) and Egln3 –/–; App-Psen1 (right) mice stained with 
Thioflavine-S (Thio-S, green) (left column in each panel) and associated neuronal 
damage immunostained with anti-phosphorylated-Tau (P-Tau, brown) antibody 
(central column in each panel). Right column in each panel shows colocalization of 
Thio-S and P-Tau markers. Scale bars are 50 µm (B) Aβ plaques size from images 
described in A. App-Psen1 mice, grey bars; Egln3 –/–; App-Psen1 mice, black bars. *p < 
0.05; Student’s t-test; n = 30 hemicortices from 5 mice per genotype (24 plaques per 
mouse). (C) Ratio P-Tau /amyloid plaque occupied area from images described in A. 
App-Psen1 mice, grey bars; Egln3 –/–; App-Psen1 mice, black bars. *** p < 0.001; 
Student’s t-test; n = 30 hemicortices from 5 mice per genotype (24 plaques per 
mouse). Bars ± error bars represent mean ± s.e.m. 
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We wondered if this result could be explained by a decrease in the fAβ halo 
specifically surrounding the Egln3 –/–; App-Psen1 compact plaques. To address this 
question, we immunostained cortical sections of Egln3 –/–; App-Psen1 and App-
Psen1 with Thio-S and anti-OC antibody to quantify total OC signal covered area, 
OC occupancy exclusively by fAβ halo, and Thio-S dense-core size in plaques 
meeting the same criteria used for neuronal dystrophies quantification (Figure 
22). Non-significant differences were observed in all the analyzed parameters 
(total fAβ, Thio-S dense core or fibrillar halo area), including the ratio between 
fibrillar halo/dense-core covered areas per plaque (Figure 23).  
Figure 22. Considered dense core and fibrillar amyloid-β (fAβ) halo in compact 
amyloid plaques. 
(A) Representative picture of a compact amyloid plaque from the cortex of a 6-
month-old App-Psen1 mouse stained with Thioflavine-S (Thio-S, green), and 
immunostained with anti-OC antibody (red). Left panel shows colocalization of both 
markers, centre panel shows Thio-S staining and right panel shows OC staining. 
Scale bars are 10 µm. (B) Contour shapes delimiting the whole OC marker quantified 
area (right), the dense core (centre) or the fAβ halo excluding the dense core (white 
arrow, left) in the amyloid plaque from A after processing with Fiji software. Scale 
bars are 10 µm. 
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These results are consistent with a neuroprotective effect around amyloid plaques 
in the absence of PHD3 that is not due to modifications of the fAβ plaques-
surrounding halo. 
Figure 23. Compact amyloid plaques do not exhibit structural changes in their 
fibrillar amyloid-β (fAβ) halo in prolyl-hydroxylase 3 (PHD3) deficient AD 
mice. 
(A-B) Representative cortical compact amyloid plaques from 6 month-old App-Psen1 
(A) and Egln3 –/–; App-Psen1 (B) mice stained with Thioflavine-S (Thio-S, green) and 
immunostained with anti-OC antibody (red). Right panel shows OC immunostaining, 
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centre panel shows Thio-S staining and left panel shows colocalization of both 
markers. Scale bars are 10 µm. (C) Quantified area occupied by total OC marker in 
cortical compact amyloid plaques from images described in A-B. App-Psen1 mice, 
grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 18 
hemicortices from 6 mice per genotype (15 plaques per mouse). (D) Quantified 
dense core occupied by Thio-S marker in cortical compact amyloid plaques from the 
same plaques in C. App-Psen1 mice, grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p 
< 0.05; Student’s t-test; n = 18 hemicortices from 6 mice per genotype (15 plaques 
per mouse). (E) Quantified area occupied by OC halo surrounding Thio-S dense core 
in cortical compact amyloid plaques from the same plaques in C. App-Psen1 mice, 
grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 18 
hemicortices from 6 mice per genotype (15 plaques per mouse). (F) Ratio OC 
halo/dense core occupied areas from the same plaques in C. App-Psen1 mice, grey 
bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 18 
hemicortices from 6 mice per genotype (15 plaques per mouse). Bars ± error bars 
represent mean ± s.e.m. 
4.2.6. Microglia association to Aβ plaques is triggered in the 
absence of PHD3 
Microglia can exert a physical barrier function by isolating neurons from Aβ 
toxicity (Condello et al., 2015). Indeed, in Trem2 haplodeficient AD-like mice, 
which exhibit a significant decrease in plaque coverage by microglia, neuronal 
dystrophies surrounding amyloid plaques are more prominent (Yuan et al., 2016). 
In order to evaluate a potentially enhanced microglial barrier in Egln3 –/–; App-
Psen1 mice, we immunostained cortical slices with IBA1 and DAPI markers to 
identify individual microglial cells, in combination with Thio-S staining, and we 
acquired images at different Z axis points of compact Aβ plaques of the same size 
(Figure 24). Next, we calculated a microglia proximity index (MPI) that represents 
the proportion of microglia directly contacting the amyloid plaque within a 40 µm 
halo from plaque’s border. This approach revealed a significant increase in the MPI 
of Egln3 –/–; App-Psen1 with respect to App-Psen1 mice (Figure 24, C). This 
increased MPI did not correlate with differences in microglia number around Aβ 
plaques (Figure 24, D). Thus, microglia in Egln3 –/–; App-Psen1 mice exhibit a 
closer physical interaction with Aβ plaques that could presumably increase 
microglia shielding from plaque’s neurotoxicity, suggesting a neuroprotective role 
of microglia in Egln3 –/–; App-Psen1 mice. 
- 58 - 
 
Figure 24. Microglia association to amyloid-β (Aβ) plaques is triggered in the 
absence of prolyl-hydroxylase 3 (PHD3) in Alzheimer’s disease (AD) mouse 
models. 
(A) Representative cortical coronal confocal images of compact amyloid plaques 
stained with Thioflavine-S (Thio-S, green) and microglia immunostained with anti-
IBA1 (red) antibody from 6 month-old App-Psen1 (left) and Egln3 –/–; App-Psen1 
(right) mice. Scale bars are 20 µm. (B) Size quantification of compact amyloid 
plaques immunostained with anti-Aβ antibody from 6 month-old App-Psen1 (grey 
bar) and Egln3 –/–; App-Psen1 (black bar) mice. * p < 0.05; Student’s t-test; n = 9 
hemicortices from 3 mice per genotype (15 plaques per mouse). (C) Microglia 
proximity index: number of microglia cells, immunostained with anti-IBA1 antibody 
and with the nuclear dye DAPI, in contact with Aβ plaques per total microglia within 
a 40 µm halo around the plaque in 6 month-old App-Psen1 (grey bar) and Egln3 –/–; 
App-Psen1 (black bar) mice. * p < 0.05; Mann Whitney’s test; n = 9 hemicortices from 
3 mice per genotype (15 plaques per mouse). (D) Number of microglial cells, 
immunostained with anti-IBA1 antibody and with the nuclear dye DAPI, within a 40 
µm halo around amyloid plaques from 6 month-old App-Psen1 (grey bar) and Egln3 –
/–; App-Psen1 (black bar) mice. * p < 0.05; Student’s t-test; n = 9 hemicortices from 3 
mice per genotype (15 plaques per mouse). Bars ± error bars represent mean ± 
s.e.m. 
To further support an increased barrier function, we immunostained whole 
cortical slices with IBA1 antibody and analyzed them with Fiji software (Schindelin 
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et al., 2012) by using a combination of settings aimed at recognizing microglial cell 
clusters. We observed a significant increase in clustered microglial burden in Egln3 
–/–; App-Psen1 versus App-Psen1 mice, suggesting increased microglial coverage 
around amyloid plaques (Figure 25). 
Figure 25. Prolyl-hydroxylase 3 (PHD3) ablation in 
Alzheimer’s disease (AD) mice correlates with an 
increased cortical coverage of clustered microglia. 
(A) Representative superimages of cortical coronal 
sections from 6 month-old App-Psen1 (left) and Egln3 –/–; 
App-Psen1 (right) mice immunostained with anti-IBA1 
antibody. Insets represent higher magnification of areas 
included in dashed gates. Scale bars are 500 µm for the 
superimages and 250 µm for the insets. (B) Quantification 
of the percentage of cortical area occupied by clustered 
microglia from images described in A. App-Psen1 mice, 
grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; 
Student’s t-test; n = 18 hemicortices from 6 mice per 
genotype. Bars ± error bars represent mean ± s.e.m. 
To discard a potential contribution of non-clustered microglial cells to the 
calculated burden, we analyzed different morphological aspects of microglia far 
from Aβ plaques. Upon immunostaining with IBA1 antibody, we explored the level 
of ramification of microglial projections by counting the number of primary 
branches, which emerge directly from the soma, and the number of intersections 
with a circumference of fixed size (Figure 26, A, green). We observed no 
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differences in App-Psen1 versus Egln3 –/–; App-Psen1 mice, either in the number of 
primary branches or in the number of intersections (Figure 26, C-D).  
 
Figure 26. Microglia morphology is not altered in prolyl-hydroxylase 3 (PHD3) 
deficient microglia far from amyloid plaques. 
(A-C) Representative microglia of cortical coronal sections from 6 month-old App-
Psen1 (B, left) and Egln3 –/–; App-Psen1 (B, right) mice immunostained with anti-
IBA1 antibody. Scale bars are 10 µm. (A) Green circumference was used to quantify 
the number of intersections with microglial projections. Red circumference was 
used to measure the occupied area by soma within this circumference. Blue 
circumference was used to analyze microglia occupied area within this 
circumference and area occupied by microglial projections, excluding the area 
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delimited by red circumference. (C) Number of primary branches emerging directly 
from microglial soma quantified in images described in B. App-Psen1 mice, grey bar; 
Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 9 hemicortices 
from 3 mice per genotype (9 cells per mouse). (D) Number of intersections in images 
described in B with green circumference in A. App-Psen1 mice, grey bar; Egln3 –/–; 
App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 9 hemicortices from 3 mice 
per genotype (9 cells per mouse). (E) Microglia occupied area in images described in 
B with blue circumference in A. App-Psen1 mice, grey bar; Egln3 –/–; App-Psen1 mice, 
black bar. * p < 0.05; Student’s t-test; n = 18 hemicortices from 6 mice per genotype 
(9 cells per mouse). (F) Ratio projections/soma occupied area in the images 
described in B with red and blue circumferences described in A. App-Psen1 mice, 
grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; Student’s t-test; n = 18 
hemicortices from 6 mice per genotype (9 cells per mouse). Bars ± error bars 
represent mean ± s.e.m. 
Given the heterogeneity of microglial morphology, we complemented the 
morphological study with an unbiased approach based on the percentage of area 
covered by individual microglial cells in a specifically selected circumference 
(Figure 26, A, blue). Our results showed the same occupancy of individual 
microglial cells within the blue circumference for App-Psen1 and Egln3 –/–; App-
Psen1 mice (Figure 26, E). Although the occupied area of individual cells was 
unmodified in this comparison, it was still possible to have variances in the ratio of 
projections and soma. To explore this possibility, we quantified the area covered 
by projections and soma of individual cells by using a similar unbiased strategy. 
We created a smaller fixed area which was placed in the center of the soma of 
every microglial cell to quantify the percentage of occupancy of the corresponding 
soma regarding this constant area (Figure 26, A, red). Afterwards, by using the 
same previously described area to measure whole cell coverage (Figure 26, A, 
blue), we quantified the proportion of area occupied by IBA1 marker excluding the 
signal contained in the red circumference (Figure 26, A, red). We decided not to 
just subtract soma area to the precedent calculated total area because, with this bit 
by bit approach, we could adopt more appropriate threshold settings for each 
compartment in order to improve the quality of data. With this separate 
quantification, we calculated the ratio between projection and soma areas and we 
did not observe significant differences in the calculated ratio in App-Psen1 versus 
Egln3 –/–; App-Psen1 microglia (Figure 26, F). 
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Altogether, these results strongly support an enhanced microglial encapsulation of 
compact amyloid plaques upon PHD3 deficiency with neuroprotective effects. 
4.2.7. PHD3 depletion rescues motor and memory 
abnormalities emerging from AD 
Reduction in the number of synapses has been reported in AD animal models upon 
Tau hyperphosphorylation (Pooler et al., 2014). In order to explore whether the 
detected differences in Tau hyperphosphorylation load between App-Psen1 and 
Egln3 –/–; App-Psen1 could result in differential synaptic affectation, we measured 
the hippocampal content of three different synaptic proteins by WB. We also 
included a control group composed by wild-type and Egln3 –/– mice, since no 
differences were observed between them, in order to identify a potential defect 
exerted by Aβ accumulation.  
Figure 27. Synaptic proteins load is not altered in Alzheimer’s disease (AD) 
mice upon prolyl-hydroxylase 3 (PHD3) absence. 
(A-E) Western blot (WB) and quantifications from hippocampal extracts of 6 month-
old control (wild-type and Egln3 –/–, light grey bars) App-Psen1 (dark grey bars) and 
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Egln3 –/–; App-Psen1 (black bars) mice. (A) Representative WB for synaptophysin 
protein (SNP-1), with α-tubulin (α-tub) as loading control. (B) Quantification of the 
WB described in A. * p < 0.05; Kruskal-Wallis ANOVA with Dunn’s multiple 
comparison test; n = 11 hemihippocapi from control mice, n = 7 hemihippocapi from 
App-Psen1 mice, n = 6 hemihippocapi from Egln3 –/–; App-Psen1 mice. (C) 
Representative WB for postsynaptic-density-95 (PSD-95) protein (upper row) and 
vesicular glutamate transporter (VGLUT-1) (lower row) with β-actin (β-act) as 
loading control. (D) Quantification of the WB for VGLUT-1 described in C. * p < 0.05; 
ANOVA with Tukey’s post-test; n = 11 hemihippocapi from control mice, n = 7 
hemihippocapi from App-Psen1 mice, n = 6 hemihippocapi from Egln3 –/–; App-Psen1 
mice. (E) Quantification of the WB for PSD-95 described in C. * p < 0.05; Kruskal-
Wallis ANOVA with Dunn’s multiple comparison test; n = 11 hemihippocapi from 
control mice, n = 7 hemihippocapi from App-Psen1 mice, n = 6 hemihippocapi from 
Egln3 –/–; App-Psen1 mice. Bars ± error bars represent mean ± s.e.m. 
Synaptophysin is a 38 kDa integral membrane glycoprotein that is restricted to the 
presynaptic compartment (Martin et al., 2014). Our results revealed no differences 
in synaptophysin-1 load among the aforementioned groups (Figure 27, A-B). 
Synaptic development, neural plasticity, and protein assembly in the postsynaptic 
compartment are mediated by postsynaptic-density-95 (PSD-95) protein, whose 
decrease has been found in different AD-related scenarios (Tu et al., 2014). PSD-95 
levels showed non-significant alterations in any of the analyzed groups (Figure 27, 
C, E). Finally, vesicular glutamate transporter (VGLUT-1) levels were evaluated in 
the same samples since they are modified in AD (Kashani et al., 2008). No 
differences were observed in VGLUT-1 levels among the hippocampi of our mice 
groups (Figure 27, C, D). 
Plaque-associated axonal dystrophies correlate with cognitive impairment 
(Dickson et al., 1999; Su et al., 1996). Therefore, although we did not detected 
differences in synaptic proteins load, we wondered if the observed reduction in 
plaque-associated peripheral dystrophies could possess further cognitive 
implications. To answer this question, we carried out behavioral assays regarding 
free locomotor activity in an open-field test and memory with a novel-object 
recognition test, in the aforementioned control, App-Psen1 and Egln3 –/–; App-Psen1 
groups. In the open-field test, spontaneous activity was examined by recording 
track length for fifteen minutes in an open-field chamber. We obtained an elevated 
locomotor activity in App-Psen1 regarding the control group, as already observed 
in previous studies using other AD mouse models (Heneka et al., 2013; Walker et 
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al., 2011). Remarkably, this increased locomotion was completely blunted in 
Egln3–/–; App-Psen1, reverting this defect to the control group phenotype (Figure 
28, A). Memory assessment was performed with a novel object recognition test, in 
which we obtained a short-term memory index calculated as the number of 
approaches of each mouse to a new object that replaced one of the two objects 
presented one hour before, divided by the total number of approaches to both 
objects. Our results showed a deficient hippocampal-dependent memory retention 
in App-Psen1 mice regarding the control group that was fully rescued in Egln3–/–; 
App-Psen1 mice (Figure 28, B). 
Figure 28. Prolyl-hydroxylase 3 (PHD3) absence rescues motor and short-term 
memory defects associated to Alzheimer’s disease (AD). 
(A) Spontaneous activity was measured in control (wild-type and Egln3 –/–, light grey 
bar), App-Psen1 (dark grey bar), and Egln3 –/–; App-Psen1 (black bar) mice. Mice 
were recorded for 15 min in an open field chamber (n = 16 control, n = 18 App-
Psen1, and n = 14 Egln3 –/–; App- Psen1 mice. ** p < 0.01; ANOVA with Tukey’s post-
test. (B) Short term memory index (1 h inter-session interval) was calculated in 
control (wild-type and Egln3 –/–), App-Psen1 and Egln3 –/–; App-Psen1 mice using the 
novel object recognition test (n = 14 control, n = 21 App-Psen1, and n = 14 Egln3 –/–; 
App-Psen1 mice. ** p < 0.01; ANOVA with Newman-Keuls’ post-test). (A-B) Bars ± 
error bars represent mean ± s.e.m. 
These results account for a cognitive and motor behavior improvement mediated 
by PHD3 depletion in AD. 
4.2.8. Egln3 ablation does not trigger a microglial hypoxic 
response 
In order to explore the potential mechanisms explaining the phenotypic 
differences detected in the microglia from Egln3 –/–; App-Psen1 with regards to 
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microglia from App-Psen1 mice, we isolated the CD11b/CD45 positive microglia 
from these two mouse models by FACS and performed microarray experiments 
and GSEA. 
Processing and GSEA of data obtained from the microarray of isolated microglia 
were performed by Dr. Ortega-de San Luis. However, we include them in this 
manuscript since they provide important clues on functional mechanisms to 
explain our results.  
Significant transcriptional changes in the comparison Egln3 –/–; App-Psen1 versus 
App-Psen1 microglia were considered when logFC (log2 scale) ≥ ±0.5 and p-value < 
0.05. A table listing significant transcriptional changes is attached in “attached 
material” section (Table 5).  
One of the expected effects of Egln3 deletion could be HIF1α accumulation and 
subsequent activation of its target genes since PHD3 is involved in a negative 
feedback loop that promotes  HIF1α stabilization in vitro (Ginouves et al., 2008). In 
this regard, WB analysis of the nuclear fraction of cortical homogenates from App-
Psen1 and Egln3 –/–; App-Psen1 mice showed no differences in HIF1α amount 
between Egln3 –/–; App-Psen1 and App-Psen1 mice (Figure 29).  
Figure 29. Hypoxia-inducible factor (HIF)1α protein levels are not modified by 
prolyl-hydroxylase 3 (PHD3) deficiency in Alzheimer’s disease (AD) mice. 
(A-B) Western blot (WB) and quantifications from cortical extracts of 6 month-old 
App-Psen1 (dark grey bars) and Egln3 –/–; App-Psen1 (black bars) mice. (A) 
Representative WB for HIF1α protein, with α-tubulin (α-tub) as loading control. (B) 
Quantification of the WB described in A. * p < 0.05; Student’s t-test; n = 4 
hemicortices per genotype. Bars ± error bars represent mean ± s.e.m. 
- 66 - 
To further confirm that Egln3 deficiency did not exacerbate a hypoxic response in 
AD microglia, a GSEA was carried out using “Biological Processes” category (which 
is integrated by 730 GS, including an endogenous “Response to Hypoxia” GS). As 
hypoxia-regulated responses are extremely cell specific (Ortiz-Barahona et al., 
2010; Schödel et al., 2013), a custom GS representing the HMS, which had 
previously been defined in our laboratory, was added to the analysis.  
Table 2. The hypoxia-induced microglia signature (HMS) gene set (GS) is not 
over-represented in prolyl-hydroxylase 3 (PHD3) deficient Alzheimer's 
disease (AD) microglia. 
Top fifteen up-regulated GS in 12-month-old isolated microglia from Egln3 –/–; App-
Psen1 versus App-Psen1 mice revealed by Gene Set Enrichment Analysis (GSEA) 
using Biological Processes category and including HMS as an additional GS. 
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We observed that neither endogenous Biological Processes category Response to 
Hypoxia GS nor the HMS were overrepresented in Egln3 –/–; App-Psen1 microglia in 
comparison with App-Psen1 microglia (Table 2). Altogether, these results suggest 
that PHD3 absence is not aggravating a hypoxic microglial expression profile in a 
β-amyloidosis context. 
4.2.9. Microglia activates anti-microbial responses in a 
PHD3-dependent manner 
In order to explore the pathways regulated by PHD3 in AD microglia, GSEA was 
performed based on “KEGG pathway database” category contained GS (171 GS). 
Top ten up-regulated and down-regulated GS are listed in Tables 3 and 4, 
respectively. Up-regulated GS in the microglia from Egln3 –/–; App-Psen1 compared 
to App-Psen1 mainly reflected a profound adjustment of the metabolic status of the 
cells (Table 3), evidencing further physiological implications. 
Name Size ES NES 
NOM p-
val 
FDR q-
val 
FWER 
p-val 
Rank at 
max 
Leading edge 
KEGG TYROSINE 
METABOLISM 
34 0.55 1.72 0.0045 0.43 0.416 3130 
tags=53%, 
list=24%, 
signal=69% 
KEGG METABOLISM OF 
XENOBIOTICS BY 
CYTOCHROME P450 
36 0.52 1.68 0.0088 0.31 0.545 4543 
tags=67%, 
list=35%, 
signal=102% 
KEGG DRUG METABOLISM 
CYTOCHROME P450 
39 0.50 1.64 0.0133 0.30 0.688 4543 
tags=62%, 
list=35%, 
signal=94% 
KEGG 
GLYCOSAMINOGLYCAN 
DEGRADATION 
20 0.58 1.62 0.0092 0.27 0.753 1058 
tags=35%, 
list=8%, 
signal=38% 
KEGG PHENYLALANINE 
METABOLISM 
16 0.59 1.59 0.0292 0.29 0.841 1846 
tags=44%, 
list=14%, 
signal=51% 
KEGG LYSOSOME 112 0.40 1.55 0.0041 0.34 0.925 1159 
tags=18%, 
list=9%, 
signal=19% 
KEGG RETINOL 
METABOLISM 
28 0.51 1.53 0.0360 0.35 0.946 4245 
tags=61%, 
list=32%, 
signal=89% 
KEGG PPAR SIGNALING 
PATHWAY 
60 0.43 1.53 0.0197 0.31 0.947 1416 
tags=18%, 
list=11%, 
signal=20% 
KEGG TRYPTOPHAN 
METABOLISM 
37 0.47 1.49 0.0375 0.35 0.979 2959 
tags=41%, 
list=22%, 
signal=52% 
KEGG GLYCOLYSIS 
GLUCONEOGENESIS 
54 0.42 1.49 0.0187 0.32 0.979 4222 
tags=52%, 
list=32%, 
signal=76% 
 
Table 3. Top up-regulated Gene Sets (GS)s from KEGG pathway database in 
isolated microglia from Egln3 –/–; App-Psen1 versus App-Psen1 mice  
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Top ten up-regulated GS from KEGG pathway database in 12-month-old isolated 
microglia from Egln3 –/–; App-Psen1 versus App-Psen1 mice revealed by Gene Set 
Enrichment Analysis (GSEA). 
Interestingly, the most down-regulated GS from KEGG pathway database in Egln3 –
/–; App-Psen1 included Nod-like, Toll-like, and Rig-I-like receptor signalling 
pathways (Table 4 and Figure 30). 
 
Table 4. Top down-regulated Gene Sets (GS)s from KEGG pathway database in 
isolated microglia from Egln3 –/–; App-Psen1 versus App-Psen1 mice  
Top ten down-regulated GS from KEGG pathway database in 12-month-old isolated 
microglia from Egln3 –/–; App-Psen1 versus App-Psen1 mice revealed by Gene Set 
Enrichment Analysis (GSEA). 
NOD signalling pathway is induced in innate immune cells in response to certain 
bacterial and viral infections (Philpott et al., 2014). On the other hand, the diversity 
of TLRs present in mammalian organisms serves as a mechanism to detect a 
number of invading pathogens, eliciting responses against bacterial and viral 
infections (Nicotra et al., 2012; Okun et al., 2011). However, RIG-I-like receptors 
essentially sense replicating viruses in the cytoplasm and can trigger antiviral 
activities dependent on Interferon (IFN) signalling (Kato et al., 2011). In addition, 
Name Size ES NES 
NOM p-
val 
FDR q-
val 
FWER 
p-val 
Rank at 
max 
Leading edge 
KEGG NOD-LIKE 
RECEPTOR SIGNALING 
PATHWAY 
47 -0.62 -2.34 0.000 0.00 0.001 1881 
tags=49%, 
list=14%, 
signal=57% 
KEGG TOLL-LIKE 
RECEPTOR SIGNALING 
PATHWAY 
95 -0.54 -2.31 0.000 0.00 0.001 1858 
tags=46%, 
list=14%, 
signal=54% 
KEGG RIG-I-LIKE 
RECEPTOR SIGNALING 
PATHWAY 
59 -0.59 -2.28 0.000 0.00 0.005 1727 
tags=37%, 
list=13%, 
signal=43% 
KEGG CYTOSOLIC DNA 
SENSING PATHWAY 
47 -0.59 -2.25 0.000 0.00 0.005 1463 
tags=38%, 
list=11%, 
signal=43% 
KEGG B CELL RECEPTOR 
SIGNALING PATHWAY 
71 -0.54 -2.19 0.000 0.00 0.012 968 
tags=32%, 
list=7%, 
signal=35% 
KEGG UBIQUITIN 
MEDIATED PROTEOLYSIS 
123 -0.41 1.83 0.000 0.08 0.288 2658 
tags=41%, 
list=20%, 
signal=50% 
KEGG NEUROTROPHIN 
SIGNALING PATHWAY 
116 -0.41 1.82 0.000 0.07 0.300 1802 
tags=29%, 
list=14%, 
signal=34% 
KEGG ERBB SIGNALING 
PATHWAY 
84 -0.43 1.81 0.000 0.07 0.320 1802 
tags=32%, 
list=14%, 
signal=37% 
KEGG NATURAL KILLER 
CELL MEDIATED 
CYTOTOXICITY 
98 -0.43 1.80 0.000 0.06 0.336 2270 
tags=40%, 
list=17%, 
signal=48% 
KEGG GLIOMA 59 -0.46 1.80 0.003 0.06 0.356 1817 
tags=34%, 
list=14%, 
signal=39% 
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many down-regulated genes contained in the most repressed GS related to type I 
interferon (IFN-I), a critical mediator of antiviral responses (Lin & Young, 2014). 
Figure 30. Prolyl-hydroxylase 3 (PHD3)-deficient microglia represses 
antimicrobial responses in Alzheimer’s disease (AD). 
(A-C) Global expression comparison between isolated microglia of 12-month-old 
Egln3 –/–; App-Psen1 versus App-Psen1 mice by Gene Set Enrichment Analysis (GSEA). 
Left plots show enrichment of antimicrobial Gene Sets (GS)s, right panels show the 
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heat map of the top 30 ranking leading edge genes included in each GS, with red 
symbolizing up-regulation and blue, down-regulation. (A) GSEA showing NOD-like 
receptor signalling pathway enrichment. (B) GSEA showing Toll-like receptor 
signalling pathway enrichment. (C) GSEA showing RIG-I-like receptor signalling 
pathway enrichment. 
This result suggests that PHD3 deficiency in AD context is limiting a microglial 
defense response against invading pathogens, with special emphasis in antiviral 
protection. 
4.2.10. PHD3-deficient microglia represses an IFN-β response 
elicited in AD 
To statistically evaluate the potential relevance of the IFN-I pathway in PHD3 
deficient microglia, an IFN-β-induced signature (IβS) from macrophages was 
generated from a previous report (Litvak et al., 2012). GSEA revealed a strong 
induction of the IβS in microglial transcriptional profiles of two different AD mouse 
models (Figure 31, A) obtained from previous reports (Orre et al., 2014; Wang et 
al., 2015). The same approach was used to test the IβS enrichment in the isolated 
microglia from Egln3 –/–; App-Psen1 microglia and a prominent repression of this 
GS was observed (Figure 31, B). In order to confirm this strong repression, the 
mRNA levels of some representative genes contained in the IFN-β signature were 
analyzed by qRT-PCR (Figure 31, C). This group of genes included Rsad2, Trim30, 
Ifit2, Oasl1, and Irf7, an orchestrator gene in the establishment of the antiviral 
response. Importantly, a significant reduction in the mRNA levels of Rsad2, Trim30, 
and Irf7 genes was observed, concomitantly with a trend to reduce mRNA levels of 
Oasl1 and Ifit2 genes.  
These findings suggest that microglia activate a potent antiviral module in AD via 
PHD3 activation. 
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Figure 31. Alzheimer’s disease (AD) microglia elicit an Interferon-β response 
mediated by prolyl-hydroxylase 3 (PHD3) 
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 (A-C) Global expression comparison between isolated microglia from different 
groups of mice by Gene Set Enrichment Analysis (GSEA). Left plots show enrichment 
of Interferon-β Signature (IβS) (Litvak et al., 2012), right panels show the heat map 
of the top 30 ranking leading edge genes included in the IβS, with red symbolizing 
up-regulation and blue, down-regulation. (A) GSEA showing IβS enrichment in the 
comparison of 15-18-month-old App-Psen1 versus wild-type microglia (Orre et al., 
2014) (up) and 8.5-month-old 5xfAD versus wild-type isolated microglia (Wang et al., 
2015). (B) GSEA showing IβS enrichment in the comparison of 12-month-old Egln3 –
/–; App-Psen1 versus App-Psen1 isolated microglia. (C) Reverse transcription real-
time polymerase chain reaction (qRT-PCR) of relevant antiviral genes contained in 
the IβS (Irf7, Rsad2, Trim30d, Ifit2, Oasl1). App-Psen1 mice, grey bar; Egln3 –/–; App-
Psen1 mice, black bar. * p < 0.05, ** p < 0.01; Student’s t-test; n = 3 pools of 2 mice 
per genotype. Bars ± error bars represent mean ± s.e.m. 
4.2.11. Overlapping responses in AD microglia and PHD3-
deficient AD microglia suggest a potentiation of beneficial 
transcriptional responses for AD 
Apparently, the overall gene expression modifications in Egln3 –/–; App-Psen1 in 
comparison to App-Psen1 microglia seemed to potentiate the microglial 
transcriptional profile already present in App-Psen1 microglia, since we found that 
a 67 % of genes up-regulated in Egln3 –/–; App-Psen1 microglia were already up-
regulated in App-Psen1 microglia (Orre et al., 2014) (Figure 32, A).  
For the purpose of confirming our hypothesis, qRT-PCR measurements of some 
representative genes that are overexpressed in microglia from AD mouse models 
(Orre et al., 2014) were performed and a significant increase was demonstrated in 
the expression levels of already up-regulated genes in AD microglia like Mamdc2 
and Cxcl14, accompanied by a trend to increase other already up-regulated genes 
like Postn and Dkk2 (Figure 32, B) 
Given that our previous results showed less neurotoxicity that correlated with 
both motor and cognitive functional improvement, we hypothesized that PHD3 
absence could be promoting beneficial functional modules in terms of AD outcome. 
Loss-of-function Trem2 gene polymorphisms, a gene whose expression in virtually 
confined to microglia within the CNS, are among the strongest risk factors 
associated to sAD (Condello et al., 2017). Interestingly, microarray data generated 
in this thesis showed a statistically significant increment in Trem2 mRNA levels 
(logFC = 0.47; p = 0.003) that we were not able to reproduce with qRT-PCR, 
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probably due to technical issues. Alternatively, gain-of-function Cd33 gene 
polymorphisms, a gene involved in phagocytosis restriction, are associated with 
sAD (Griciuc et al., 2013). We obtained a significant reduction in Cd33 mRNA levels 
from Egln3 –/–; App-Psen1 microglia in comparison with App-Psen1 microglia 
(Figure 33). 
Figure 32. Prolyl-hydroxylase 3 (PHD3) absence in the microglia from 
Alzheimer's disease (AD) mouse models potentiates AD-related microglial 
responses. 
(A) Venn diagram including up-regulated genes in the comparison between 15-18-
month-old App-Psen1 versus wild-type isolated microglia (Orre et al., 2014) and up-
regulated genes in the comparison between 12-month-old Egln3 –/–; App-Psen1 
versus App-Psen1 isolated microglia. (B) Reverse transcription real-time polymerase 
chain reaction (qRT-PCR) of some genes contained in the overlapping area in A 
(Mamdc2, Postn, Cxcl14, Dkk2). App-Psen1 mice, grey bar; Egln3 –/–; App-Psen1 mice, 
black bar. * p < 0.05, ** p < 0.01; Student’s t-test; n = 3 pools of 2 mice per genotype. 
Bars ± error bars represent mean ± s.e.m. 
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These results suggest a potentiation of beneficial responses upon Egln3 deletion in 
AD. 
 
 
Figure 33. Microglial transcriptional changes 
associated to beneficial outcomes for Alzheimer's 
disease (AD) are observed in AD-related genetic risk 
factors upon prolyl-hydroxylase 3 (PHD3) deficiency. 
Reverse transcription real-time polymerase chain reaction 
(qRT-PCR) of Cd33 gene, a genetic risk factors with loss-of-
function polymorphisms associated to AD. App-Psen1 mice, 
grey bar; Egln3 –/–; App-Psen1 mice, black bar. * p < 0.05; 
Student’s t-test; n = 3 pools of 2 mice per genotype. Bars ± 
error bars represent mean ± s.e.m.  
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5. Discussion 
In order to facilitate a comprehensive and conceptual organization, the discussion 
is presented according to the objectives. 
5.1. Objective 1: Hypoxia on AβPP 
processing 
Our results show that neither ASH nor CSH promotes AβPP overproduction or an 
AβPP processing shift towards the amyloidogenic pathway, in wild-type C57/BI6J 
or App-Psen1 mice. mRNA levels of the genes encoding for Aβ-degrading enzymes 
were also similar in our hypoxic paradigms versus normoxia. We validated our ASH 
approach by corroborating brain HIF1α stabilization and transcriptional induction 
of Vegfa. Our CSH protocol was also confirmed by the moderate transcriptional 
induction and protein accumulation of VEGF, concomitantly with an increased 
hematocrit load, revealing local and systemic adaptations to hypoxia. Young wild-
type C57/BI6J mice did not show transcriptional changes in App gene, AβPP 
processing-related genes or genes encoding for Aβ-degrading enzymes either in 
ASH or in CSH. Neither AβPP production nor BACE1 protein levels increased in 
sustained hypoxic conditions in wild-type C57/BI6J mice. In fact, we detected a 
reduction in BACE1 protein levels after 16 h of ASH. Although Aβ peptides could 
not be quantified, an estimation of non-amyloidogenic processing of AβPP versus 
amyloidogenic AβPP proteolysis was obtained in CSH by calculating the ratio 
between C99 and C83 fragments and no differences were obtained. We extended 
our CSH approach to young and aged App-Psen1 mice in order to test potential 
effects in an Aβ-accumulation scenario and no changes in AβPP or sAβPPα protein 
levels were detected in their brains. Importantly, we also measured by ELISA Aβ 
load in these mice and observed no differences either in Aβ1-40 or Aβ1-42 burden 
regarding normoxia. 
Our findings are in sharp contrast with a number of previous studies in which 
hypoxia resulted in increased Aβ accumulation due to differences in mRNA levels 
and protein levels of AβPP or Aβ-related enzymes. Some studies proposed an 
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increment in AβPP production itself (Chen et al., 2003; Liu et al., 2016; Moussavi et 
al., 2012; Zhang et al., 2013) concomitantly, in some cases, with elevated 
transcription or protein levels of the most rate-limiting pro-amyloidogenic enzyme 
BACE1 (Guglielmotto et al., 2009; Liu et al., 2016; Moussavi et al., 2012; Sun et al., 
2006; Zhang et al., 2007). Higher levels of the different components of ɣ-secretase 
complex are linked to increased Aβ production. In this sense, PS1 (Moussavi et al., 
2012; Smith et al., 2004), PS2 (Moussavi et al., 2012), APH1a (Li et al., 2009; Liu et 
al., 2016; Wang et al., 2006), nicastrin (Liu et al., 2016) and PS enhancer 2 (Liu et 
al., 2016) are among the reported up-regulated components of ɣ-secretase 
complex in hypoxia. Inhibition or down-regulation of Aβ-degrading enzymes is an 
important contributor to Aβ accumulation (Fukami et al., 2002; Jha et al., 2015). 
Some studies have described a decrease in neprilysin enzyme, one of the most 
relevant Aβ-degrading enzymes, upon hypoxia treatment (Kerridge et al., 2015; Liu 
et al., 2016; Zhang et al., 2013). 
Different hypothesis and mechanisms have emerged from these studies in order to 
explain the observed Aβ metabolism and phenotypic alterations in hypoxia. Most 
of these mechanisms are based on HIF1α stabilization under hypoxia. Moreover, 
HREs have been reported in promoter regions of some Aβ-related genes. Sun et al. 
found HIF1α binding to an HRE element upstream Bace1 gene that activated Bace1 
expression in in vivo SH-SY5Y cells (Sun et al., 2006) and posterior studies have 
explained their augmentation in BACE1 on the basis of this HIF1α binding to Bace1 
upstream HRE (Guglielmotto et al., 2009; Zhang et al., 2007). Although we 
validated a HIF1α increment in our ASH protocol and Vegfa gene and VEGF protein 
up-regulation under CSH, we did not observe Bace1 up-regulation, either at the 
mRNA or at the protein levels. Accordingly, other studies with AD mouse models 
and neuroblastoma SH-SY5Y cells also found equal levels of BACE1 protein in 
normoxia and hypoxia (Shiota et al., 2013) and some of them reported a decrease 
in ADAM10 and/or TACE proteins instead ( Lee et al., 2006; Marshall et al., 2006; 
Webster et al., 2002, 2004), something that we did not detect in our study. A 
similar HRE has been found upstream of Aph1a gene, what would explain an 
increase in ɣ-secretase activity reported in hypoxia by some studies (Li et al., 2009; 
Wang et al., 2006), again arguing against our results. Furthermore, HIF binding 
regions have also been described in Psen1 gene promoter (Bazan & Lukiw, 2002). 
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Importantly, HIF1α binding to HREs has been studied in cell lines in conditions 
where HIF is stabilized and no chromatin immunoprecipitation studies have so far 
demonstrated the binding of this transcription factor to Aβ-related HREs in vitro 
(Schödel et al., 2011) or in vivo, to our knowledge. Moreover, promoter availability 
might be different in diverse cell lines and so, HIF1α-induced genes vary 
accordingly in a cell-type and context-dependent manner (Benita et al., 2009). 
Alternatively, microarray data from different cell-types like MCF7 (Elvidge et al., 
2006), HEK293T (Wang et al., 2005), neuronal (Felfly et al., 2011) and microglial 
cells (unpublished data from our lab) do not show alterations in the mRNA levels 
of any of  Aβ-related genes. Therefore, these apparent contradictions among 
different studies might obey to the different experimental approaches performed.  
Oxidative stress constitutes another extensively recurring mechanism to explain 
transcriptional and biochemical changes reported from previous studies in AβPP 
processing in hypoxia. Mitochondria have long been considered as a high-sensitive 
oxygen sensor. In response to decreased O2 levels, mitochondria produce reactive 
oxygen species (ROS). Although ROS can produce molecular damage, these 
molecules are also associated with increased mitochondrial lifespan and to 
signaling cascades to promote different functional responses (Raamsdonk, 2015). 
In fact, it has been proposed that ROS can stabilize HIFα through inhibition of 
PHDs (Guzy & Schumacker, 2006), potentially leading to transcriptional activation 
of Aβ-related enzymes production by HIFα binding to putative upstream HREs. On 
the other hand, Smith et al. proposed an extra mechanism to promote ɣ-secretase 
activity and subsequent Aβ accumulation based on HIF1α binding to PS1 after 
HIF1α induced stabilization by ROS (Smith et al., 2004). However, posterior 
studies described an apparently HIF1α-independent positive feedback loop in 
which ROS activates JNK signaling that in turn induces Bace1 and ɣ-secretase 
genes. Upon this induction, Aβ accumulates and provokes mitochondrial electron 
transport chain impairment, reinforcing ROS production (Moussavi et al., 2012; 
Tamagno et al., 2008). Although we did not test ROS accumulation, we did not 
observe alteration of the C99/C83 ratio in wild-type mice or Aβ1-40 and Aβ1-42 levels 
in App-Psen1 mice submitted to CSH, strongly arguing against a hypoxia-generated 
ROS triggering of amyloidogenic AβPP processing or Aβ accumulation. Moreover, 
ROS generation in hypoxia are broadly discussed and it has been described that 
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hypoxia produces a short-term ROS burst (Hernansanz-Agustín et al., 2014), but 
hypoxia/reperfusion dynamics provokes an exacerbated ROS accumulation 
(Murphy & Steenbergen, 2008). Remarkably, GWAS studies have revealed that 
genetic modifications altering endolysosomal function, lipid metabolism or 
immune response are more likely to predispose to sAD but no ROS induction-
related genes have emerged from these exhaustive studies, supporting a limited 
contribution for ROS formation in the comorbidity between hypoxia and sAD 
(Pimenova et al., 2018). 
Apart from ROS and HIF1α accumulation-based hypothesis, other mechanisms 
have also been described. Among them, autophagy, caspase activation or 
epigenetics constitute some examples. Li et al. described an increased ɣ-secretase 
activity that accounted for Aβ accumulation in hypoxia due to the formation of 
autophagic vesicles containing ɣ-secretase complex. C99 fragments colocalized 
with autophagic vesicles, suggesting an altered protein trafficking that favors C99 
and ɣ-secretase interaction in these vesicles, facilitating Aβ production (Li et al., 
2009). It has been described that hypoxia during pregnancy has a profound impact 
on AD development and progression in the offspring, very likely exerted by 
epigenetic modifications during development (Zhang et al., 2013). In this sense, it 
has been reported that hypoxia down-regulates the expression of a 
methyltransferase called DNMT3b, resulting in up-regulation of amyloidogenic 
processes (Liu et al., 2016). Kerridge et al. claimed an AICD fragment implication in 
epigenetic processes, mediated by caspases, that decreases Aβ-degrading enzymes 
such as neprilysin and TTR, promoting Aβ accumulation (Kerridge et al., 2014, 
2015). Since all of these mechanisms would be triggering Aβ accumulation, an 
effect that we did not observe with our approach, we did not explore any potential 
involvement of them in our paradigms. Important technical and methodological 
differences among studies may explain such different or even contradictory 
conclusions. First of all, as already mentioned, hypoxic response is highly cell-type 
dependent and therefore, very likely to be different between cell cultures and 
animal models (Harris et al., 2014; Tátrai et al., 2017). A number of studies 
claiming a hypoxia impact on Aβ metabolism have been performed in primary or 
cell lines cultures (Chen et al., 2003; Guglielmotto et al., 2009; Kerridge et al., 2015; 
Smith et al., 2004; Wang et al., 2006; Zhang et al., 2007), while our approach has 
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been integrally based on in vivo wild-type and AD mouse models. Nevertheless, 
remarkable differences are observed even when using the same model organism. 
For example, Lee et al. showed no significant changes in the expression or activity 
of BACE1 after ischemic challenge, while Sun et al. described an up-regulated 
BACE1 activity using the same AD transgenic mice model (Tg2576) (Lee et al., 
2006; Sun et al., 2006). Consequently, other factors are implicated in this 
discrepancy and one of the most relevant ones is the control and proportion of 
hypoxic conditions. 
HIF1α responses are extremely dose-dependent involving even opposing 
responses in the same cell-type upon different O2 tensions. Pulmonary arterial 
smooth muscle cell, cancer cell, and cardiomyocyte proliferation is activated by 
hypoxia; however, if hypoxia exceeds a certain threshold, it leads to cell cycle 
arrest (Hubbi & Semenza, 2015). Therefore, a validated hypoxia treatment must be 
used to draw appropriate conclusions. Our ASH and CSH protocols were validated 
by examining both cellular (HIF1α and VEGF) and systemic (hematocrit) responses 
to hypoxia by using the same hypoxia chambers that we used for the subsequent 
experiments, in which O2, CO2, and humidity conditions are tightly controlled. 
Furthermore, our collaborators had previously confirmed no neuronal death 
induced by our hypoxia treatment (9 % O2), being properly tolerated by mice. 
Moreover, they confirmed a pure induced hypoxemia in this hypoxia treatment, 
discarding off-target hypercapnia or acidosis that could affect our results 
(D’Anglemont de Tassigny et al., 2015). On the contrary, an array of oxygen 
tensions and equipment has been used in previous studies with not fine-control of 
hypoxia conditions in many cases. In studies using primary cell cultures or cell 
lines, some of them have used sealed chambers but not leak-proof (Chen et al., 
2003); others performed NiCl2 treatments in culture medium (Li et al., 2009; Wang 
et al., 2006), so possible side effects could be involved in their results. Previous 
studies involving animal models used semi-sealable chambers with diary 
reoxygenation for 16 h in some cases, so risk of O2 perturbation is significant (Sun 
et al., 2006). In other cases, hypobaric chambers were used to simulate high 
altitude conditions (Liu et al., 2016; Zhang et al., 2013). However, this scenario can 
lead to hypercapnia, alkalosis, pulmonary hypertension and vasogenic edema, so 
side effects apart from pure hypoxemia may account for their finds (Hackett & 
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Roach, 2001; Wilson et al., 2009). Other methodologies involved enclosure of mice 
in sealed jars “until last breath gasping”, a situation of absolutely not controlled O2 
or CO2 levels and that cannot be confounded with chronic hypoxia (Gao et al., 
2013; Li et al., 2009). Therefore, methodological approach and paradigm validation 
may not have been adequate in previous studies to study pure hypoxemia. 
We designed a sustained hypoxia paradigm for two main reasons. The first one is 
that epidemiological studies link many different conditions that involve chronic 
hypoperfusion to sAD (Kalaria, 2000). Secondly, our hypoxia chambers allow as to 
precisely control sustained hypoxia conditions in animals, so we can attribute our 
results directly to the hypoxic treatment. Nevertheless, other studies reporting an 
increased Aβ accumulation and pathology in animal models after hypoxia have 
used chronic intermittent hypoxia paradigms. These approaches were based on 
hypoxia/renormoxia cycles consisting of from minutes to hours of hypoxia on a 
daily basis for up to 1 or 2 months, a scenario hardly translatable to human 
disease.  With this approach, it is not possible to rule out the possibility that 
continuous hypoxia/reperfusion consequences rather than pure hypoxemia were 
provoking their described alterations (Gao et al., 2013; Li et al., 2009; Liu et al., 
2016; Shiota et al., 2013; Sun et al., 2006; Zhang et al., 2013). In this sense, it has 
been reported that intermittent hypoxia is a more potent stimulus than sustained 
hypoxia to elicit HIF1α, c-fos gene, activator protein-1, NF-κB and cAMP-response-
element-binding protein activation, with a number of implications for cell cultures 
and the full animal (Nanduri & Nanduri, 2007). Importantly, as previously said, 
hypoxia/reperfusion also leads to ROS accumulation (Murphy & Steenbergen, 
2008). In fact, we obtained statistically significant increased levels of App and 
Psen1 mRNA levels upon reoxygenation after ASH and CSH, although the 
magnitude of this changes turned them unlikely relevant for the pathology. 
However, we cannot discard further consequences of a greater number of 
hypoxia/reoxygenation cycles in our paradigm. In any case, mimicking conditions 
like OSA would require equipment with the capacity of dramatically changing FiO2 
following the patient’s breathing dynamics (seconds), something that was not 
faithfully emulated by previous studies. 
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Finally, control conditions in previous studies using animal models are also 
doubtful. Chronic stress is linked to increments in Aβ levels (Jeong, 2006). On the 
contrary, environmental enrichment is known to reduce Aβ levels (Lazarov et al., 
2005). In order to avoid any off-target results due to differential stress conditions, 
our control mice were exposed to normoxic conditions in the same hypoxia 
chamber for the same period of time. 
5.2. Objective 2: PHD3 and AD microglia 
We uncover a detrimental role for PHD3 activation in microglia in AD mouse 
models. In AD, upon PHD3 ablation, microglia numbers were unchanged but 
acquired a higher surface expression of CD45 protein. This CD45 enrichment was 
coincident with a moderate increase in in vivo Aβ phagocytosis that correlated with 
a decrease in total Aβ1-42 peptide content. Concomitantly, neuronal dystrophies 
surrounding compact Aβ plaques were diminished, presumably due to the 
detected significant increased microglial direct interaction with Aβ plaques. 
Importantly, these findings resulted in rescue of motor and short-term memory 
alterations exhibited by AD mice. Microarray analysis of Egln3-/-; App-Psen1 versus 
App-Psen1 microglia revealed a selective repression of antimicrobial responses and 
a potentiation of the transcriptional pattern of AD microglia. Particularly, a sterile 
microglial IFN-β response activated in AD mouse models was strongly repressed 
by PHD3 absence.  
Egln3 is poorly expressed by microglia according to single cell RNA-seq 
experiments in the wild-type CD-1 mouse primary somatosensory cortex (Zeisel et 
al., 2015). However, Aβ accumulation induces Egln3 expression in microglia, 
something that we confirmed by in situ. Interestingly, Egln3 mRNA transcription 
was almost exclusively restricted to microglia surrounding amyloid plaques, 
suggesting a triggering factor for Egln3 transcription confined to plaques vicinity. 
In this sense, studies on atherosclerotic plaques, which are also deposits with 
associated macrophages, reported hypoxia and the concomitant HIF1α 
stabilization in surrounding cells  (Marsch et al., 2013; Parathath et al., 2011; 
Silvola et al., 2011). Previous results in our lab demonstrated that a notable 
proportion of Egln3 expression in AD microglia relies on HIF1α, that contributes to 
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the high HMS enrichment exhibited by microglia from aged AD mouse models 
(Orre et al., 2014), in which plaques burden is relatively high. On the other hand, 
since we have used a full Egln3 knock-out mouse, the almost exclusive induction of 
Egln3 in microglia is a supportive argument to attribute our findings to PHD3 
absence in these cells. Nevertheless, a microglial-specific conditional knock-out 
mouse should be used in order to discard off-target effects due to deletion in other 
Egln3-expressing cells. 
The virtually absent expression of Egln3 gene in microglia not associated to 
amyloid plaques might explain the coincident results observed in wild-type and 
Egln3 –/– microglia regarding the same proportion and expression surface markers 
CD11b and CD45. As extensively described in the literature, microglia proliferate 
in Aβ accumulation mouse models (Kamphuis et al., 2012; Olmos-Alonso et al., 
2016), although microglia numbers do not seem to rise in AD patients (Serrano-
Pozo, Gómez-Isla, et al., 2013). We quantified the proportion of cortical microglia 
from App-Psen1 and Egln3 –/–; App-Psen1 mice and found a similar significant 
increase in both genotypes with respects to the control group, suggesting that 
PHD3 absence is not limiting proliferative capacity of AD microglia. We further 
confirmed the same microglial cell number per cortical area by stereological cell 
counting with IBA1, a different microglial marker broadly used. Involvement of 
PHD3 in survival of innate immune cells shows cell-type specificity. PHD3 exerts a 
pro-survival effect in neutrophils that results in delayed inflammatory resolution 
(Walmsley et al., 2011). However, PHD3 induction acts as a pro-apoptotic signal 
for mouse serum-starved cultured macrophages (Swain et al., 2014). Our results 
suggest that, in an AD model, PHD3 induction does not activate a pro-apoptotic 
microglial phenotype, as we did not detect any changes in cell number associated 
with PHD3 deficiency. However, specific experimental approaches would be 
needed to demonstrate this hypothesis. 
Peripheral monocytes infiltration within the brain can occur under certain 
circumstances in which blood-brain barrier is impaired, where they differentiate 
into MDM (Nayak et al., 2014) However, parabiosis experiments showed minimal 
contribution of infiltrating monocytes in AD brains, being microglia responsible for 
the increased macrophage cell number (Wang et al., 2016). MDM usually express 
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high CD45 levels in their surface (Campanella et al., 2002; Denker et al., 2007) and 
we found that Egln3-/-; App-Psen1 microglia displayed an increased CD45 surface 
expression marker regarding App-Psen1 microglia. Although it has been described 
that under steady-state and degenerative conditions brain macrophage number 
increases upon microglial precursors proliferation (Nayak et al., 2014), it could be 
possible that PHD3 absence facilitated the entry of monocytes to the brain 
parenchyma. Therefore, high CD45-expressing events would belong to MDM 
instead of a phenotypically different resident microglia. We ruled out this 
possibility for two main reasons. First of all, we had the same microglial 
proportion and number in App-Psen1 and Egln3 –/–; App-Psen1, according to flow 
cytometry and stereological experiments. Hence, an entry of monocytes from the 
bloodstream without altering total proportions would necessarily involve a 
proportional microglial death or proliferation arrest, something even more 
unlikely to happen if we consider the potential inhibition of apoptosis due to the 
lack of PHD3 in macrophages, as previously described (Swain et al., 2014). 
Secondly, the differentially expressed genes between microglia from Egln3 –/–; App-
Psen1 and App-Psen1 mice did not reveal any increase in macrophage or decrease 
in microglia markers, something that should be expected if microglia were being 
replaced by MDM (Hickman et al., 2013). 
We also analyzed in vivo Aβ phagocytic capacity of microglia in Egln3 –/–; App-Psen1 
and App-Psen1 mice. We observed a modest increase in the proportion of 
phagocytic microglia in Egln3 –/–; App-Psen1 versus App-Psen1 mice. Our results are 
consistent with previous studies relating CD45 increase with enhanced phagocytic 
skills in microglia. For instance, Zhu et al. used primary microglial cultures treated 
with agonistic CD45 antibodies and found an enhanced Aβ phagocytic activity. By 
contrast, loss of CD45 resulted in a pro-inflammatory phenotype with unexpected 
decreased Aβ phagocytic ability (Zhu et al., 2011). On the other hand, a different 
approach was used to study CD45 involvement in microglia phagocytosis. 
Rangaraju et al. isolated CD11b+ CD45low separately from CD11b+ CD45high 
microglia from 5xfAD mouse models, an aggressive Aβ accumulation transgenic 
mouse model, by FACS. Next, they assessed phagocytosis of fAβ1-42 of the acute ex 
vivo isolated microglia and described an increased phagocytic activity in CD45high 
microglia (Rangaraju et al., 2018).  The increased phagocytosis observed in Egln3 –
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/–; App-Psen1 microglia is in fair agreement with the detected decrease in Cd33 
mRNA levels that we confirmed in these microglia regarding App-Psen1 microglia, 
since CD33 has been described as a blocker of phagocytosis for these cells (Griciuc 
et al., 2013). On the order hand, we hypothesize that the increased proximity of 
microglia to Aβ plaques detected in Egln3 –/–; App-Psen1 mice could also favor Aβ 
phagocytosis because of their closer interaction with these Aβ reservoirs, as 
already suggested (Wang et al., 2015). Presumably, an increment in the number of 
individuals for phagocytosis experiments would provide enough statistical power 
to raise significant differences, given the strong trend observed. 
An increased phagocytic capacity could potentially correspond to diminished Aβ 
levels, which associate with a good prognosis for AD (Rangaraju et al., 2018). We 
measured total Aβ1-40 and Aβ1-42 content in mouse cortices by ELISA and we 
obtained a modest decrease in Aβ1-40 and a significant decrease in Aβ1-42 in cortical 
extracts from Egln3 –/–; App-Psen1 versus App-Psen1 mice. This decrease in total Aβ 
content might be due to the observed elevated phagocytic activity in Egln3 –/–; App-
Psen1. However, other factors could also be playing a role in Aβ content decrease. 
For instance, experiments performed with cultured adult mouse astrocytes 
demonstrated an Aβ-degrading activity for these cells that could be mediated by 
extracellular degradation, since these cells produce Aβ-degrading enzymes, or 
intracellularly, given that astrocytes are capable of engulf Aβ and attempt to 
perform lysosomal degradation in AD patients (Birch, 2014; Funato et al., 1998; 
Wyss-Coray et al., 2003). Nevertheless, a direct impact of PHD3 absence in 
astrocytes is unexpected since Egln3 is not induced in astrocytes in AD mouse 
models (Orre et al., 2014), although we cannot discard an indirect effect on 
astrocyte-mediated Aβ degradation by Egln3 microglial deletion. Microglia are also 
a source of Aβ-degrading enzymes (Tarasoff-Conway et al., 2015). Although our 
microarray data did not show up-regulated expression of genes of some of the 
main Aβ-degrading enzymes like neprilysin or IDE enzyme in Egln3 –/–; App-Psen1 
microglia, we cannot discard other mechanisms influencing the activity, amount or 
localization of these enzymes in which PHD3 could be involved. Finally, clearance 
of Aβ across the blood-brain barrier constitutes one of the main Aβ drainage 
systems from the brain (Tarasoff-Conway et al., 2015) and we have not explored a 
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possible involvement of PHD3 deficiency in Aβ efflux from the brain, either by 
direct or indirect consequences of Egln3 microglial. 
Unexpectedly, we detected a statistically significant increase in soluble Aβ1-40 and a 
trend to increase soluble Aβ1-42 in Egln3 –/–; App-Psen1 regarding App-Psen1 mice. 
Both the diminished neuronal damage surrounding amyloid plaques that we 
detected and, above all, the rescue of the motor and memory-related symptoms are 
in sharp contrast with a growing body of evidence that attributes significant 
neurotoxic functions to soluble Aβ oligomers. In fact, cognitive deficit and synaptic 
loss have been shown to correlate more accurately with soluble Aβ oligomers than 
with amyloid plaques load (Finder & Glockshuber, 2007; Haass & Selkoe, 2007; 
Walsh & Selkoe, 2007). However, two important aspects deserve to be considered 
in order to interpret our result. Firstly, the magnitude of soluble Aβ increase is 
relatively small, so its pathogenic significance remains unclear. Secondly, the 
soluble Aβ concentrations measured in the samples were very close to the 
detection limits of the used technique, so reliability of this data is uncertain. In any 
case, it is important to remark that the soluble concentration of Aβ detected 
constitutes a derisory contribution to the reliable, in technical terms, detected 
decrease in total Aβ1-42 concentration in Egln3 –/–; App-Psen1 regarding App-Psen1 
mice, reportedly the most toxic Aβ peptide fragment (Mattson et al., 1992; Selkoe, 
2001). Moreover, the soluble Aβ fraction is composed by different Aβ populations 
in several oligomerization stages, which exhibit different potential toxicity (Finder 
& Glockshuber, 2007). Thus, it could be possible that oligomerization states of Aβ 
in the soluble fraction of Egln3 –/–; App-Psen1 mice are less neurotoxic than the 
oligomerization states in App-Psen1 mice. 
PHD3 deficiency resulted in modification of amyloid plaque parameters. Egln3 –/–; 
App-Psen1 mice exhibited increased proportion of dense-core amyloid plaques due 
to an elevated number of small compact plaques. Concomitantly, a significant 
increase in fAβ plaques burden was observed in these mice. Although Aβ 
accumulation is accepted to constitute the initial event leading to the downstream 
effects that culminate in AD (Hardy & Higgins, 1992), a poor correlation is found 
between plaques burden and the disease progression (Serrano-Pozo et al., 2011). 
In fact, it has even been proposed that amyloid plaques could contribute to 
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inactivation and nucleation of more neurotoxic Aβ species, potentially reducing 
neuronal damage (Finder & Glockshuber, 2007). On the other hand, our burden 
measurements are not recapitulating the total Aβ content measurements. While we 
observed a significant decrease in Aβ1-42 concentration and a strong trend to 
diminish Aβ1-40 concentration in Egln3 –/–; App-Psen1 regarding App-Psen1 mice, 
we obtained an increased occupied burden by fAβ conformations and a trend to 
elevated dense-core amyloid burden. The natural explanation for these results 
would involve a less dense conformation in amyloid deposits of Egln3 –/–; App-
Psen1 mice. Even though a closer interaction between microglia and amyloid 
plaques is hypothetically promoting plaque compaction (Yuan et al., 2016), we did 
not see enhanced plaque compaction activity on the fAβ halo upon closer 
interaction of microglia with big compact amyloid plaques, in which neuronal 
dystrophies were quantified. Therefore, it could be possible that, considering the 
high aggregation properties of Aβ1-40 and Aβ1-42 peptides and their higher 
concentrations in App-Psen1 mice, App-Psen1 mice’s amyloid plaques contain more 
Aβ load than Egln3 –/–; App-Psen1 mice’s plaques, something that we could not 
capture in our immunostaining quantifications since we did not quantify 
fluorescence intensity but occupied area. Whether the microglia promoted 
somehow the formation of the small amyloid plaques in Egln3 –/–; App-Psen1 is 
unknown, but we speculate that the closer proximity of microglia with amyloid 
plaques could be related. In any case, a deeper study on the different properties of 
amyloid deposits from App-Psen1 and Egln3 –/–; App-Psen1 and their microglia 
compaction activity would be needed to fully explain our results. 
We observed an increased microglia proximity to amyloid plaques in Egln3 –/–; 
App-Psen1 versus App-Psen1 mice. A greater microglia proximity to amyloid 
plaques entails an improved microglia chemotactic and migratory capacity and 
some of our results are consistent with this hypothesis. Firstly, microglia from 
CD45 Egln3 –/–; App-Psen1 mice displayed enriched CD45 protein and it has been 
described that CD45 knock-out MDM exhibit disrupted adhesion and motility (St-
Pierre & Ostergaard, 2013). Hypothetically, CD45 overexpression might potentially 
lead to increased motile ability. Secondly, one of the most prominent described 
genes regulating microglial migration towards Aβ plaques is Trem2. Trem2 
mutations constitute one of the strongest genetic risk factors that predispose to AD 
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and its deficiency directly impairs microglial migration, clustering and activation 
around amyloid plaques (Wang et al., 2015). Interestingly, we observed an 
increase in Trem2 mRNA by microarray analysis. Moreover, other up-regulated 
genes, according to microarray data, could be promoting microglial migration. In 
this regard, genes encoding for chemotactic receptors were significantly induced in 
the microglia from Egln3 –/–; App-Psen1 versus App-Psen1. Among them, Plxna2 and 
Plxnc1 genes encode for Semaphorin receptors. Semaphorins are extracellular or 
secreted proteins that regulate different aspects of the nervous system, like axon 
guidance, and immune system response via signaling through Plexin receptors 
(Worzfeld & Offermanns, 2014). In hypoxic tumor areas, macrophages migration is 
regulated by the chemoattractant activity of Sema3A, that promotes macrophage 
motility and trapping via Nrp1 and PlexinA1/PlexinA4 binding (Casazza et al., 
2013).  Moreover, Egln3 –/–; App-Psen1 microglia also up-regulated the expression 
of Ccr2, a well-characterized chemoreceptor that participates in the migration of 
immune cells ( Liu et al., 2014). In spite of the overexpression of these genes, 
production of the ligands for their encoded receptors should be verified in plaques 
vicinity in order to establish a likely implication in PHD3 deficient AD microglia 
enhanced migration. 
The increased microglia proximity to amyloid plaques correlated with a reduction 
in neuronal dystrophies surrounding amyloid plaques. fAβ has been associated to 
increased neurotoxicity and its compaction can be mediated by direct interaction 
with microglial processes (Condello et al., 2015; Yuan et al., 2016). We estimated 
the size of the fAβ halo surrounding amyloid plaques with the same features than 
the ones used for neuronal dystrophies quantification and it remained unchanged. 
This result discards a microglia protective effect on plaques surrounding neurons 
based on modification of plaques conformation. On the other hand, microglia can 
act as a physical barrier to prevent neuronal contact with amyloid plaques (Yuan et 
al., 2016). We speculate that microglial insulation of amyloid plaques, potentially 
enhanced by increased microglia proximity, could account for the decreased 
neuronal damage observed in Egln3 –/–; App-Psen1 mice. In fact, the increased 
clustered microglia burden in the cortex of Egln3-/-; App-Psen1 with respects to 
App-Psen1 mice, without changes in microglia number, suggests a more extensive 
microglial coverage of plaques vicinity. Moreover, we discarded a contribution of 
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morphological changes in non-clustered microglia to the increased calculated 
burden, since their morphology remained unaltered, something consistent with 
the low mRNA levels of Egln3 in these cells in App-Psen1 mice that we obtained by 
in situ hybridization. Furthermore, morphological alterations in clustered 
microglia that increase their plaque coverage could also be implicated, since Egln3 
–/–; App-Psen1 microglia exhibit more CD45 protein load and CD45 has been linked 
to morphological changes in macrophages (St-Pierre & Ostergaard, 2013). In any 
case, the precise protective mechanism and whether it relies directly on microglial 
barrier effect remains unclear.  
Behavioural experiments aimed to test motor and short-term memory assessment 
of control mice, App-Psen1 and Egln3 –/–; App-Psen1 revealed a protection of AD-
related impairment. However, we cannot confirm whether it is due to a delay of 
behavioural symptoms occurrence or a complete prevention. On the other hand, 
microglial conditional knock-out Egln3 mice should be used to confirm whether 
these results rely exclusively on microglia Egln3 deletion or if they could be due to 
Egln3 deficiency in other cell types. Moreover, whether PHD3 absence would exert 
beneficial effects once the disease is developed is an open question. Furthermore, 
we could not confirm a synaptic defect and subsequent rescue of AD upon PHD3 
deficiency. In spite of that, the fact that we did not detect a decrease in synaptic 
proteins could obey to compensatory mechanisms consisting in enlargement of 
remaining synapses, keeping a constant load of synaptic markers. Thus, an existing 
decline in the number of synapses might not be detected by measuring synaptic 
proteins load, so a more detailed imaging approach would be needed to ascertain 
synaptic changes. Hence, mechanistic insights linking histological and behavioural 
phenotypes are lacking. 
We analyzed the microarray data of isolated microglia of from App-Psen1 and 
Egln3 –/–; App-Psen1 mice in order to identify the molecular mechanisms that 
explain the microglial phenotype observed upon PHD3 absence. As PHD3 if a well-
known HIF1α prolyl-hydroxylase, we expected a further increase in HMS elicited 
mediated by increased HIF1α stabilization in Egln3 –/–; App-Psen1. We did not 
observe either higher levels of HIF1α protein or over-expression of the HMS in 
Egln3 –/–; App-Psen1 versus App-Psen1 microglia. We did not observe any clues 
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about elicited compensatory mechanisms to reduce HIF1α stabilization either. In 
this regard, we did not obtain transcriptional changes in Egln1, Egln2, Epas1 or 
Arnt genes in microarray data, although a significant low-magnitude change was 
detected for Arnt2 gene. This is in agreement with myeloid specific Egln3 knock-
out MDM in which no compensatory induction of other PHDs and HIF1α or HIF2α 
levels remained unaltered (Swain et al., 2014). By contrast, Kiss et al. found 
enhanced HIF1α stabilization, but not HIF2α, in macrophages subjected to LPS 
treatment in the absence of PHD3 (Kiss et al., 2012). Therefore, compensatory 
mechanisms might be promoted in a context-dependent manner. On the other 
hand, this absence of compensatory mechanisms suggests additional functions for 
PHD3 in AD microglia. In this sense, PHD3 has been suggested to have non-HIF 
targets and downstream effectors and even non-catalytic effects have been 
attributed to PHD3 (Jaakkola & Rantanen, 2013; Rodriguez et al., 2016; Walmsley 
et al., 2011). 
A complex metabolic readjustment was manifested Egln3 –/–; App-Psen1 versus 
App-Psen1 microglia from GSEA analysis using “KEGG pathway database”. Even 
though we did not go deeper into metabolic regulation due to PHD3 deficiency, it 
has broadly been described the close interaction between metabolic status and 
immune response (Ganeshan & Chawla, 2014; Osborn & Olefsky, 2012) so further 
analysis could be worthwhile. Notable enough was the prominent repression of 
antimicrobial modules in general and IFN-β response in particular, in Egln3 –/–; 
App-Psen1 microglia. Interestingly, IFN-β response has been described upon HIF1α 
stabilization (Hwang et al., 2006). Conversely, a potentiation of other AD-
microglial transcriptional responses was observed in Egln3 –/–; App-Psen1 
microglia. In spite of the fact that PHD3 had not previously been associated with 
antimicrobial responses, it was induced in macrophages from patients suffering 
from ulcerative colitis or Crohn’s disease (Escribese et al., 2012). Interestingly, the 
absence of PHD3 has been associated with clinical improvement in mouse models 
of ulcerative colitis and acute lung injury, through HIF-independent mechanisms 
(Walmsley et al., 2011), but with worse outcome in a HIF1-dependent manner in 
a sepsis mouse model (Kiss et al., 2012). We hypothesize that microglial fitness has 
not been under selective pressure to confront pathological Aβ accumulation since 
it is an aging-associated event that takes place after fertile age has culminated. 
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Microglia, as immune cells, are equipped with an arsenal of receptors (Hickman et 
al., 2013), many of which are activated by Aβ (Lucin & Wyss-Coray, 2009). We 
propose that the IFN-β-related response activated by the HIF1-PHD3 pathway in 
AD microglia is maladaptive, inducing the activation of microglial cells against a 
non-real threat, like viruses or bacteria. Similar “sterile” (in the absence of 
pathogen) activation of immune cells has been observed in the peripheral immune 
system and can be pathogenic (Rock et al., 2010). Silencing of this “sterile” 
response could favor beneficial modules, like CD33 decrease to promote Aβ 
phagocytosis. Our results also indicate that the reduction of the anti-
microorganism modules observed in AD microglia by PHD3 deficiency allows a 
better microglial response to the pathology, strongly suggesting that specific 
pathways can be modulated in microglia to optimize biological responses to AD. 
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6. Conclusions 
1. Both ASH and CSH protocols used in this study promote a cellular and 
systemic hypoxic response in mice. 
2. Neither ASH nor CSH significantly impact on the mRNA levels of App, α-
secretase (Adam9, Adam10, and Adam17/TACE), β-secretase (Bace1), ɣ-
secretase (Psen1, Psen2, Ncstn, Pen2, Aph1a, and Aph1b-c), and Aβ-
degrading enzymes (Bace2, Ide, and Mme) genes in wild-type mice. 
3. A reoxygenation cycle after sustained hypoxia protocols increases the 
mRNA levels of Psen1 gene, after ASH, and App gene, after CSH, without 
altering mRNA levels of the rest of Aβ-related enzymes. 
4. Wild-type mice under ASH or CHS do not modify protein levels of BACE1 or 
AβPP as well as C99/C83 ratio in CSH, discarding a pro-amyloidogenic shift 
of AβPP processing. 
5. CSH in 8-month-old and 14-month-old App-Psen1 mice does not alter 
protein levels of FL-AβPP, sAβPPα, Aβ1-40 and Aβ1-42, so a pro-
amyloidogenic shift of AβPP processing is not promoted. 
6. Egln3 mRNA expression in microglia of App-Psen1 mice is specifically 
induced in amyloid plaques vicinity. 
7. PHD3 deficiency in App-Psen1 mice does not affect microglia proliferation 
whereas increases CD45 protein load and microglial Aβ phagocytic capacity, 
what associates with decreased total Aβ1-42 content but elevated number of 
small compact plaques and fAβ cortical coverage. 
8. An increased microglia proximity to amyloid plaques correlates with 
decreased neuronal dystrophies in plaques vicinity and motor and memory 
defects in App-Psen1 mice upon PHD3 absence. 
9. Microarray data from PHD3 deficient microglia reveals a repression of anti-
microbial responses elicited in App-Psen1 microglia that correlates with a 
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potentiation of functional modules associated with beneficial outcomes for 
AD. 
10. Hypoxia does not affect Aβ-related genes or AβPP processing by-products 
but can induce the activation of HIF target genes, like Egln3, whose 
expression entails detrimental outcomes for AD. 
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7. Materials and methods 
7.1. Mice models, housing and handling 
Mice were housed under controlled temperature (22 °C) and humidity (55 %) 
conditions in a 12 h light/dark cycle with ad libitum access to food and water. 
Housing and treatments were performed according to the animal care guidelines of 
European Community Council (86/60/EEC). The Animal Research Committee at 
the Hospital Universitario Virgen del Rocío approved all procedures. Experimental 
groups were homogenously distributed by sex and assigned to each experiment 
without previous observation of the mice by the experimenter. No randomization 
methods were employed. Mice were euthanized intraperitoneally by 
administration of 200 mg/Kg of sodium thiopental (Braun) at 5 % (m/v) in saline 
solution (Fresenius Kabi España S. A.). When sublethally anesthetized, a 150 
mg/kg dosage of the same solution was used.  
Mice of Objective 1 were sacrifice and their samples were obtained as described 
below. Mice of Objective 2 destined to ELISA, WB or immunostaining were 
euthanized and subjected to intracardiac perfusion of 30 mL of phosphate-buffered 
saline (PBS) to promote blood drainage. Whole brains were extracted from skulls 
and subsequently divided into two hemibrains. One of them was dissected to 
obtain cortical and hippocampal samples for ELISA and WB experiments. The 
remaining one was fixed over night for posterior immunostaining techniques in 4 
% paraformaldehyde (Sigma) in PBS (m/v), pH 7.4. 
7.1.1. Mouse models for Objective 1: Hypoxia on AβPP 
processing 
Heterozygous B6.Cg-Tg(APPswe,PSEN19E)85Dbo/J (App-Psen1; stock number 
005864) was obtained from Jackson Laboratories. This transgenic mouse was 
generated by genomic insertion in the same locus of two genetic constructions 
harboring fAD mutations, whose transcription is restricted to the CNS because of 
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being under the control of prion protein promoter (Jankowsky et al., 2001). One of 
these genetic constructions consists of human Psen1 gene with a mutation that 
involves loss of exon 9 in Psen1 mRNA during splicing, resulting in a PS1 version 
that promotes Aβ1-42 production (Jankowsky et al., 2004). The other genetic 
construction is a chimeric version of the mouse App gene carrying two base pair 
transversions found in human fAD plus the human Aβ sequence, which replaces 
the mouse one within this App chimera. The resulting AβPP protein exhibits the 
substitution of a lysine for an asparagine and a methionine for a leucine 
(K594N/M595L) preceding the Aβ fragment, what turns it more prone to 
amyloidogenic processing (Haass et al., 1995). This animal model exhibits early 
amyloid deposition, with senile plaques detectable from 4-6 months old and 
modest neuronal loss surrounding plaques from 9 months old, although NTFs have 
not been reported. Therefore, it is considered as an appropriate AD mouse model 
to explore pathological and biochemical aspects related to Aβ deposition (Garcia-
Alloza et al., 2006; Jackson et al., 2016) 
Wild-type mice were obtained by crossing C57/Bl6J mice with App-Psen1 mice. 
7.1.2. Mouse models for Objective 2: PHD3 and AD microglia 
Egln3 –/– (Bishop et al., 2008) mouse was a generous gift from Prof. Peter J. 
Ratcliffe. It was generated by introducing a neomycin resistance cassette within 
exon 1 of Egln3 gene. Wild-type, Egln3 –/–, App-Psen1 and Egln3 –/–; App-Psen1 
littermates were obtained by successive crosses among Egln3 –/– and App-Psen1 
mice and resulting offspring. 
7.2. Mouse genotyping 
Mice biopsies were incubated with 75 µL of “Solution A” (NaOH 25 mM, EDTA 0.2 
mM, in ultrapure H2O) for 30 min at 98 ºC in a Thermomixer (Eppendorf) at 450 
rpm in order to digest mice tissues and extract DNA. Then, 75 µL of “Solution B” 
(Tris-HCl 40 mM pH 5, in ultrapure H2O) were added and vortexed to stop 
“Solution A” reaction. 
Polymerase Chain Reaction (PCR) in a Thermocycler (Biometra Professional Trio) 
was performed with oligonucleotides collected in Table 6, following the programs 
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detailed in Table 7. Polymerase reaction was prepared in a final volume of 25 µL 
containing 5 µL NH4 10x (Bioline), 2.5 mM MgCl2 (Bioline), 1 mM of each 
deoxyribonucleotide (dNTP, Invitrogen), 0.66 µM of forward primer (Sigma), 0.66 
µM of reverse primer (Sigma), 5 µL of extracted DNA, 1.5 U of DNA polymerase 
enzyme (BIOTAQTM, Bioline) and fill up to 25 µL with sterilized distilled H2O 
(dH2O).  
PCR 
Forward primer  
sequence (5’ 3’) 
Reverse primer  
sequence (5’ 3’) 
Wild-type Egln3  GAGCACCCTTATAAAAAGCAAGTGA TGCAGAAACACCCCAGATGA 
Egln3 Knock-out GGAAAAGCGCCTCCCCTA GGTTATTTAGTGCAGAAACACCCC 
App-Psen1 CTTGTAAGTTGGATTCTCTATATCCG GACTGACCACTCGACCAGGTTCTG 
 
Table 6. Primers used for genotyping. 
Primers used for mice genotyping by polymerase chain reaction (PCR). 
PCR Wild-type Egln3 Egln3 Knock-out 
App-Psen1 
insertion 
Phases Temp. Time Temp. Time Temp. Time 
DNA denaturation 94 °C 2 min 94 °C 2 min 94 °C 2 min 
Amplification 
(41 cycles for both Egln3 and 
36 cycles for App-Psen1 ) 
94 °C 30 s 94 °C 30 s 94 °C 30 s 
65 °C 30 s 65 °C 30 s 65 °C 30 s 
72 °C 1 min 72 °C 1 min 72 °C 1 min 
Final elongation 72 °C 10 min 72 °C 10 min 72 °C 10 min 
Storage 4 °C Pause 4 °C Pause 4 °C Pause 
Amplicon size (Kb) 300 250 350 
 
Table 7. Polymerase chain reaction (PCR) conditions. 
PCR conditions for the different genetic sequences using the primers from table 7. 
Size of PCR products was tested by agarose gel electrophoresis. Briefly, 2.5 µL of 
loading buffer (bromophenol blue 0.25 % v/v, xylene-cyanol FF 0.25 %,  glycerol 
30 %) were added to each sample prior to loading 25 µL of each of them into 2.5 % 
agarose gel prepared in TBE buffer (Tris-base 0.09 M, boric acid 0.0899 M, EDTA 2 
mM) and supplemented with 4 % Midori Green AdvanceTM (Nippon Genetics). PCR 
products were observed under UV light after migration. 
7.3. Hypoxia treatment and hematocrit 
measurement  
Mice were exposed to a 9 % O2 environment by using a hermetic chamber specially 
designed for hypoxia studies in animals (Coy Laboratory Products, Inc., Grass Lake, 
MI). This chamber is equipped with O2 and CO2 controllers and temperature and 
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humidity monitoring. A pump connected with the humidity and CO2 controllers 
mobilizes the air within the chamber and enables to regulate these parameters. O2 
levels were monitored every other day and only ±0.5 % differences were 
considered acceptable. CO2 within the chamber was kept at a minimum (< 0.1 %) 
by filtering the air through a sodasorb (Grace) filter. Humidity was maintained 
below 70 % at all times by filtering the air through a silica gel (Panreac) filter. 
Access into the chamber to feed the mice and clean their cages was achieved 
without altering the experimental conditions through glove ports and an airlock 
(transfer chamber). Light/dark, feeding, and cleaning cycles were kept uniform for 
all groups.  
2-3-month-old wild-type mice were exposed to either ASH (9 % O2, 4 to 16 h), 
followed or not by subsequent 24 h of reoxygenation, or CSH (9 % O2 
uninterrupted for 21 or 30 d), with or without subsequent reoxygenation for 24 h. 
8 and 14-month-old App-Psen1 mice were exposed to CSH (9 % O2, 21 d) without 
reoxygenation. 
Littermate wild-type and App-Psen1 “normoxic” control mice of the same ages as 
above were also exposed to the same chamber for the same period of time, but 
under a 21% O2 environment.    
Animals were euthanized within the hypoxia chamber in order to minimize 
potential reoxygenation effects after the ASH and CSH protocols. Brains were 
extracted within the hypoxia chamber, snap frozen in liquid nitrogen, and stored at 
-80 °C for later use -qRT-PCR, WB, and ELISA-. 
Hematocrit was measured in 14-month-old App-Psen1 mice subjected to CSH (21 d, 
9 % O2, n = 4) or normoxia (21 d, 21 % O2, n = 4). Mice were sublethally 
anesthetized straight after taking them out of the chamber. After dissection of 
abdominal and thoracic skin, the hearth was exposed by thoracic cage removal. 
Blood from right atrium after a small incision was collected in capillaries for 
subsequent centrifugation at 5000 rpm for 5 min to isolate the granular 
component of the blood from the plasma (P Selecta Centrolit II). Hematocrit was 
calculated as the ratio of the length of the granular part, measured with a ruler, 
divided by the total length occupied by blood in the capillaries and multiplied by 
100. 
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7.4. RNA extraction and qRT-PCR 
7.4.1. Objective 1: Hypoxia on AβPP processing 
Whole hemibrain samples of 2-3-month-old wild-type mice per group (n = 4) were 
digested with a tissue homogenizer (Omni TH) in the presence of TRIzol (Life 
technologies), following manufacturer’s instructions to obtain RNA. RNA samples 
(0.5 µg) were treated with RNAase-free DNAse treatment (GE Healthcare) and 
subsequently retro-transcribed to cDNA with SuperScriptII reverse transcriptase 
(Invitrogen) in a final volume of 20 µL. ABI Prism 7500 Sequence Detection System 
(Applied Biosystems) using Power SYBR-Green PCR Master Mix (Applied-
Biosystems) was used to perform the qRT-PCR. Normalization of results by input 
cDNA amount was performed by including a real time PCR for 18S mRNA in each 
plate. ΔΔCt method was used for quantification (Livak & Schmittgen, 2001; Nolan 
et al., 2006). Primer sequences used are listed in Table 8.  
Gene Forward primer sequence (5’  3’) Reverse primer sequence (5’  3’) 
App CAAAGAGACATGCAGCGAGAAG AGCATGCCATAGTCGTGCAA 
Adam9 GTGCATATGGCGACTGTTGTAAA ATGGAGCCTCCTGGAAGGAA 
Adam10 GTTGCCGCCTCCTAAACCA  GGCGGTCTCCTCCTCTTTAAAG 
Adam17/TACE AACAACGACACCTGCTGCAATA CTGCACACCCGGCTTCAG 
Bace1 CAATCAGTCCTTCCGCATCAC ACCGGCCGTAGGTATTGCT 
Bace2 TTTGGTATCTCCTCTTCCACAAATG CATCACGGTCGCACCAATC 
Aph1a CCTTCTACAGGAAGTGTTCCGTTT TCTGCCTTCTTAAGGAGCTTGTAGT 
Aph1b-c GCGACTGTTGGCCTATGTTTCT CACTCCACTCATGATTCCAAAGC 
Psen1 CTCATGGCCCTGGTATTTATCAA GAGCCATGCGGTCCATTC 
Psen2 GCGAAACGTGTGATCATGCTAT CACGATCATACACAGCGTGACA 
Ncstn CAAGCAGTGCTATCAAGATCACAA CTTGGTGCAGAGCCATTCTG 
Pen2 AGTTGAACCTGTGCCGGAAGT AAGGCAGGAACGCAAATCC 
Ide GAGGTGAACGCTGTCGATTCA GGCATCGTTCATCACATTCTTCT 
Mme ATTAAGTCTGTCCCTAGTGGCTAAGAA GCAACACAGATACAGTTAGACCCTTTC 
Irf7 GAAGACCCTGATCCTGGTGAAG GAAGACCCTGATCCTGGTGAAG 
Rsad2 CTGATTGGCCGTGGTCAAG CTGATTGGCCGTGGTCAAG 
Trim30d TGGAAAAGCTGGAAGAGTCTGAA TGGAAAAGCTGGAAGAGTCTGAA 
Ifit2 CACAGCAGTCATGAGTACAACGAG CTTCTGCTATCAGGTTCCAGGTG 
Oasl1 TCCTGAGGCAGGAGAATTTC CCCAAAGCAGCCTACCTTGA 
Mamdc2 TGCGTTTCTGCCTTGGATACT TCCATATAGACATAATGGCCTTCCT 
Postn TGGAAACCATTGGAGGCAAA TGGAAACCATTGGAGGCAAA 
Cxcl14 GCGAGGAGAAGATGGTTATCGT CCCGGTACCTGGACATGCT 
Dkk2 TTTTGTTGTGCTCGCCACTT ATGGAGCACTGGTTTGCAGAT 
Cd33 GAGGCAGGAAGCGATCACAT GTGTATGGAACATCCTGGAGTCAC 
 
Table 8. Primers used for reverse transcription real-time polymerase chain 
reaction (qRT-PCR) 
Primers used for mRNA levels quantification by qRT-PCR. 
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7.4.2. Objective 2: PHD3 and AD microglia 
After microglia FACS of six pools of two 12-month-old mice per genotype (n = 3 of 
App-Psen1 and n = 3 of Egln3 –/–; App-Psen1), cells were pelleted with 200 g 
centrifugation for 5 min at 4 °C. Supernatant was removed and RNA was extracted 
with 1 mL TRIzol (Life technologies) following manufacturer’s instructions. The 
quality of RNA was analyzed using Agilent 2100 Bioanalyzer (Agilent). Only RNA 
samples with RNA integrity number higher than 7 were further processed for 
microarray analysis and qRT-PCR. RNA was amplified and labeled using GeneChip 
WT Pico Reagent Kit (total isolated RNA was used as starting material; Affymetrix), 
subsequently treated with PerfeCTa DNase (Quanta Biosciences) and then copied 
to cDNA using qScript cDNA Supermix (Quanta Biosciences) in a final volume of 20 
µL. The amplified cDNA was quantified and used for microarray analysis with 
GeneChip® Mouse Transcriptome 1.0 Array (Affymetrix) and qRT-PCR. ViiA 7 
Real-Time PCR System (Applied-Biosystems) using Power SYBR-Green PCR Master 
Mix (Applied-Biosystems) was used to perform the qRT-PCR. Normalization of 
results by input cDNA amount was performed by including a real time PCR for 
Hmbs mRNA in each plate. ΔΔCt method was used for quantification (Livak & 
Schmittgen, 2001; Nolan et al., 2006). Primer sequences used are listed in Table 8.  
7.5. Protein extraction and ELISA 
7.5.1. Objective 1: Hypoxia on AβPP processing 
Frozen hemibrains (wild-type mice) or hemicortices (App-Psen1 mice) were 
homogenized with a dounce grinder (Sigma), in 4x m/v solution of PBS containing 
Protease Inhibitor Cocktail (Roche, 1:25) and Phosphatase Inhibitor (Sigma, 
1:100). Afterwards, samples were subjected to a multistep centrifugation to 
separate soluble from insoluble fractions. First, the samples were centrifuged at 
600 g for 5 min at 4 °C to pellet the nuclear fraction. Next, the supernatants were 
ultracentrifuged at 100000 g for 1 h at 4 °C to isolate PBS-insoluble material 
(pellets) from PBS-soluble proteins (supernatants). Nuclear and PBS-soluble 
fractions were stored at -80 °C until use. The 100000 g pellets were dissolved in 
buffer (8.2 guanidine HCl, 50 mM Tris-HCl), following dilution until 5 M guanidine 
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and incubated for 4 h at room temperature, with occasional inversion to promote 
dissolution. These samples were stored at -20 °C until use. 
For wild-type mice, total protein concentration was quantified with RC-DC kit 
(Biorad), according to manufacturer’s guidelines and using bovine serum albumin 
(BSA) for the standard curve. VEGF concentration in PBS-soluble fraction was 
tested in 2-3-month-old wild-type mice (n = 4 per condition) by ELISA 
(Quantikine), according to manufacturer’s instructions. 
For App-Psen1 samples, total protein concentration was quantified in dissolved 
PBS-insoluble fraction with RC-DC kit (Biorad), according to manufacturer’s 
guidelines and using bovine serum albumin (BSA) for the standard curve. Aβ1-40 
and Aβ1-42 concentrations were tested in dissolved 100000 pellets of 8-month-old 
and 14-month-old mice (n = 3-4 per group) by using Human Aβ40 ELISA and 
Human Aβ42 ELISA (Invitrogen) kits, according to manufacturer’s guidelines. 
7.5.2. Objective 2: PHD3 and AD microglia 
For total Aβ1-40 and Aβ1-42 quantification, 5 hemicortices of 6-month-old App-Psen1 
mice (n = 5) and 4 hemicortices of 6-month-old Egln3 –/–; App-Psen1 mice (n = 4) 
were homogenized with a Dounce grinder (Sigma), in 8x m/v buffer (5 M 
guanidine HCl, 50 mM Tris-HCl pH 8.0) supplemented with Protease Inhibitor 
Cocktail (Roche, 1:25) and Phosphatase Inhibitor (Sigma, 1:100). Total protein 
concentration was quantified with RC-DC kit (Biorad), according to manufacturer’s 
guidelines and using bovine serum albumin (BSA) for the standard curve. Aβ1-40 
and Aβ1-42 concentrations were tested by using Human Aβ40 ELISA and Human 
Aβ42 ELISA (Invitrogen) kits, according to manufacturer’s guidelines. 
For soluble Aβ1-40 and Aβ1-42 quantification, 8 pools of 2 hemicortices from 
different 6-month-old App-Psen1 (n = 4) and Egln3 –/–; App-Psen1 (n = 4) were 
homogenized in 1 mL PBS supplemented with Protease Inhibitor Cocktail (Roche, 
1:25), Phosphatase Inhibitor (Sigma, 1:100) and 1,10-Phenanthroline 2 mM 
(Sigma) with a Dounce grinder. Next, samples were subjected to a multistep 
centrifugation to separate soluble from insoluble fractions. First, the samples were 
centrifuged at 600 g for 5 min at 4 °C to pellet the nuclear fraction. Next, the 
supernatants were ultracentrifuge at 100000 g for 1 h at 4 °C to isolate PBS-
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insoluble material (pellets) from PBS-soluble proteins (supernatants). Nuclear and 
PBS-soluble fractions were stored at -80 °C until use. Total protein concentration 
of 100000 g supernatants was quantified with RC-DC kit (Biorad), according to 
manufacturer’s guidelines and using bovine serum albumin (BSA) for the standard 
curve. Aβ1-40 and Aβ1-42 concentrations were tested by using Human Aβ40 ELISA 
and Human Aβ42 ELISA (Invitrogen) kits, according to manufacturer’s guidelines. 
7.6. Protein extraction and WB 
WB was performed in order to quantify the amount of specific proteins or 
fragments in different samples and fractions, both for objectives 1 and 2 
(Mahmood & Yang, 2012). For objective 1, samples were prepared as previously 
described for ELISA measurements and particular fractions were used to detect 
the different protein or samples. In particular, AβPP, C99 and C83 fragments, and 
BACE1 were detected in the PBS-insoluble fraction; HIF1α was quantified in the 
nuclear fraction and; sAβPPα was analyzed in the PBS-soluble fraction. For 
objective 2, HIF1α protein was quantified in the nuclear fraction obtained in the 
protein extraction process for ELISA Aβ1-40 and Aβ1-42 measurements and for 
synaptic proteins detection, total extracts from hemihippocampi were obtained as 
described next. Protein hippocampal extracts were obtained by homogenization of 
6 wild-type, 6 Egln3 –/–, 6 App-Psen1 and 6 Egln3 –/–; App-Psen1 hemihippocampi in 
lysis buffer (Tris-HCl 30 mM, Thiourea 2 M, Urea 7 M, CHAPS 4 % m/v, pH 8.5). 
Control group was integrated by wild-type and Egln3 –/– measurements to increase 
statistical power, since no differences were observed between these two groups. 
Tissue homogenization was performed in a tissue homogenizer (Bullet Blender, 
Next Advance) in the presence of glass beads. Supernatant protein concentration 
after 15000 g spin was quantified with RC-DC kit (Biorad), according to 
manufacturer’s guidelines and using bovine serum albumin (BSA) for the standard 
curve. 
In brief, WBs were performed on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) in order to identify proteins from a 
complex mixture by molecular weight. Tris-glycine gels at 10 % polyacrylamide 
(40 % Acrylamide/Bis Solution, 29:1, 3.3 % C, Biorad) gels were used for all WBs 
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except for C99/C83 gels, which were based on Tris-tricine gels at 16 % 
polyacrylamide. Gels were polymerized using Mini-Protean® II Cell (Biorad) 
system and protein samples were boiled in the presence of 2-mercaptoethanol 
(Sigma) prior electrophoretic migration, except from V-GLUT 1 samples. Protein 
transfer from protein-containing gels to polyvinylidene difluoride (PVDF, 
Millipore) previously activated membranes, following manufacturer’s instructions, 
was performed with semi-dry system (Sigma). Protein-containing membranes 
were blocked with 5 % skimmed milk in PBS-Tween20 0.1 % (m/v) and incubated 
over night with corresponding primary antibodies diluted in blocking solution. 
Secondary antibodies were diluted in PBS-Tween20 0.1 % and applied to protein-
containing membranes for 1 h at room temperature. Secondary antibody signal 
was detected in ImageQuantTM LAS 4000 (GE Healthcare) system after incubation 
with ClarityTM Western ECL Substrate (Biorad), following manufacturer’s 
guidelines. Acquired images were quantified with ImageQuant software and 
protein load was obtained after normalization by corresponding lane control load 
protein. 
Table 9 lists all identified proteins or fragments, used samples for identification, 
protein loads in each well of the corresponding gels and antibodies used in each 
case. Table 10 contains relevant data on the antibodies utilized. 
Protein Sample Load (ug) Antibodies (manufacturer) 
HIF1α Nuclear fraction 50 Anti-HIF1a (Cayman) 
BACE1 PBS-insoluble fraction 20 Anti-Bace (Cell signaling) 
FL-AβPP PBS-insoluble fraction 40 Anti-CTF (Millipore) 
sAβPPα PBS-soluble fraction 30 Anti-sAPPa (Takara) 
Synaptophysin 1 
LB1 hippocampal 
extract 
1 
Anti-Synaptophysin 1 (Synaptic 
Systems) 
PSD-95 
LB1 hippocampal 
extract 
5 Anti-PSD95 (Millipore) 
V-GLUT 1 
LB1 hippocampal 
extract 
10 Anti-VGLUT 1 (Synaptic Systems) 
C99 and C83 PBS-insoluble fraction 30 
Anti-Ab 6e10 clone (Biolegend) and 
Anti-Ab 82E1 clone (IBL) 
 
Table 9. Proteins or peptides detected by western blot (WB) and 
corresponding antibodies. 
Detected proteins or peptides by WB, fraction or sample of origin, protein load in the 
gel for electrophoresis, and used antibodies. Loading control proteins are excluded. 
Abbreviations: HIF1α, hypoxia-inducible factor 1α; FL-AβPP: full length amyloid-β 
precursor protein; sAβPPα, soluble amyloid-β precursor protein; PSD-95, 
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postsynaptic-density-95; VGLUT-1, vesicular glutamate transporter-1; C83, α C-
terminal fragment; C99; β C-terminal fragment. 
Antibody Manufacturer Catalog # Dilution 
Approximate 
MW 
Rabbit anti-HIF1α (C-Term) Cayman 10006421 1:100 140 KDa 
Rabbit anti-Bace (D10E5) Cell signaling #5606 1:1000 70 Kda 
Rabbit anti-Amyloid β Precursor 
Protein, C-Terminal (751-770) 
Millipore 171610 1:5000 110 Kda 
Mouse anti-β-Amyloid, 1-16 
Antibody (clon 6e10) 
Biolegend 803003 1:6000 
C99 11 Kda,  
C83 4 Kda 
Mouse anti-Human Amyloid β 
(N) (clon 82E1) 
IBL 10323 1:6000 
C99 11 Kda,  
C83 4 Kda 
Mouse anti-sAβPPα (2B3) Takara 11088 1:500 95 Kda 
Rabbit anti-synaptophysin 1 
Synaptic 
Systems 
101 002 1:5000 40 Kda 
Mouse anti-PSD-95 Millipore MAB1596 1:1000 95 Kda 
Rabbit anti-VGLUT-1 
Synaptic 
Systems 
135 303 1:1000 60 Kda 
Mouse anti-α-tubulin SIGMA T5168 1:4000 55 Kda 
Mouse anti-β-actin Abcam ab6276 1:5000 45 Kda 
Mouse anti-pan Cadherin Abcam ab6528 1:1000 130 Kda 
Rabbit anti-RPL26 Sigma R0655 1:1000 17 Kda 
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, HRP 
ThermoFisher 31460 1:10000 N/A 
Sheep anti-Mouse IgG, HRP-
Specific Whole Antibody 
Amersham NA931 1:10000 N/A 
 
Table 10. Data on used antibodies for western blot (WB). 
List of all antibodies utilized for protein quantification by WB with additional data. 
Abbreviations: MW, molecular weight; HIF1α, hypoxia-inducible factor 1α; sAβPPα, 
soluble amyloid-β precursor protein; PSD-95, postsynaptic-density-95; VGLUT-1, 
vesicular glutamate transporter-1; C83, α C-terminal fragment; C99; β C-terminal 
fragment; RPL26, ribosomal protein L26. 
7.7. Microglia FACS and in vivo 
phagocytosis assay 
Microglia isolation was performed as previously described (Orre, Kamphuis, 
Osborn, Melief, et al., 2014) in 6 wild-type, 3 Egln3 –/–, 5 App-Psen1 and 5 Egln3 –/–; 
App-Psen1 mice. In order to increase statistical power, wild-type and Egln3 –/– data 
were pooled as control group (n = 9) since no differences were observed in any of 
the analyzed parameters. Briefly, mice were anesthetized and transcardially 
perfused with HBSS (-CaCl2/-MgCl2) (Gibco) and complete cortex was dissected 
and subsequently subjected to dissociation using a Tissue Chopper (Vibratome 800 
series). A chemical digestion was performed using a combination of Papain 
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(Worthington) at a final concentration of 8 U/mL and DNAse I at a final 
concentration of 80 Kunitz units/mL (Sigma) followed by a Percoll gradient (GE 
healthcare) at 90 % in PBS (v/v) for microglia enrichment. Cells were incubated 
with anti-CD11b-APC and anti-CD45-PE antibodies at 4 °C for 30 min. Staining with 
isotype control-PE and isotype control-APC was used as negative control staining. 
Both control and experimental samples were incubated with anti-CD16/CD32 
blocker antibody. All antibodies were used at 1:200 dilution. Table 11 lists 
antibodies, manufacturers and catalog number. 7-AAD (BD Pharmingen) was 
added at a concentration of 1:100 to samples to confirm alive microglia isolation, 
as previously described (Orre, Kamphuis, Osborn, Melief, et al., 2014). Cells were 
washed and sorted using a FACS Aria Fusion (Becton Dickinson) flow cytometer 
and data were acquired and analysed with FACSDiva software 8.0 (Becton 
Dickinson). 
Antibody Host species Manufacturer Catalog # 
Anti-CD16/CD32 (Mouse BD Fc 
Block) 
Rat BD Biosciences 553142 
Anti-CD45 PE Rat Thermo scientific 12-0451 
Rat IgG2b Kappa Isotype Control 
PE 
Rat Thermo scientific 12-4031 
Anti-CD11b APC Rat Thermo scientific 17-0112 
Rat IgG2b K Isotype Control APC Rat Thermo scientific 17-4031 
 
Table 11. Data on used antibodies for flow cytometry. 
List of antibodies used for fluorescent-activated cell sorting (FACS) and phagocytic 
assays. 
Gating strategy and data analysis was made according to guidelines and previous 
reports (Herzenberg et al., 2006; Orre, Kamphuis, Osborn, Melief, et al., 2014) 
(Figure 34). Debris and dead cells were discarded by forward and side scatter 
pattern. Alive cells were selected by 7-AAD fluorescence. FSC-A and FSC-H events 
distribution was used to gate single cells. Microglial cells were identified as a 
positive population for both CD11b and CD45 markers. Microglial subpopulation 
gating was performed on contour density plot scaled at 15% probability. A second 
microglial population was considered when more than one independent focus was 
observed with these settings. Percentages are relative to total single cells. 
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Microglial phagocytosis was tested by measuring % of microglia from total single 
cells incorporating methoxy-X04 (Tocris Bioscience) as previously described 
(Heneka et al., 2013). Concisely, 3 App-Psen1 and 3 Egln3 –/–; App-Psen1 12-month-
old mice were injected with 10 mg/Kg of methoxy-X04 in 50 % DMSO/50 % NaCl 
0.9 % intraperitoneally. After 3 h of incubation, the same microglia isolation 
protocol previously described was applied. Cells were analysed in FACSCanto II 
(Becton Dickinson) and data were acquired and analysed with FACSDiva software 
8.0 (Becton Dickinson). The same gating strategy was used to select microglia and 
negative threshold for methoxy-X04 was established considering microglia from 
Egln3 –/– mice subjected to this protocol and App-Psen1 mice without methoxy-X04 
injections. 
Figure 34. Gating strategy used for isolation and analysis of viable microglial 
cells in vivo and microglial amyloid-β phagocytosis measurement. 
(A-D) Gating strategy was performed according to guidelines and previous reports 
(Herzenberg et al., 2006; Orre et al., 2014) in contour density plots. (A) Debris and 
dead cells were discarded by forward (FSC) and side (SSC) scatters dispersion of 
events. (B) Singlets of events were selected according to FSC area versus height. (C) 
- 108 - 
7-ADD staining was performed as control to test alive microglial cells isolation. (D) 
Microglial cells, positive for CD45 and CD11b markers, were selected and a 
subdivided according to CD45 axis when a second microglial subpopulation was 
observed. 
7.8. Tissue processing for immunostaining 
Mice were euthanized and cerebral samples fixed as previously described. Except 
for tissues for in situ hybridization protocol, tissues were included in paraffin by an 
automated tissue processor (Leica) that sequentially dehydrates the sample until 
final embed in paraffin. Paraffin samples were further embedded in paraffin blocks 
for posterior 20 µm slicing with a paraffin microtome (Leica). Tissue slices were 
kept at 37 °C over night to allow full drying of samples. 
7.9. Immunofluorescent staining for IBA1, 
Aβ, Thio-S and DAPI 
Slices were deparaffinized and rehydrated by sequential incubation in xylene, 
declining ethanol concentration washes, and H2Od. Antigen retrieval was 
performed in an automated system (2100 Retriever) in sodium citrate buffer (10 
mM Tri-sodium citrate dehydrate (Merk), pH 6). Next, slices were washed and 
permeabilized with PBS washes, a PBS-Triton X100 (Amresco) 0.3 % (v/v) and 
PBS-Triton X100 0.1 % (v/v) washes. Following blocking and over-night 
corresponding primary anti-IBA1 (Wako, Cat.# 019-19741, 1:500) and/or anti-Aβ 
antibody (Biolegend, , Cat.# 803001, 1:1000) incubation were performed with 
blocking solution (1 % bovine serum albumin (m/v, Applichem), 10 % goat serum 
(v/v, Gibco), in PBS-Triton X100 0.1 % (v/v)). 
After PBS-Triton X100 0.1 % (v/v) washes, secondary fluorescent antibodies anti-rabbit 
conjugated with Alexa-568 (Invitrogen, Cat.# A11011, 1:800), anti-mouse 
conjugated with Alexa-488 (Invitrogen, Cat.# A11001, 1:800). Slices were mounted 
in aqueous medium (Fluoromount-G, Southern biotech) after PBS-Triton X100 0.1 % 
(v/v) and PBS washes. 
When corresponding, prior to mounting, Thio-S (Sigma) 0.005 % (m/v) in PBS 
staining was performed and, whether appropriate, DAPI (Sigma, 1:1000) staining 
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was performed afterwards. After several PBS-Triton X100 0.1 % (v/v) and PBS 
washes, slices were mounted in aqueous medium (Fluoromount-G, Southern 
biotech). 
7.10. Immunofluorescent staining for fAβ 
All steps were common to previously described protocol for IBA1 and Aβ staining, 
but the protocol was extended after secondary antibody incubation. Also, both 
primary and secondary employed antibodies were different. Primary anti-OC 
(Millipore, Cat.#AB2286, 1:1000) and secondary anti-rabbit-biotin-SP-Conjugated 
(Jackson IR, Cat.#711-065-152, 1:800) antibodies were used. Then, after PBS 
washes, Cy3-conjugated streptavidin (Jackson IR, Cat.#016-160-084, 1:500) was 
used to amplify primary antibody’s signal. Thio-S staining, as previously described, 
and mounting were the final steps. 
7.11. Immunochemical staining for IBA1, 
fAβ and P-Tau 
Slices were deparaffinized, rehydrated, and their antigens were retrieved as 
previously described for immunofluorescent staining. Then, tissue endogenous 
peroxidase was neutralized with 3 % H2O2 (DAKO) for 5’, with previous and 
posterior H2O washes. Blocking was performed with 1 % bovine serum albumin 
(m/v), 5 % goat serum (v/v), in PBS-Triton X100 0.2 % (v/v) and followed by 
primary antibody incubation, either anti-OC (Millipore, Cat.#AB2286, 1:500), anti-
IBA1 (Wako, Cat.# 019-19741, 1:500)  or anti-phosphorylated-Tau (Pierce, 
Cat.#MN1020, 1:300) in 1 % BSA (m/v), 5 % goat serum (v/v), in PBS overnight. 
After PBS washes, labeled polymer-HRP anti-rabbit (DAKO) was used to label anti-
OC and anti-IBA1 antibodies and labeled polymer-HRP anti-mouse (DAKO) was 
used to label anti-phosphorylated-Tau antibody. 
Chemical reaction to visualize antibodies location was performed with Master 
Diagnostica Kit, according to manufacturer’s guidelines, and samples were 
subsequently washed. 
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In the case of anti-OC and anti-IBA1 antibody staining, samples were dehydrated 
with increasing ethanol concentration washes, ended up in xylene prior to DPX 
mounting (Sigma).  
In the case of anti-phosphorylated-Tau staining, amyloid plaques were stained 
with Thio-S 0.05% in ethanol 50 % (m/v) and mounted in Fluoromount-G 
afterwards. 
7.12. In situ hybridization in combination 
with immunostaining and image 
acquisition 
Mice were euthanized and cerebral samples fixed as previously described. Tissues 
were cryoprotected in sucrose 10 %, 20 % and 30 % in PBS (m/v) at 4 °C for 18 h 
and embedded in OCT compound (Tissue-Tek) prior to -80 °C storage. Coronal 
slices of 10 μm were obtained with a cryostat (Leyca) and stored at -80 °C until 
use. 
RNAscope 2.5 (ACD) protocol was used to detect Egln3 mRNA with Egln3 probe 
(ACD) according to manufacturer's instructions for frozen tissue, using a HybEZ 
oven (ACD). Subsequent immunostaining was performed for microglia staining 
(with IBA1 marker) and nuclear staining (DAPI dye). After RNAscope 2.5 protocol, 
slices were incubated for 10 min in PBS-Triton X100 0.3 % (v/v) and washed in 
PBS. Anti-IBA1 antibody (Wako, Cat.# 019-19741, 1:500) was prepared in PBS-
Triton X100 0.05 % (v/v), goat serum 2 % (v/v, Gibco) and used to incubate the 
samples over night at 4 °C. After several PBS washes, slices were incubated with 
anti-rabbit conjugated with Alexa 488 (Invitrogen, A11034, 1:400) for 1 h at room 
temperature. Several PBS washes and DAPI (Sigma, 1:1000) for 5 min were the 
final steps before mounting with Fluoromount-G. 
Images from compact amyloid plaques in cortical regions of App-Psen1 mice were 
acquired in a confocal microscope (Nikon) in Z-stack series and colocalization 
images were performed by decreasing opacity of the fluorescent images. 
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7.13. Burden quantification of IBA1, Thio-S, 
Aβ and fAβ 
Staining of paraffin-embedded hemibrain slices was performed as previously 
described for each marker, with immunofluorescent staining in the case of IBA1, 
Thio-S, and Aβ, and immunochemical staining of fAβ with anti-OC antibody. 
Measurements were performed in superimages, blind to the genotypes and 
neuroanatomy was assessed using The Mouse Brain in Stereotaxic Coordinates 
(Franklin & Paxinos, 2008). Superimages were obtained at 10x magnification from 
3 whole hemicortices of 3-6 App-Psen1 and 3-6 Egln3 –/–; App-Psen1 6-month-old 
mice with New CAST BX61 (Olympus), by using the same microscope settings for 
all images of the same staining. Briefly, 3 slices of each mouse, from -1.70 mm to -
2.30 mm relative to Bregma, were selected. With New CAST BX61, upper-left and 
bottom-right limits of every hemibrain slice were set, delimiting a virtual rectangle 
that comprised the whole area to be pictured in the superimage. Then, an 
automated acquisition was launched with the microimager utility that resulted in a 
superimage composed of all the different pictures taken at the specified settings to 
cover the whole previously delimited area.  
Fiji software (Schindelin et al., 2012) was utilized to analyze the superimages. 
Superimages were transformed into 8-bit images and only cortical area was 
selected for analyses. Cortical area was manually outlined and regions with evident 
noise or artifacts were subtracted from the analysis. A specific upper and lower 
threshold was applied for each marker and maintained throughout all the 
quantifications to create segmented binary masks (table 12). Analyze particles 
utility was used to calculate the total area covered by all particles contained in the 
segmented binary mask, meeting size criteria of the analyze particles utility. The 
percentage of occupancy was calculated as the ratio of total particles area divided 
by total cortical area for each slice and multiplied by 100. In the case of Thio-S 
stained amyloid plaques, number and size of each quantified particle was obtained 
for further analysis. Amyloid plaques density was calculated for each slice as the 
total number of particles quantified in each cortical area divided by total cortical 
area of that specific slice. Average size was obtained as the mean size of all the 
particles quantified in each hemicortex. Size distribution plot was obtained with 
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Graphpad Prism 6.0 version by calculating the mean number of particles of each 
size interval detected in each cortex. All showed data and statistical analyses 
correspond to the consideration of every slice as a replicate (n for each marker is 
listed in table 12). 
 
Marker 
Minimum detected 
 size (µm2) 
Lower threshold Upper threshold 
Number of 
replicates 
IBA1 14.2 21 255 18 
Thio-S 42.50 25 255 9 
Aβ 1.5 13 255 18 
OC 11.0 78 169 18 
 
Table 12. Settings used for image analysis with Fiji software. 
Quantified markers with more limiting settings and number of considered replicates 
for statistical analysis of results. Abbreviations: IBA1, ionized calcium-binding 
adapter molecule 1; Thio-S, Thioflavine-S; Aβ, amyloid-β. 
7.14. Neuronal dystrophies occupied area 
Staining of paraffin-embedded hemibrain slices was performed as previously 
described for both markers in the same samples, with immunofluorescent staining 
in the case of Thio-S and immunochemical staining of P-Tau. 
Compact Thio-S stained plaques along the whole hemicortex of 5 App-Psen1 and 5 
App-Psen1, Egln3 –/– 6 month-old mice (24 plaques in 3 slices per animal) of same 
size were randomly pictured, with the same settings in all cases. 16-slice-Z-
projections at 40x magnification were performed to acquire all P-Tau signal of 
each selected plaque by generating a maximum intensity projection image 
afterwards, in an Olympus BX61 microscope, from -1.70 mm and -2.06 mm relative 
to Bregma. Fiji software (Schindelin et al., 2012) was used to quantify occupied 
area by amyloid plaques and P-Tau. Pictures were transformed into 8-bit images 
and automated thresholding segmentation with lower threshold of 16 for Thio-S 
area and 0 for P-Tau area and upper threshold of 255 for both markers was carried 
out and subsequent analyze particles utility revealed calculated sizes. Ratio P-Tau 
area/amyloid plaque area was calculated. All showed data and statistical analyses 
correspond to the consideration of every slice as a replicate (n = 15). 
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7.15. fAβ from individual plaques 
Immunofluorescent staining of paraffin-embedded hemibrain slices was 
performed as previously described for both Thio-S and OC markers in the same 
samples. 
Compact Thio-S stained plaques along the whole hemicortex of 6 App-Psen1 and 6 
App-Psen1, Egln3 –/– 6 month-old mice (15 plaques in 3 slices per animal) of same 
size were randomly pictured, with the same settings in all cases. Fluorescent OC 
signal of each selected plaque was also acquired, with same settings for all images. 
Images were acquired in an Olympus BX61 microscope at 40x magnification, from 
-1.70 mm and -2.06 mm relative to Bregma. 
Fiji software (Schindelin et al., 2012) was used to quantify occupied area by dense 
core of Aβ plaques and fAβ (OC signal). A third analysis omitting occupied area of 
Thio-S calculated dense core was performed to exclusively quantify fAβ halo. 
Pictures were transformed into 8-bit images and automated thresholding 
segmentation with lower threshold of 35 for Thio-S area and 0 for OC area and 
upper threshold of 255 for both markers was carried out and subsequent analyze 
particles utility revealed calculated sizes. Ratio OC halo area / Aβ dense core area 
was calculated. All showed data and statistical analyses correspond to the 
consideration of every slice as a replicate (n = 18). 
7.16. MPI 
Immunofluorescent staining of paraffin-embedded hemibrain slices was 
performed as previously described for all DAPI, Aβ, with anti-Aβ antibody, and 
IBA1 markers in the same samples. 
MPI was calculated as the proportion of microglial cells in contact with each Aβ 
plaque considering all microglia closer than 40 μm from Aβ plaque's border. It was 
obtained through the analysis of randomly compact selected plaques of the same 
size from 3 App-Psen1 and 3 App-Psen1, Egln3-/- 6 months old mice (15 plaques in 3 
slices per mouse). All pictures were taken with New CAST BX61 (Olympus) at 40x 
magnification, with 3 pictures per plaque in Z-axis and generating a maximum 
intensity projection image afterwards. Sampling area included the whole cortex 
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areas from Auditory Cortex to Piriform Cortex from -1.94 mm and -2.30 mm 
relative to Bregma.  
Aβ plaques area was measured by using Fiji software (Schindelin et al., 2012), by 
transforming pictures into 8-bit images, applying a lower threshold of 0 and an 
upper threshold of 255, and using analyze particles utility. The region of interest 
generated after amyloid plaques measurement by Fiji was submitted to enlarge 
function of this software in order to extend its periphery 40 μm. All microglia 
whose soma was within the increased halo was quantified by IBA1 marker 
colocalization with nuclear DAPI staining. Separately, microglia directly in contact 
with Aβ plaque within the increased halo was also quantified. A ratio between 
microglia directly in contact with Aβ plaque and previously quantified total 
microglia in each plaque was obtained. All showed data and statistical analyses 
correspond to the consideration of every slice as a replicate (n = 9). 
7.17. Microglia morphology 
Immunochemical staining of paraffin-embedded hemibrain slices was performed 
as previously described for IBA1 marker. 
Individual microglial cells from the dorso-lateral hemicortex of 6 App-Psen1 and 6 
App-Psen1, Egln3 –/– 6 month-old mice (12 cells in 3 slices per animal) were 
randomly pictured, with the same settings in all cases. Images were acquired in 18 
Z-stacks in an Olympus BX61 microscope at 100x magnification, from -1.70 mm 
and -2.06 mm relative to Bregma. Maximum intensity projections were obtained 
for further analysis. 
The described process in results section was used to get insights in the 
ramification levels of microglia and their occupied area, as well as their ratio of 
projections size and soma size. Blue circumference area was 1108.24 µm2, green 
circumference area was 667.91 µm2 and red circumference area was 155.02 µm2. 
All quantified data and statistical analyses correspond to the consideration of 
every slice as a replicate (n = 18). 
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7.18. Stereological microglia density 
estimation 
Immunofluorescent staining of paraffin-embedded hemibrain slices was 
performed as previously described for both DAPI and IBA1 markers in the same 
samples. 
Microglia density estimation by unbiased stereological analysis was accomplished 
by systematic random sampling using a CAST Grid System (Olympus). A 25 % of 
complete hemicortex was sampled with dissectors of 106954.7 μm2 in 3 slices per 
animal, with 6 App-Psen1 and 4 Egln3 –/–; App-Psen1 of 6 month-old mice, from -
1.70 mm and -2.06 mm relative to Bregma. Cortical area was manually outlined at 
4x magnification. Microglia cell number in dissectors was quantified by IBA1 
marker colocalization with nuclear DAPI staining at 20x magnification. For each 
hemicortex, total sampled area was obtained by multiplying dissector area by 
number of dissectors. Microglial density was obtained by dividing total microglial 
cell number by total sampled area. All showed data and statistical analyses 
correspond to the consideration of every slice as a replicate (n = 18 for App-Psen1 
and n = 12 for Egln3 –/–; App-Psen1 mice). 
7.19. Stereological amyloid plaques density 
estimation 
Immunofluorescent staining of paraffin-embedded hemibrain slices was 
performed as previously described for Thio-S. 
All Thio-S positive dense-core amyloid plaques bigger than 55 µm2 were quantified 
in the whole cortical area and classified into filamentous, if no dense core was 
visible, or compact plaques, in which a dull and compact dense core is identifiable. 
Plaques were visualized at 20x magnification in CAST Grid System (Olympus). 
Total cortical area was calculated in this microscope with the Cavalieri method. 
Plaque densities, in terms of number of plaques per area, were obtained by 
dividing total number of each type of plaques by total cortical area. Quantifications 
were performed in 3 slices per animal, with 6 App-Psen1 and 7 Egln3 –/–; App-Psen1 
of 6 month-old mice, from -1.46 mm to -1.82 mm relative to Bregma. All showed 
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data and statistical analyses correspond to the consideration of every slice as a 
replicate (n = 18 for App-Psen1 and n = 21 for Egln3 –/–; App-Psen1 mice). 
7.20. Behavioural tests 
Wild-type and Egln3 –/– were grouped as control mice given that no differences 
were shown in any of the analyzed parameters. 
For behavioural assessment of locomotion activity and open field test was used. 6 
month-old mice were filmed in a 45 x 45 cm floor box using an automatic tracking 
system (SMART). 16 control mice, 18 App-Psen1 and 14 App-Psen1, Egln3 –/– mice 
were recorded for 15 min following the protocol from the International Mouse 
Phenotyping Resource of Standardized Screens (IMPRESS; 
https://www.mousephenotype.org/impress/protocol/81/7) and the travelled 
distance was calculated using the SMART software 3.0 (Panlab-Harvard 
Apparatus).  
Short-term memory was evaluated following a previously published protocol 
(Leger et al., 2013) based on a novel object recognition strategy. 14 control mice, 
21 App-Psen1 mice and 14 App-Psen1, Egln3 –/– mice of 6 months old were 
submitted to the test. In brief, two objects were presented to each mouse for 15 
min. After one hour, the mouse was exposed to one of the previous objects being 
the other one replaced for a new object. A short-term memory index was 
calculated by subtracting the number of the approaches to the novel object minus 
the number of approaches to the old object divided by the total number of 
approaches. Recording and analyzing software was SMART 3.0 (Panlab-Harvard 
Apparatus). 
7.21. Statistical analysis 
All measurements were performed in at least 3 independent mice.  
7.21.1. Statistical analysis for objective 1 
Given the small size of the groups, only non-parametric statistical tests were used. 
Comparisons between two groups were performed with Mann-Whitney U test, 
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whereas comparisons among three groups were done with Kruskal-Wallis ANOVA 
with Dunn’s multiple comparison test. Level of significance was set at p < 0.05. 
Data are expressed as mean ± s.e.m. Statistical analyses and graphs were 
performed in GraphPad Prism version 7.0 (GraphPad Inc.). 
7.21.2. Statistical analysis for objective 2 
Samples with an n ≥ 5 were evaluated for normal distribution using Kolmogorov-
Smirnov’s normality test. Non-normal samples were analysed using non-
parametric tests. Samples with an n < 5 were analysed using parametric tests. 
Comparisons between two groups were performed with two-tail unpaired 
Student's t-test (for normally distributed data) or Mann Whitney’s U test (non-
normally distributed data). Comparison among more than two groups was done 
with Kruskal-Wallis’s ANOVA with Dunn’s multiple comparison test, if data were 
not-normally distributed or with ANOVA followed by Tukey’s test or Newman-
Keuls’ test, if more power was required, for normally-distributed data. Plots are 
represented with mean ± s.e.m.; p ≤ 0.05 was considered statistically significant. 
Statistical analyses and graphs were performed in GraphPad Prism version 6.0 
(GraphPad Inc.). 
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9. Attached material 
9.1. Table 5 
Table 5. Differentially expressed genes in microglia from Egln3 –/–; App-
Psen1 versus App-Psen1 mice. 
 
Gene name/loci logFC linealFC P.Value 
Mamdc2 2,13 4,39 0,00009 
Prkd1 2,02 4,05 0,00000 
H2-Eb1 1,99 3,96 0,00009 
Postn 1,98 3,95 0,00003 
Dkk2 1,81 3,51 0,00018 
Gdpd3 1,76 3,38 0,00007 
Cxcl14 1,54 2,92 0,00009 
Ly6k 1,45 2,74 0,00010 
D630028G08Rik 1,43 2,70 0,04255 
Lgi2 1,42 2,68 0,01549 
Ctnna3 1,41 2,65 0,00216 
Gpnmb 1,36 2,57 0,02569 
H2-Ab1 1,36 2,57 0,00019 
Spp1 1,35 2,56 0,00611 
Flt1 1,29 2,44 0,00007 
Lpl 1,26 2,39 0,00006 
BC018473 1,25 2,37 0,00237 
Klrb1a 1,22 2,33 0,01011 
Pianp 1,22 2,33 0,00001 
Abi3bp 1,22 2,32 0,04246 
H2-Aa 1,22 2,32 0,00051 
Gm13669 1,18 2,27 0,00604 
Trpc4 1,16 2,24 0,00012 
Cd74 1,11 2,16 0,00021 
Colec12 1,10 2,15 0,00431 
Slc41a2 1,10 2,15 0,00027 
Tgfb2 1,09 2,13 0,00310 
Fn1 1,07 2,10 0,00390 
Cspg4 1,07 2,09 0,00116 
Actr3b 1,07 2,09 0,00126 
Cxcl13 1,05 2,07 0,01451 
Plp2 1,03 2,05 0,00294 
Gm6166 1,03 2,04 0,00029 
Fam189a2 1,02 2,03 0,00074 
Fam19a2 1,02 2,03 0,01948 
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Ahr 1,02 2,03 0,00007 
Gm14328 1,00 2,01 0,00011 
Sh3pxd2b 0,99 1,99 0,00250 
Fabp5 0,97 1,96 0,00019 
Fabp5l2 0,97 1,96 0,00030 
Gm6100 0,95 1,93 0,00001 
Alcam 0,94 1,92 0,00064 
Gm3601 0,94 1,92 0,00077 
Tmem163 0,93 1,90 0,00006 
Atp6v0d2 0,92 1,89 0,01671 
Gm5423 0,91 1,87 0,00238 
Yipf7 0,90 1,86 0,00228 
Perp 0,89 1,86 0,00024 
Elovl7 0,88 1,84 0,00137 
Gm13998 0,88 1,84 0,00030 
Sulf2 0,88 1,84 0,00074 
Fbln5 0,87 1,83 0,00008 
Adssl1 0,86 1,82 0,00166 
Mxra8 0,86 1,82 0,00692 
Msr1 0,85 1,81 0,01291 
Agap1 0,84 1,79 0,00072 
Hal 0,83 1,78 0,00012 
Fxyd6 0,82 1,77 0,00487 
Olr1 0,81 1,75 0,00372 
St8sia6 0,80 1,74 0,00152 
Plxna2 0,80 1,74 0,03748 
Igfbp5 0,80 1,74 0,01142 
Mrc2 0,80 1,74 0,00244 
Cxcr4 0,79 1,73 0,01018 
Lgals1 0,79 1,73 0,01309 
Ptprg 0,78 1,72 0,01286 
Gm25911 0,78 1,72 0,00011 
Cacnb4 0,77 1,71 0,00847 
Gm14584 0,77 1,70 0,00244 
Wdr35 0,76 1,70 0,00021 
Plxnc1 0,75 1,68 0,00142 
Galc 0,74 1,67 0,00012 
Gm25732 0,73 1,66 0,00037 
Clec7a 0,72 1,65 0,00543 
Tmem176a 0,72 1,65 0,00009 
Vegfa 0,71 1,64 0,00177 
Fyn 0,71 1,64 0,00400 
Efr3b 0,71 1,63 0,00222 
Kif1a 0,71 1,63 0,00392 
Atp1a3 0,70 1,63 0,00094 
Fndc4 0,70 1,63 0,00104 
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Igsf10 0,70 1,63 0,02138 
Rnf128 0,70 1,63 0,00157 
Gm19386 0,70 1,62 0,00257 
Gpr81 0,69 1,62 0,00223 
5430435G22Rik 0,68 1,60 0,01909 
Gm11166 0,68 1,60 0,02907 
Gas7 0,68 1,60 0,00274 
Itgax 0,67 1,59 0,00163 
AI504432 0,66 1,58 0,00949 
Ephx1 0,66 1,58 0,00398 
Ank 0,65 1,57 0,00074 
Asb10 0,65 1,57 0,00009 
Tmem176b 0,64 1,56 0,00032 
Laptm4a 0,64 1,56 0,00010 
Zfp618 0,63 1,55 0,00200 
Galns 0,63 1,55 0,00043 
Arap2 0,63 1,55 0,00195 
Fgf13 0,63 1,55 0,00043 
Etl4 0,63 1,55 0,00213 
Crip1 0,63 1,55 0,00149 
Ccr2 0,63 1,55 0,03799 
Chst11 0,63 1,54 0,00050 
Wif1 0,63 1,54 0,00965 
Maoa 0,62 1,54 0,00110 
n-R5s54 0,62 1,53 0,02924 
Fam214a 0,62 1,53 0,00022 
Vim 0,61 1,53 0,01223 
Rasd1 0,61 1,53 0,00074 
Procr 0,61 1,52 0,00171 
Myo5a 0,61 1,52 0,00609 
Emp2 0,60 1,52 0,00383 
Ighv1-69 0,60 1,52 0,00863 
Gm24245 0,60 1,51 0,00070 
Gm24270 0,60 1,51 0,00070 
Gm24187 0,60 1,51 0,00054 
Gm26993 0,60 1,51 0,00994 
Gm26214 0,60 1,51 0,02184 
Apoc1 0,59 1,51 0,02315 
Bambi 0,59 1,51 0,00789 
Cers4 0,59 1,51 0,00076 
Usp30 0,59 1,50 0,00123 
Wfdc17 0,59 1,50 0,02544 
Gm8034 0,58 1,50 0,00685 
Leprel4 0,58 1,50 0,00105 
Naaa 0,58 1,50 0,00227 
Pdcd1 0,58 1,49 0,00729 
- 146 - 
Gm3788 0,58 1,49 0,00162 
Slc44a1 0,57 1,49 0,00166 
Gm23388 0,57 1,49 0,00047 
Arnt2 0,57 1,49 0,01024 
Nr4a2 0,57 1,48 0,00282 
Iqcg 0,57 1,48 0,00196 
Gm15418 0,57 1,48 0,02237 
Lama3 0,57 1,48 0,00510 
Ppap2a 0,56 1,48 0,00329 
Arrdc4 0,56 1,48 0,00304 
Rai14 0,56 1,48 0,00237 
Gpx3 0,55 1,46 0,04271 
Selm 0,55 1,46 0,00429 
Tmem203 0,55 1,46 0,00168 
Acp5 0,55 1,46 0,00438 
Mcam 0,54 1,46 0,00569 
Gm25554 0,54 1,46 0,00362 
Lyzl4 0,54 1,45 0,03060 
Ipcef1 0,53 1,45 0,00864 
Fmr1nb 0,53 1,45 0,01723 
A830039N20Rik 0,53 1,44 0,00578 
F2r 0,53 1,44 0,00078 
Dapk1 0,53 1,44 0,00543 
Tbc1d4 0,53 1,44 0,00163 
Kcnk3 0,52 1,44 0,00053 
Prr15 0,52 1,44 0,02006 
Arg2 0,52 1,44 0,00642 
Olfr152 0,52 1,44 0,01459 
St14 0,52 1,44 0,00509 
Hdac9 0,52 1,44 0,00210 
Sycp3 0,52 1,44 0,03402 
Gramd3 0,52 1,43 0,00078 
Crtap 0,52 1,43 0,00856 
S100a1 0,52 1,43 0,00930 
Gyg 0,52 1,43 0,00613 
Rgs1 0,52 1,43 0,01377 
Ptn 0,52 1,43 0,02694 
Mptx1 0,51 1,43 0,03055 
Pvrl1 0,51 1,42 0,02228 
Maged1 0,51 1,42 0,00090 
Mt2 0,51 1,42 0,00216 
Naglu 0,51 1,42 0,02009 
Cd34 0,50 1,42 0,00971 
Fabp3-ps1 0,50 1,42 0,01169 
mmu-mir-6398 0,50 1,42 0,04493 
Tmem181a -0,50 0,71 0,01863 
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Vsnl1 -0,50 0,71 0,01248 
Egr3 -0,50 0,71 0,02021 
Gm11883 -0,50 0,71 0,00105 
D130012P04Rik -0,51 0,70 0,00455 
AA667203 -0,51 0,70 0,02651 
Gm10337 -0,51 0,70 0,00925 
Gm11912 -0,51 0,70 0,02735 
Optn -0,51 0,70 0,03637 
C5ar1 -0,51 0,70 0,01158 
Prkab2 -0,51 0,70 0,03554 
Rab1 -0,51 0,70 0,04144 
BC094916 -0,51 0,70 0,00068 
Gbp10 -0,52 0,70 0,01346 
Stard9 -0,52 0,70 0,00078 
Tmem181b-ps -0,52 0,70 0,02214 
Dst -0,52 0,70 0,00756 
Trim25 -0,52 0,70 0,00927 
Gm7278 -0,52 0,70 0,00211 
Gm11261 -0,52 0,70 0,00222 
Gm25271 -0,52 0,70 0,02986 
Mir342 -0,52 0,70 0,04072 
Mir342 -0,52 0,70 0,04072 
Mir221 -0,52 0,70 0,01455 
G2e3 -0,52 0,70 0,00987 
Lilra5 -0,52 0,70 0,02375 
Man1a -0,52 0,70 0,02555 
Grap -0,52 0,70 0,00432 
Gm22060 -0,53 0,69 0,02348 
Rbbp8 -0,53 0,69 0,02864 
Gm21886 -0,53 0,69 0,00089 
Dock4 -0,53 0,69 0,00354 
Gm14737 -0,53 0,69 0,00421 
Mir3074-1 -0,53 0,69 0,00733 
Peg10 -0,54 0,69 0,00122 
Bzw1 -0,54 0,69 0,04535 
Gm25109 -0,54 0,69 0,02185 
Gm12812 -0,54 0,69 0,00682 
Mir325 -0,54 0,69 0,02566 
Phxr4 -0,54 0,69 0,02530 
Il12rb2 -0,54 0,69 0,00860 
Ifnb1 -0,54 0,69 0,02909 
Fth-ps2 -0,54 0,69 0,02475 
Mir103-2 -0,54 0,69 0,01741 
Gm14265 -0,55 0,69 0,00105 
Gm11886 -0,55 0,68 0,00037 
Ptpn23 -0,55 0,68 0,01372 
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Gm14888 -0,55 0,68 0,00196 
Ifitm3 -0,55 0,68 0,02003 
4930486L24Rik -0,56 0,68 0,02427 
Gm13570 -0,56 0,68 0,00473 
Gm23121 -0,56 0,68 0,02856 
Camkk2 -0,56 0,68 0,02477 
Gm12840 -0,56 0,68 0,00735 
Gem -0,56 0,68 0,04839 
Cryba4 -0,56 0,68 0,00759 
Gm15186 -0,56 0,68 0,01144 
Lilrb3 -0,57 0,68 0,00540 
Gm11652 -0,57 0,68 0,00792 
Gm26857 -0,57 0,67 0,00084 
Btaf1 -0,57 0,67 0,02151 
Oasl2 -0,57 0,67 0,01245 
Zfhx3 -0,57 0,67 0,01429 
mmu-mir-6541 -0,57 0,67 0,01666 
Gm11995 -0,58 0,67 0,00220 
Gm5844 -0,58 0,67 0,03148 
B230325K18Rik -0,58 0,67 0,03465 
AC168977.2 -0,58 0,67 0,00276 
Abl2 -0,58 0,67 0,00048 
Gm15368 -0,58 0,67 0,02492 
Gm13710 -0,58 0,67 0,00238 
Enpp4 -0,58 0,67 0,00110 
Hbb-bs -0,58 0,67 0,00245 
Tmem181c-ps -0,58 0,67 0,02008 
RP23-142E18.5 -0,58 0,67 0,00388 
AW046200 -0,58 0,67 0,02614 
Gm26520 -0,58 0,67 0,00083 
Cd40 -0,58 0,67 0,00127 
Bco2 -0,58 0,67 0,00621 
Lonrf1 -0,59 0,67 0,02994 
Gm26430 -0,59 0,66 0,01300 
Stab1 -0,59 0,66 0,00396 
Gm13765 -0,59 0,66 0,00488 
Gm24273 -0,59 0,66 0,01784 
Gm4583 -0,60 0,66 0,02542 
BC035044 -0,60 0,66 0,00494 
Gm10099 -0,60 0,66 0,00162 
Trim30a -0,60 0,66 0,00517 
Hivep1 -0,60 0,66 0,00531 
Clec4a3 -0,60 0,66 0,02731 
Gm23247 -0,61 0,66 0,00741 
LOC432823 -0,61 0,66 0,00350 
Pira2 -0,61 0,66 0,00601 
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Gm10091 -0,61 0,66 0,00730 
Trim12c -0,61 0,65 0,01290 
Gm14749 -0,61 0,65 0,00076 
Gm19279 -0,61 0,65 0,00960 
Gm23734 -0,61 0,65 0,00525 
Ddx58 -0,61 0,65 0,01245 
Rufy3 -0,62 0,65 0,01806 
Gm12346 -0,62 0,65 0,02916 
Gm25993 -0,62 0,65 0,04386 
Gm23553 -0,62 0,65 0,02554 
fasapoptosis -0,63 0,65 0,01117 
Pttg1 -0,63 0,65 0,00481 
ST7-OT4_4 -0,63 0,65 0,01146 
Gm23730 -0,63 0,65 0,04994 
Crybb1 -0,63 0,65 0,00121 
Gm19703 -0,63 0,65 0,03090 
Gm22888 -0,63 0,65 0,02123 
Xdh -0,63 0,65 0,00189 
Elmo1 -0,63 0,65 0,00264 
LOC432823 -0,63 0,64 0,00118 
Gm13519 -0,64 0,64 0,00014 
Swap70 -0,64 0,64 0,00670 
Atp6v1d -0,64 0,64 0,00667 
Gm12437 -0,64 0,64 0,00637 
Gm24198 -0,64 0,64 0,00793 
Olfr755-ps1 -0,64 0,64 0,00342 
Tank -0,64 0,64 0,01364 
Gm20689 -0,64 0,64 0,00353 
LOC432823 -0,64 0,64 0,00119 
Ap4s1 -0,64 0,64 0,00272 
Ccl5 -0,64 0,64 0,00138 
Parp14 -0,65 0,64 0,00500 
Gm25966 -0,65 0,64 0,04124 
Mir5124 -0,65 0,64 0,00191 
Gm4992 -0,65 0,64 0,00091 
Gm24959 -0,65 0,64 0,04018 
Pira1 -0,65 0,64 0,00416 
Lst1 -0,66 0,63 0,00020 
Gm17024 -0,66 0,63 0,01789 
Gm22731 -0,66 0,63 0,00089 
Gm14063 -0,66 0,63 0,00081 
Tnfsf9 -0,66 0,63 0,00486 
Dock10 -0,66 0,63 0,01132 
mmu-mir-7679 -0,67 0,63 0,00269 
Gm11545 -0,67 0,63 0,03635 
Ifit2 -0,67 0,63 0,01858 
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Gm15971 -0,67 0,63 0,01723 
Epha2 -0,67 0,63 0,00059 
Gm14814 -0,68 0,63 0,00066 
Dapp1 -0,68 0,62 0,02917 
Gm10933 -0,68 0,62 0,02700 
Ccl9 -0,69 0,62 0,00623 
B230217C12Rik -0,69 0,62 0,03068 
Gm11753 -0,70 0,62 0,02018 
Trim30b -0,70 0,62 0,00500 
Gbp7 -0,70 0,62 0,00481 
Usp18 -0,70 0,62 0,00747 
Lgals3bp -0,70 0,61 0,01330 
Mir505 -0,70 0,61 0,00683 
Gm14941 -0,70 0,61 0,00168 
4930594C11Rik -0,70 0,61 0,02950 
Gm13701 -0,71 0,61 0,00295 
Gm14702 -0,71 0,61 0,00272 
Gm13468 -0,71 0,61 0,00150 
Gm20100 -0,71 0,61 0,01098 
Gm14928 -0,72 0,61 0,00041 
Slc2a5 -0,72 0,61 0,04417 
Gm14672 -0,72 0,61 0,00682 
Gm14654 -0,72 0,61 0,00273 
AC133103.3 -0,73 0,60 0,00307 
Sp100 -0,73 0,60 0,00112 
Odc1 -0,73 0,60 0,00066 
LOC432823 -0,73 0,60 0,00098 
Gm3513 -0,74 0,60 0,00047 
Gm23136 -0,74 0,60 0,01239 
Gm16558 -0,74 0,60 0,00619 
Gm13357 -0,75 0,60 0,02617 
Gm14969 -0,75 0,60 0,00006 
Baiap2 -0,75 0,60 0,00328 
D130007C19Rik -0,75 0,59 0,02376 
Gm14700 -0,75 0,59 0,00554 
Slfn8 -0,75 0,59 0,00337 
n-R5s47 -0,76 0,59 0,03126 
Hba-a1 -0,76 0,59 0,00696 
Gm14708 -0,76 0,59 0,00041 
Gm15470 -0,77 0,59 0,00056 
Gm4955 -0,77 0,59 0,00357 
Bank1 -0,78 0,58 0,00235 
Rtp4 -0,78 0,58 0,01008 
Gm13574 -0,78 0,58 0,00300 
F830016B08Rik -0,79 0,58 0,00251 
Mnda -0,79 0,58 0,01373 
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Sorl1 -0,80 0,57 0,00434 
Gm14778 -0,80 0,57 0,00150 
mmu-mir-6963 -0,80 0,57 0,02001 
Gm12197 -0,80 0,57 0,00454 
Gm24783 -0,80 0,57 0,02781 
Gm23300 -0,81 0,57 0,00019 
Gm9115 -0,81 0,57 0,00033 
Gm13840 -0,81 0,57 0,00294 
LOC215866 -0,82 0,57 0,00570 
4931406H21Rik -0,82 0,57 0,02206 
Trim5 -0,82 0,57 0,00059 
6330407A03Rik -0,82 0,56 0,00995 
Gm11187 -0,83 0,56 0,00978 
Gm15371 -0,84 0,56 0,00617 
Gm15146 -0,84 0,56 0,01155 
Gm17709 -0,85 0,56 0,00047 
Gm14734 -0,85 0,56 0,01189 
Mir15a -0,85 0,55 0,00627 
Hbb-bt -0,85 0,55 0,01025 
Gm15724 -0,87 0,55 0,00719 
Gm19313 -0,87 0,55 0,00434 
mmu-mir-6972 -0,88 0,54 0,00057 
Il1f9 -0,89 0,54 0,04514 
Gm13018 -0,89 0,54 0,01099 
Mir3075 -0,90 0,54 0,01756 
Rbpms -0,90 0,54 0,01504 
Gm12651 -0,90 0,53 0,00344 
Ggta1 -0,91 0,53 0,00016 
Hba-a1 -0,92 0,53 0,00501 
Mrgpra2a -0,92 0,53 0,00867 
Ccl12 -0,92 0,53 0,01106 
Mir5123 -0,92 0,53 0,01465 
Nlrp1b -0,92 0,53 0,00150 
Gm14693 -0,93 0,53 0,00987 
Mir146 -0,93 0,53 0,01968 
Gm24112 -0,94 0,52 0,00961 
Gm24927 -0,94 0,52 0,00387 
Trim12a -0,96 0,52 0,00015 
Rsad2 -0,96 0,51 0,00140 
Ifi27l2a -0,98 0,51 0,00309 
Gm25931 -0,98 0,51 0,00977 
Myo1g -0,99 0,51 0,00223 
Gm12424 -0,99 0,50 0,00434 
Gm14604 -1,00 0,50 0,00655 
Gm25138 -1,00 0,50 0,00008 
Gm25549 -1,02 0,49 0,00176 
- 152 - 
Gm11247 -1,03 0,49 0,00370 
Gm24842 -1,04 0,49 0,01264 
AI607873 -1,04 0,49 0,00396 
Gm11522 -1,04 0,49 0,00053 
Oas2 -1,04 0,49 0,00080 
Ifi204 -1,08 0,47 0,00323 
2610024D14Rik -1,08 0,47 0,01072 
Gm12785 -1,11 0,46 0,01148 
Gm14060 -1,13 0,46 0,00329 
Rnf213 -1,13 0,46 0,00128 
Pyhin1 -1,14 0,45 0,00104 
Oas1g -1,16 0,45 0,00122 
Gm26497 -1,20 0,44 0,02295 
G530011O06RIK -1,23 0,43 0,01047 
Hsph1 -1,24 0,42 0,02032 
Oas1a -1,27 0,41 0,00445 
Gm14801 -1,28 0,41 0,01429 
Fpr1 -1,33 0,40 0,03973 
Gm15445 -1,33 0,40 0,00402 
Trim30c -1,36 0,39 0,00023 
Cwc22 -1,37 0,39 0,02667 
Mid1 -1,42 0,37 0,00080 
Mir34a -1,50 0,35 0,00314 
Gm25720 -1,53 0,35 0,00720 
Gm15064 -1,53 0,35 0,02397 
Gm13800 -1,56 0,34 0,01458 
Zfp125 -1,56 0,34 0,00001 
Gm13691 -1,57 0,34 0,03382 
Gm21742 -1,65 0,32 0,00022 
Nlrp1c-ps -1,67 0,31 0,00183 
Trim30d -1,72 0,30 0,00832 
S100a9 -1,81 0,29 0,02556 
Gm13695 -1,81 0,29 0,02972 
Gm13698 -1,81 0,29 0,03023 
Gm13693 -1,81 0,29 0,03023 
Gm13696 -1,81 0,29 0,03023 
Gm13694 -1,81 0,29 0,03023 
Gm13697 -1,81 0,29 0,03023 
Retnlg -1,93 0,26 0,03561 
Gm22748 -2,13 0,23 0,00000 
S100a8 -2,29 0,20 0,04194 
Egln3 -3,48 0,09 0,00000 
Table 5. Transcriptional changes in isolated microglia from Egln3 –/–; App-Psen1 
versus App-Psen1 mice. 
- 153 - 
Up-regulated and down-regulated genes in 12-month-old isolated microglia from 
Egln3 –/–; App-Psen1 versus App-Psen1 mice (logFC ≥ ±0.5, p < 0.05). 
9.2. Figure index 
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